US20220186208A1 - Devices and methods for nucleic acid extraction - Google Patents
Devices and methods for nucleic acid extraction Download PDFInfo
- Publication number
- US20220186208A1 US20220186208A1 US17/508,519 US202117508519A US2022186208A1 US 20220186208 A1 US20220186208 A1 US 20220186208A1 US 202117508519 A US202117508519 A US 202117508519A US 2022186208 A1 US2022186208 A1 US 2022186208A1
- Authority
- US
- United States
- Prior art keywords
- module
- sample
- lysing
- volume
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 149
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 144
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 139
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 139
- 238000000605 extraction Methods 0.000 title claims description 24
- 239000000523 sample Substances 0.000 claims abstract description 233
- 239000012472 biological sample Substances 0.000 claims abstract description 94
- 230000002934 lysing effect Effects 0.000 claims description 160
- 230000003321 amplification Effects 0.000 claims description 119
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 119
- 230000002779 inactivation Effects 0.000 claims description 98
- 238000002405 diagnostic procedure Methods 0.000 claims description 57
- 239000012530 fluid Substances 0.000 claims description 50
- 238000006243 chemical reaction Methods 0.000 claims description 49
- 102000004190 Enzymes Human genes 0.000 claims description 44
- 108090000790 Enzymes Proteins 0.000 claims description 44
- 239000012139 lysis buffer Substances 0.000 claims description 43
- 239000003153 chemical reaction reagent Substances 0.000 claims description 40
- 238000001514 detection method Methods 0.000 claims description 36
- 108091093088 Amplicon Proteins 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 4
- 238000003752 polymerase chain reaction Methods 0.000 abstract description 56
- 238000005464 sample preparation method Methods 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 160
- 210000004027 cell Anatomy 0.000 description 69
- 239000012528 membrane Substances 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 49
- 102000053602 DNA Human genes 0.000 description 49
- 230000009089 cytolysis Effects 0.000 description 48
- 241000700605 Viruses Species 0.000 description 44
- 238000010828 elution Methods 0.000 description 44
- 229940088598 enzyme Drugs 0.000 description 41
- 239000003480 eluent Substances 0.000 description 40
- 239000007788 liquid Substances 0.000 description 33
- 238000010438 heat treatment Methods 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 30
- 239000000203 mixture Substances 0.000 description 28
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 26
- 238000010790 dilution Methods 0.000 description 25
- 239000012895 dilution Substances 0.000 description 25
- 241000606153 Chlamydia trachomatis Species 0.000 description 23
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 22
- 239000003599 detergent Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- -1 polypropylene Polymers 0.000 description 20
- 239000012723 sample buffer Substances 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- 239000011148 porous material Substances 0.000 description 18
- 229920002477 rna polymer Polymers 0.000 description 17
- 108010067770 Endopeptidase K Proteins 0.000 description 15
- 239000002518 antifoaming agent Substances 0.000 description 15
- 238000005406 washing Methods 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 238000007400 DNA extraction Methods 0.000 description 14
- 229940098773 bovine serum albumin Drugs 0.000 description 14
- 238000003753 real-time PCR Methods 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- 238000012546 transfer Methods 0.000 description 13
- 239000004677 Nylon Substances 0.000 description 12
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 229920001778 nylon Polymers 0.000 description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 238000011534 incubation Methods 0.000 description 10
- 229940038705 chlamydia trachomatis Drugs 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000002699 waste material Substances 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 238000009835 boiling Methods 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 241000711549 Hepacivirus C Species 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 238000011143 downstream manufacturing Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 241001529453 unidentified herpesvirus Species 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 241000709661 Enterovirus Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 241000700721 Hepatitis B virus Species 0.000 description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 5
- 241000224527 Trichomonas vaginalis Species 0.000 description 5
- 241000700647 Variola virus Species 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 241000203069 Archaea Species 0.000 description 4
- 241000606161 Chlamydia Species 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 241000709687 Coxsackievirus Species 0.000 description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 4
- 238000007397 LAMP assay Methods 0.000 description 4
- 241000589248 Legionella Species 0.000 description 4
- 208000007764 Legionnaires' Disease Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000016943 Muramidase Human genes 0.000 description 4
- 108010014251 Muramidase Proteins 0.000 description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241000713112 Orthobunyavirus Species 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- 241000709664 Picornaviridae Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 208000019802 Sexually transmitted disease Diseases 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 241000710772 Yellow fever virus Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000005336 cracking Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229960000274 lysozyme Drugs 0.000 description 4
- 239000004325 lysozyme Substances 0.000 description 4
- 235000010335 lysozyme Nutrition 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 229940051021 yellow-fever virus Drugs 0.000 description 4
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 3
- 241000589968 Borrelia Species 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- 241000725619 Dengue virus Species 0.000 description 3
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 3
- 241000991587 Enterovirus C Species 0.000 description 3
- 241000711950 Filoviridae Species 0.000 description 3
- 241000710831 Flavivirus Species 0.000 description 3
- 241000709721 Hepatovirus A Species 0.000 description 3
- 241000829111 Human polyomavirus 1 Species 0.000 description 3
- 241000701460 JC polyomavirus Species 0.000 description 3
- 208000016604 Lyme disease Diseases 0.000 description 3
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000714209 Norwalk virus Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 241000710799 Rubella virus Species 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 241000589886 Treponema Species 0.000 description 3
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 3
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- 241000710886 West Nile virus Species 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000005388 borosilicate glass Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229940035044 sorbitan monolaurate Drugs 0.000 description 3
- 239000001587 sorbitan monostearate Substances 0.000 description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 description 3
- 229940035048 sorbitan monostearate Drugs 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 238000013022 venting Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- 241000712891 Arenavirus Species 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001302800 Beak and feather disease virus Species 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001467055 Caviid betaherpesvirus 2 Species 0.000 description 2
- 241001502567 Chikungunya virus Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000709675 Coxsackievirus B3 Species 0.000 description 2
- 208000000307 Crimean Hemorrhagic Fever Diseases 0.000 description 2
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 2
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 2
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 2
- 241000712471 Dhori virus Species 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 241000725630 Ectromelia virus Species 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 2
- 241000190598 Flexal mammarenavirus Species 0.000 description 2
- 108010033128 Glucan Endo-1,3-beta-D-Glucosidase Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000190708 Guanarito mammarenavirus Species 0.000 description 2
- 241000150562 Hantaan orthohantavirus Species 0.000 description 2
- 241000589989 Helicobacter Species 0.000 description 2
- 241000700739 Hepadnaviridae Species 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 2
- 241000342334 Human metapneumovirus Species 0.000 description 2
- 241000702617 Human parvovirus B19 Species 0.000 description 2
- 241000555269 Ippy mammarenavirus Species 0.000 description 2
- 241000701372 Iridovirus Species 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 241000712890 Junin mammarenavirus Species 0.000 description 2
- 241001466978 Kyasanur forest disease virus Species 0.000 description 2
- 241000713102 La Crosse virus Species 0.000 description 2
- 241000712902 Lassa mammarenavirus Species 0.000 description 2
- 241000190596 Latino mammarenavirus Species 0.000 description 2
- 241000712898 Machupo mammarenavirus Species 0.000 description 2
- 241001115401 Marburgvirus Species 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 241000351643 Metapneumovirus Species 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 241000555271 Mobala mammarenavirus Species 0.000 description 2
- 241000700627 Monkeypox virus Species 0.000 description 2
- 241000712897 Mopeia mammarenavirus Species 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 241000186362 Mycobacterium leprae Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 239000012807 PCR reagent Substances 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 241000190594 Parana mammarenavirus Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241000712910 Pichinde mammarenavirus Species 0.000 description 2
- 241001505332 Polyomavirus sp. Species 0.000 description 2
- 241000710884 Powassan virus Species 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000702263 Reovirus sp. Species 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 241000713124 Rift Valley fever virus Species 0.000 description 2
- 241000710942 Ross River virus Species 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000710960 Sindbis virus Species 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- 241000710888 St. Louis encephalitis virus Species 0.000 description 2
- 241000122971 Stenotrophomonas Species 0.000 description 2
- 241000712908 Tacaribe mammarenavirus Species 0.000 description 2
- 241000190592 Tamiami mammarenavirus Species 0.000 description 2
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 241000710951 Western equine encephalitis virus Species 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000003116 impacting effect Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000011901 isothermal amplification Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HRNGDAQBEIFYGL-UHFFFAOYSA-N 3,4-dihydroxy-4-tetradeca-3,6-dienoyloxybutanoic acid Chemical compound CCCCCCCC=CCC=CCC(=O)OC(O)C(O)CC(O)=O HRNGDAQBEIFYGL-UHFFFAOYSA-N 0.000 description 1
- IXOCGRPBILEGOX-UHFFFAOYSA-N 3-[3-(dodecanoylamino)propyl-dimethylazaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O IXOCGRPBILEGOX-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000186041 Actinomyces israelii Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241000190711 Amapari mammarenavirus Species 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 206010073941 Anorectal human papilloma virus infection Diseases 0.000 description 1
- 241000710189 Aphthovirus Species 0.000 description 1
- 241000907515 Apoi virus Species 0.000 description 1
- 241000565310 Aquareovirus A Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000907340 Aroa virus Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241001533362 Astroviridae Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000829156 Aves polyomavirus 1 Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000907523 Bagaza virus Species 0.000 description 1
- 241001536481 Banzi virus Species 0.000 description 1
- 241000710946 Barmah Forest virus Species 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 241000120506 Bluetongue virus Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000907510 Bouboui virus Species 0.000 description 1
- 241000886138 Bovine atadenovirus D Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241001509299 Brucella canis Species 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- 241001148111 Brucella suis Species 0.000 description 1
- 241000907516 Bukalasa bat virus Species 0.000 description 1
- 241001493154 Bunyamwera virus Species 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 208000027312 Bursal disease Diseases 0.000 description 1
- 241000907338 Cacipacore virus Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241001493160 California encephalitis virus Species 0.000 description 1
- 241001137864 Camelpox virus Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 241000701931 Canine parvovirus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000710190 Cardiovirus Species 0.000 description 1
- 241000907522 Carey Island virus Species 0.000 description 1
- 241001428800 Cell fusing agent virus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 241000659008 Chapare mammarenavirus Species 0.000 description 1
- 241000725585 Chicken anemia virus Species 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241001533384 Circovirus Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 241000204955 Colorado tick fever virus Species 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000907509 Cowbone Ridge virus Species 0.000 description 1
- 241000700626 Cowpox virus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241001208518 Cypovirus 1 Species 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000907513 Dakar bat virus Species 0.000 description 1
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000187845 Dermatophilus congolensis Species 0.000 description 1
- 241000725618 Duck hepatitis B virus Species 0.000 description 1
- 241000149824 Dugbe orthonairovirus Species 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000709643 Echovirus E9 Species 0.000 description 1
- 241000907511 Edge Hill virus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000907514 Entebbe bat virus Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000709691 Enterovirus E Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001302129 Fiji disease virus Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241001411198 Fowl aviadenovirus A Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241001208403 Frog siadenovirus A Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 241000531123 GB virus C Species 0.000 description 1
- 241000907343 Gadgets Gully virus Species 0.000 description 1
- 241001112691 Goatpox virus Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000893570 Hendra henipavirus Species 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 241001529916 Hepatitis GB virus B Species 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 241000709715 Hepatovirus Species 0.000 description 1
- 241001136039 Heron hepatitis B virus Species 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 241000487062 Histoplasma capsulatum var. capsulatum Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241001479210 Human astrovirus Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000046923 Human bocavirus Species 0.000 description 1
- 241000699727 Human echovirus Species 0.000 description 1
- 241001207270 Human enterovirus Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000620571 Human mastadenovirus A Species 0.000 description 1
- 241001545456 Human mastadenovirus B Species 0.000 description 1
- 241000620147 Human mastadenovirus C Species 0.000 description 1
- 241000886679 Human mastadenovirus D Species 0.000 description 1
- 241000886703 Human mastadenovirus E Species 0.000 description 1
- 241000886705 Human mastadenovirus F Species 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 241001238082 Idnoreovirus 1 Species 0.000 description 1
- 241000609530 Ilheus virus Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000907506 Israel turkey meningoencephalomyelitis virus Species 0.000 description 1
- 241000907342 Jugra virus Species 0.000 description 1
- 241000907512 Jutiapa virus Species 0.000 description 1
- 241000907327 Kadam virus Species 0.000 description 1
- 241000701646 Kappapapillomavirus 2 Species 0.000 description 1
- 241000907518 Karshi virus Species 0.000 description 1
- 241000907328 Kedougou virus Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000178323 Kokobera virus Species 0.000 description 1
- 241000178324 Koutango virus Species 0.000 description 1
- 241000710770 Langat virus Species 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 229920002011 Lauryl methyl gluceth-10 hydroxypropyl dimonium chloride Polymers 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000589929 Leptospira interrogans Species 0.000 description 1
- 241000144128 Lichtheimia corymbifera Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241000710769 Louping ill virus Species 0.000 description 1
- 241001573276 Lujo mammarenavirus Species 0.000 description 1
- 241000609846 Lumpy skin disease virus Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241001042466 Mammalian orthoreovirus Species 0.000 description 1
- 241000608292 Mayaro virus Species 0.000 description 1
- 241001492366 Meaban virus Species 0.000 description 1
- 241000893980 Microsporum canis Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000907337 Modoc virus Species 0.000 description 1
- 241000700560 Molluscum contagiosum virus Species 0.000 description 1
- 241000907325 Montana myotis leukoencephalitis virus Species 0.000 description 1
- 241000588771 Morganella <proteobacterium> Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000710908 Murray Valley encephalitis virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241001467553 Mycobacterium africanum Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000187917 Mycobacterium ulcerans Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 241001238110 Mycoreovirus 1 Species 0.000 description 1
- 241000700562 Myxoma virus Species 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 241000710765 Negishi virus Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241001136170 Neisseria subflava Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- 241000907507 Ntaya virus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000146363 Oliveros mammarenavirus Species 0.000 description 1
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 241000700635 Orf virus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000150218 Orthonairovirus Species 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010058096 Pancreatic necrosis Diseases 0.000 description 1
- 241000588912 Pantoea agglomerans Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001537205 Paracoccidioides Species 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000682990 Pegivirus A Species 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- 241000908523 Phnom Penh bat virus Species 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 241000700667 Pigeonpox virus Species 0.000 description 1
- 241000245926 Pirital mammarenavirus Species 0.000 description 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 241001631648 Polyomaviridae Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000928435 Porcine circovirus 1 Species 0.000 description 1
- 241001673669 Porcine circovirus 2 Species 0.000 description 1
- 208000005585 Poxviridae Infections Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000713126 Punta Toro virus Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700564 Rabbit fibroma virus Species 0.000 description 1
- 241000714203 Rabbit hemorrhagic disease virus Species 0.000 description 1
- 241001455645 Rabbitpox virus Species 0.000 description 1
- 241000700638 Raccoonpox virus Species 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000235525 Rhizomucor pusillus Species 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- 241000702632 Rice dwarf virus Species 0.000 description 1
- 241000144068 Rice ragged stunt virus Species 0.000 description 1
- 241000606695 Rickettsia rickettsii Species 0.000 description 1
- 241000711897 Rinderpest morbillivirus Species 0.000 description 1
- 241000907520 Rio Bravo virus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001137860 Rotavirus A Species 0.000 description 1
- 241000907521 Royal Farm virus Species 0.000 description 1
- 241000192617 Sabia mammarenavirus Species 0.000 description 1
- 241000907519 Saboya virus Species 0.000 description 1
- 241000907335 Sal Vieja virus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000907336 San Perlita virus Species 0.000 description 1
- 241000369753 Sapporo virus Species 0.000 description 1
- 241000120605 Saumarez Reef virus Species 0.000 description 1
- 241000132889 Scedosporium Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 241000178331 Sepik virus Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000700665 Sheeppox virus Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 241000150288 Sin Nombre orthohantavirus Species 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241000283925 Spermophilus Species 0.000 description 1
- 241000732549 Sphaerius Species 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 241001149963 Sporothrix schenckii Species 0.000 description 1
- 241001476589 Squirrel fibroma virus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 241001478880 Streptobacillus moniliformis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000700565 Swinepox virus Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 241000338155 Tamana bat virus Species 0.000 description 1
- 241000404000 Tanapox virus Species 0.000 description 1
- 241000907504 Tembusu virus Species 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 241000701364 Thermoproteus tenax virus 1 Species 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 241000893962 Trichophyton equinum Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241000120643 Tyuleniy virus Species 0.000 description 1
- 241000907508 Uganda S virus Species 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- 241000907517 Usutu virus Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 241001494970 Vesicular exanthema of swine virus Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000366208 Wesselsbron virus Species 0.000 description 1
- 241000205658 Whitewater Arroyo mammarenavirus Species 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 241000907334 Yaounde virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000907505 Yokose virus Species 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- ORBBVPFDROYXQS-UHFFFAOYSA-N ammonium perfluorononanoate Chemical compound N.OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ORBBVPFDROYXQS-UHFFFAOYSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- XVBRCOKDZVQYAY-UHFFFAOYSA-N bronidox Chemical compound [O-][N+](=O)C1(Br)COCOC1 XVBRCOKDZVQYAY-UHFFFAOYSA-N 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 229940038698 brucella melitensis Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092259 cell-free RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 229960002788 cetrimonium chloride Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- UMCMPZBLKLEWAF-UHFFFAOYSA-N chaps detergent Chemical compound OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)C1(C)C(O)C2 UMCMPZBLKLEWAF-UHFFFAOYSA-N 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940073499 decyl glucoside Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- 229940018602 docusate Drugs 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003060 endolymph Anatomy 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- VOWCXSYDBWCCCF-QIBOXNKSSA-N gbv-b Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C1=CC=C(O)C=C1 VOWCXSYDBWCCCF-QIBOXNKSSA-N 0.000 description 1
- ASKSDLRLUXEOOR-SUFRFZPQSA-N gbv-c Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC(C)C)=CNC2=C1 ASKSDLRLUXEOOR-SUFRFZPQSA-N 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 108010070857 gluculase Proteins 0.000 description 1
- 229940074046 glyceryl laurate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- LAPRIVJANDLWOK-UHFFFAOYSA-N laureth-5 Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCO LAPRIVJANDLWOK-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 208000001581 lymphogranuloma venereum Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010056929 lyticase Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 241000609532 mosquito-borne viruses Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940087419 nonoxynol-9 Drugs 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- ZVVSSOQAYNYNPP-UHFFFAOYSA-N olaflur Chemical compound F.F.CCCCCCCCCCCCCCCCCCN(CCO)CCCN(CCO)CCO ZVVSSOQAYNYNPP-UHFFFAOYSA-N 0.000 description 1
- 229960001245 olaflur Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- JGTNAGYHADQMCM-UHFFFAOYSA-N perfluorobutanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F JGTNAGYHADQMCM-UHFFFAOYSA-N 0.000 description 1
- UZUFPBIDKMEQEQ-UHFFFAOYSA-N perfluorononanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F UZUFPBIDKMEQEQ-UHFFFAOYSA-N 0.000 description 1
- YFSUTJLHUFNCNZ-UHFFFAOYSA-N perfluorooctane-1-sulfonic acid Chemical compound OS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YFSUTJLHUFNCNZ-UHFFFAOYSA-N 0.000 description 1
- SNGREZUHAYWORS-UHFFFAOYSA-N perfluorooctanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F SNGREZUHAYWORS-UHFFFAOYSA-N 0.000 description 1
- 210000004049 perilymph Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- ONQDVAFWWYYXHM-UHFFFAOYSA-M potassium lauryl sulfate Chemical compound [K+].CCCCCCCCCCCCOS([O-])(=O)=O ONQDVAFWWYYXHM-UHFFFAOYSA-M 0.000 description 1
- 229940116985 potassium lauryl sulfate Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 229940075118 rickettsia rickettsii Drugs 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 description 1
- MDSQKJDNWUMBQQ-UHFFFAOYSA-M sodium myreth sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O MDSQKJDNWUMBQQ-UHFFFAOYSA-M 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- GOJYXPWOUJYXJC-UHFFFAOYSA-M sodium;2-[1-(2-hydroxyethyl)-2-undecyl-4,5-dihydroimidazol-1-ium-1-yl]acetate;hydroxide Chemical compound [OH-].[Na+].CCCCCCCCCCCC1=NCC[N+]1(CCO)CC([O-])=O GOJYXPWOUJYXJC-UHFFFAOYSA-M 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- 108010082737 zymolyase Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1017—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502715—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0636—Integrated biosensor, microarrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/18—Means for temperature control
- B01L2300/1805—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21064—Peptidase K (3.4.21.64)
Definitions
- sample preparation methods involving the extraction of nucleic acid molecules from biological cells are widely used. Oftentimes, the nucleic acid molecules are to be used in downstream applications, for example, amplification (e.g., PCR) or sequencing methods. These methods, however, can be sensitive to additional components found in the sample mixture. These additional components may be residual components carried over from the sample preparation method. Thus, the sample preparation method should be able to generate a nucleic acid sample of sufficient quality to perform the intended downstream application. Furthermore, standard sample preparation methods may be time-consuming, ranging on the order of hours to be complete.
- a method for nucleic acid extraction comprising: (a) obtaining a biological sample comprising one or more biological entities; (b) capturing the one or more biological entities on a filter; (c) washing the filter; (d) eluting the one or more biological entities from the filter; and (e) lysing the one or more biological entities, thereby releasing a plurality of nucleic acid molecules therefrom, wherein the method extracts the nucleic acid molecules from the one or more biological entities within 5 minutes or less at a quality sufficient to successfully perform a polymerase chain reaction (PCR).
- the one or more biological entities comprise one or more biological cells.
- the one or more biological cells comprise one or more bacterial cells, fungal cells, mammalian cells or a combination thereof.
- the one or more biological entities comprise one or more viruses.
- the nucleic acid molecules comprise RNA.
- the nucleic acid molecules comprise DNA.
- the lysing further comprises flowing a lysis solution over the one or more biological entities on the filter.
- the lysis solution comprises a lysis enzyme.
- the lysis enzyme is proteinase K.
- the proteinase K is present in the lysis solution at a concentration of about 0.001 mg/ML to about 10 mg/mL.
- the washing further comprises, (i) pushing a wash solution through the filter; (ii) pushing air through the filter; (iii) or a combination of both.
- the lysis solution is back-flushed over the filter.
- the wash solution comprises bovine serum albumin and/or a detergent.
- the wash solution comprises about 0.1% to 5% bovine serum albumin.
- the wash solution comprises about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 1.5%. 2%, 2.5%, 3%, 4%, or 5% bovine serum albumin.
- the wash solution comprises about 0.1% to 20% detergent. In some cases, the wash solution comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% detergent. In some cases, the detergent is Tween-20.
- the biological sample comprises urine, a vaginal swab, a cervical swab, or blood.
- the filter comprises cellulose, polyethersulfone (PES), nylon, polyvinylidene fluoride (PVDF), polycarbonate or borosilicate glass fiber. In some cases, the filter has a pore size of about 0.2 ⁇ m to about 20 ⁇ m.
- the lysing further comprises incubating the biological sample in the lysis solution for a period of time at a specified temperature.
- the period of time comprises from about 0.01 seconds to about 48 hours.
- the specified temperature comprises from about 4° C. to about 75° C.
- the method further comprises inactivating said lysis solution.
- the inactivating comprises incubating said lysis solution at a temperature of about 57° C. to about 100° C. at a time period from about 0.01 seconds to about 48 hours.
- the nucleic acid molecules comprise DNA and the DNA is extracted from the one or more biological entities with a A260/A280 ratio of at least 1.5.
- the nucleic acid molecules comprise RNA and the RNA is extracted from the one or more biological entities with a A260/A280 ratio of at least 1.7.
- the method further comprises performing a polymerase chain reaction on the extracted nucleic acid molecules.
- the polymerase chain reaction successfully amplifies a target nucleic acid sequence present in the extracted nucleic acid molecules.
- a device configured to perform a method of the disclosure.
- the device comprises: (a) an input port, configured to receive the biological sample comprising one or more biological entities; (b) a filter assembly comprising a filter configured to capture the one or more biological entities, wherein the input port is configured to relay the biological sample to the filter assembly; (c) one or more reservoirs comprising a wash solution, a lysis solution, or both, operably coupled to the filter assembly; (d) a waste chamber, operably coupled to the filter assembly and configured to receive waste from the filter assembly; and (e) an elution chamber, operably coupled to the filter assembly and configured to receive an eluent from the filter assembly.
- the elution chamber further comprises a heating element in contact with the elution chamber.
- the device further comprises an inactivation chamber, operably coupled to the elution chamber.
- the inactivation chamber further comprises a heating element.
- the inactivation chamber comprises a serpentine flow path in contact with the heating element.
- the input port, the filter assembly, the one or more reservoirs, the waste chamber, and the elution chamber are contained within a housing.
- the device is handheld.
- the device is configured for one-time use.
- the device is configured to extract said nucleic acid molecules from the biological entities in 5 minutes or less at a quality sufficient to successfully perform a polymerase chain reaction.
- the device further comprises one or more additional elements for performing a polymerase chain reaction.
- a method for nucleic acid extraction comprising: obtaining a biological sample comprising one or more biological entities; capturing said one or more biological entities on a filter; eluting said one or more biological entities front said filter; and lysing said one or more biological entities, thereby releasing a plurality of nucleic acid molecules therefrom, wherein said method extracts said nucleic acid molecules from said one or more biological entities within 5 minutes or less at a quality sufficient to successfully perform a polymerase chain reaction (PCR).
- the method further comprises that the filter consists of two filter membranes, a first filter membrane and a second filter membrane with a smaller pore size than the first filter membrane.
- the method further comprises a wash step, whereby once the biological entities are captured on the filter the filter and biological entities are washed with an air wash.
- a method for nucleic acid extraction comprising: obtaining a biological sample comprising one or more biological entities; and lysing said one or more biological entities, thereby releasing a plurality of nucleic acid molecules therefrom, wherein said method extracts said nucleic acid molecules from said one or more biological entities within 5 minutes or less art a quality sufficient to successfully perform a polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- the method is performed by a handheld device.
- a quality sufficient to successfully perform a polymerase chain reaction comprises nucleic acid molecules which amplify with at least 70% efficiency as determined by a qPCR standard curve.
- the method produces at least 100 ⁇ L of a solution containing the nucleic acid molecules.
- the method produces at least 300 ⁇ L of a solution containing the nucleic acid molecules. In some cases the method produces at least 500 ⁇ L of a solution containing the nucleic acid molecules. In some cases the method further comprises catching biological entities on a filter and subjecting the biological entities and filter to an air wash. In some cases the biological entities are washed with a volume of air sufficient to dry the filter. In some cases the biological entities are washed with at least about 1.5 mL of air.
- a device in another aspect, comprises: an input port, configured to receive said biological sample comprising one or more biological entities; a holding tank, operably coupled to said input port, an inactivation section, and containing a heating element; and an output port.
- the device further comprises a permanent vent.
- the holding tank further comprises an electrical probe which can sense the presence of liquid in the holding tank.
- the inactivation chamber comprises a serpentine path.
- a method of nucleic acid extraction comprises: conveying a biological sample into a sample input module of a. molecular diagnostic test device; and actuating the molecular diagnostic test device to: convey the biological sample from the sample input module to a lysing module, the lysing module including a heater and defining a first reaction volume and a second reaction volume; maintain an input solution containing the biological sample and a lysis buffer within the first reaction module to lyse at least a portion of the biological sample thereby releasing a plurality of nucleic acid molecules; activate the heater to heat a portion of the lysing module to produce an inactivation temperature zone within the second reaction volume; and produce a flow of the input solution within the second reaction volume such that a volume of the input solution is heated within the inactivation temperature In some cases the volume of the input solution is at least 10 microliters.
- the volume of the input solution is produced within five minutes or less.
- the second reaction volume is a serpentine flow path.
- a wall of the lysing module that defines the second reaction volume has a surface area, a ratio of the surface area to the second reaction volume being greater than about 10 cm ⁇ 1 . In one example, a ratio of the surface area to the second reaction volume is about 20 cm ⁇ 1 .
- the volume of the input solution is heated to an inactivation temperature of between about 57 degrees Celsius and about 100 degrees Celsius for a time period from about 15 seconds.
- the flow of the input solution is such that the volume of the input solution is heated to an inactivation temperature of between about 92 degrees Celsius and about 98 degrees Celsius for a time period of at least about 25 seconds.
- the first reaction volume is in fluid communication with the second reaction volume; and the lysing module defines a vent opening into the first reaction volume.
- the volume of the input solution is heated to an inactivation temperature of at least about 95 degrees Celsius; and the input solution within the first reaction module contains at least one of a salt or a sugar formulated to raise a boiling temperature of the input solution.
- the actuating the molecular diagnostic test device further causes the molecular diagnostic test device to: heat a first portion of the lysing module to produce a lysing temperature zone within the second reaction volume, the flow of the input solution within the second reaction volume being such that the volume of the input solution is heated within the lysing temperature zone to lyse a biological entity within the volume of the input solution.
- the plurality of nucleic acid molecules includes DNA, the DNA being extracted from said one or more biological entities with a A260/A280 ratio of at least 1.5.
- the actuating the molecular diagnostic test device causes the molecular diagnostic test device to: convey the biological sample from the sample input module through a filter to retain a biological entity with the biological sample on the filter; and produce a flow of an elution butler through the filter to produce the input solution and convey the input solution to the lysing module.
- the actuating the molecular diagnostic test device includes moving a sample actuator to produce a pressure within the sample input module to convey the biological sample from the sample input module towards the lysing module.
- the sample actuator is a non-electronic actuator.
- the actuating the molecular diagnostic test device further causes the molecular diagnostic test device to: receive an electronic signal from a sensor within the lysing module, the electronic signal indicating the presence of the input solution within the first reaction module; and activate the heater in response to the electronic signal.
- the actuating the molecular diagnostic test device further causes the molecular diagnostic test device to: heat a portion of an amplification module within the molecular diagnostic test device to amplify a nucleic acid from the plurality of nucleic acid molecules to produce an output containing a target amplicon; and convey the Output to a detection module of the molecular diagnostic test device.
- a method described herein further comprises viewing a visible signal indicating a presence of the target amplicon; and discarding, after the viewing, the molecular diagnostic test device.
- an apparatus comprising a housing; a sample input module defining an input reservoir configured to receive a biological sample, the biological sample containing a biological entity; a lysing module disposed within the housing, the lysing module including a heater and first flow member, the first flow member defining a first volume and a second volume, the first volume configured to receive an input solution containing at least the biological sample and a lysis buffer, the heater coupled to the first flow member and configured to convey thermal energy into the second volume to A) lyse at least a portion of the biological sample thereby releasing a plurality of nucleic acid molecules and B) inactivate an enzyme within the input solution when a volume of the input solution flows through the second volume; and an amplification module disposed within the housing, the amplification module including a second flow member configured to receive the volume of the input solution from the lysing module, the amplification module configured to amplify a nucleic acid molecule from the plurality of nucleic acid molecules within the
- the second volume is a serpentine flow path.
- a wall of the lysing module that defines the second volume has a surface area, a ratio of the surface area to the second reaction volume being greater than about 20 cm ⁇ 1 . In one example, a ratio of the surface area to the second reaction volume is about 20 cm ⁇ 1 .
- the first volume is in fluid communication with the second reaction volume; and the lysing module defines a vent opening into the first volume.
- the lysing module includes a sensor disposed within the first volume, the sensor configured to produce an electronic signal indicating the presence of the input solution within the first module, the heater activated in response to the electronic signal.
- the heater is a first heater; the second flow member defines an amplification flow path; and the amplification module includes a second heater different from the first heater, the second heater coupled to the second flow member and configured to convey thermal energy into the amplification flow path to amplify the nucleic acid molecule from the plurality of nucleic acid molecules.
- an apparatus further comprises a non-electronic sample actuator to produce a pressure within the sample input module to convey the biological sample from the sample input module towards the lysing module; and a fluid pump disposed within the housing, the fluid pump configured to produce a flow of the input solution from the lysing module to the amplification module.
- the flow of the input solution from the lysing module to the amplification module is in a first direction; and the lysing module includes a check valve to configured to prevent a flow of the input solution in a second direction.
- a device comprising a holding tank which contains two electrical probes which may be used to determine the electrical resistance of the fluid within the holding tank, thus determining whether liquid has entered the holding tank.
- FIG. 1 depicts data generated from a real-time PCR reaction performed on DNA extracted from clinical samples utilizing the methods provided herein.
- FIG. 2 depicts data generated from a real-time PCR reaction performed on DNA extracted from clinical samples utilizing standard DNA extraction methods.
- FIG. 3 depicts a comparison of data generated from a real-time PCR reaction performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122) and a clinical sample positive for N. gonorrhoeae (Sample 117) utilizing the methods provided herein versus standard DNA extraction methods.
- FIG. 4 depicts a comparison of data generated from a real-time PCR reaction performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122) and a clinical sample positive for N. gonorrhoeae (Sample 117) utilizing the methods provided herein versus standard DNA extraction methods.
- FIG. 5 depicts a comparison of data generated from a real-time PCR reaction performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122), a clinical samples positive for C. trachomatis (Samples 101 and 108) utilizing the methods provided herein versus standard DNA extraction methods.
- FIG. 6 depicts a comparison of data generated from a real-time PCR reaction performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122) and clinical samples positive for C. trachomatis (Samples 101 and 108) utilizing the methods provided herein versus standard DNA extraction methods.
- FIG. 7 depicts a comparison of data generated from a real-time PCR reaction performed on N. gonorrhoeae DNA utilizing different sets of primers.
- FIG. 8 depicts a comparison of data generated from a real-time PCR reaction performed on C. trachomatis DNA utilizing different sets of primers.
- FIG. 9 depicts data generated from a real-time PCR reaction performed on N. gonorrhoeae DNA spiked into a sample and PCR mixture to test for sample inhibition.
- FIG. 10 is a schematic illustration of a molecular diagnostic test device, according to an embodiment, which can perform the methods described herein.
- FIG. 11 is an exploded view of the molecular diagnostic test device shown schematically in FIG. 10 .
- FIG. 12 depicts an example of a sample preparation device amenable to performing the methods as described herein.
- FIG. 13 is a perspective view of a lysing module according to an embodiment, which is amenable to performing the methods as described herein.
- FIG. 14 is an exploded view of the lysing module shown in FIG. 13 .
- FIG. 15 is a top view of a portion of the lysing module shown in FIG. 13 .
- FIG. 16 is a cross-sectional view of the lysing module shown in FIG. 13 .
- FIGS. 17 and 18 is are perspective views of a lysing module according to an embodiment, which can perform any of the methods described herein.
- FIG. 19 is a bottom view of the lysing module shown in FIGS. 17 and 18 .
- FIG. 20 is a cross-sectional view of the lysing module shown in FIGS. 17 and 18 taken along line X 1 -X 1 in FIG. 19 .
- FIG. 21 is a cross-sectional view of the lysing module shown in FIGS. 17 and 18 taken along line X 2 -X 2 in FIG. 19 .
- FIG. 22 is a perspective view of a portion of the lysing module shown in FIGS. 17 and 18 .
- FIG. 23 is a schematic illustration of a portion of a molecular diagnostic test device, according to an embodiment, which can perform the methods described herein.
- FIG. 24 is a schematic illustration of a molecular diagnostic test device, according to an embodiment, which can perform the methods described herein.
- FIG. 25 illustrates the results of a PCR reaction performed upon DNA extracted using the methods of this disclosure.
- FIG. 26 illustrates the results of a PCR reaction performed upon DNA extracted using the methods of this disclosure.
- FIG. 27 illustrates the results of a PCR reaction performed upon DNA extracted using the methods of this disclosure.
- the devices and methods are utilized for the extraction of nucleic acid molecules from a biological sample. In some cases, the devices and methods are utilized for the purification of nucleic acid molecules from a biological sample.
- the devices described herein may include self-contained, handheld devices.
- the devices described herein may include one or more components that aid in the extraction, purification, and/or processing of a biological sample and the nucleic acids contained therein.
- the methods include the use of a device that includes one or more components that aid in the extraction, purification, and/or processing of a biological sample and the nucleic acids contained therein.
- a method for nucleic acid extraction may include one or more steps including: (a) obtaining a biological sample comprising one or more biological entities; (b) capturing the one or more biological entities on a filter; (b) washing the filter with a wash solution and/or air; (c) eluting the one or more biological entities from the filter; and (d) lysing the one or more biological entities, thereby releasing a plurality of nucleic acid molecules therefrom.
- the wash solution comprises bovine serum albumin and/or a detergent.
- the wash solution comprises about 0.1% to 5% bovine serum albumin.
- the wash solution comprises about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4%, or 5% bovine serum albumin. In some cases, the wash solution comprises about 0.1% to 20% detergent. In some cases, the wash solution comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% detergent. In some cases, the detergent is Tween-20. In some embodiments the method may not require use of a filter. In other embodiments the method may use a filter but not require a wash solution.
- the method involves obtaining or providing a biological sample.
- the biological sample can be derived from a non-cellular entity comprising polynucleotides (e.g., a virus) or from a cell-based organism (e.g., member of archaea, bacteria, or eukarya domains).
- the biological sample will contain one or more biological entities that comprise one or more polynucleotides or nucleic acid molecules.
- a “nucleic acid molecule”, “nucleic acid” or “polynucleotide” may be used interchangeably throughout and may refer to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) including known analogs or a combination thereof unless otherwise indicated.
- Nucleic acid molecules to be profiled herein can be obtained from any source of nucleic acid, The nucleic acid molecule can be single-stranded or double-stranded. In some cases, the nucleic acid molecules are DNA.
- the DNA can be mitochondrial DNA, complementary DNA (cDNA), or genomic DNA.
- the nucleic acid molecules are genomic DNA (gDNA).
- the DNA can be plasmid DNA, cosmid DNA, bacterial artificial chromosome (BAC), or yeast artificial chromosome (YAC).
- the DNA can be derived from one or more chromosomes. For example, if the DNA is from a human, the DNA can derived from one or more of chromosomes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, X, or Y.
- the nucleic acid molecules are RNA.
- RNA can include, but is not limited to, mRNAs, tRNAs, snRNAs, rRNAs, retroviruses, small non-coding RNAs, microRNAs, polysomal RNAs, pre-mRNAs, intronic RNA, viral RNA, cell free RNA and fragments thereof.
- the non-coding RNA, or ncRNA can include snoRNAs, microRNAs, siRNAs, piRNAs and long nc RNAs.
- the source of nucleic acid for use in the methods and compositions described herein can be a sample comprising the nucleic acid.
- the methods involve capturing one or more biological cells or biological entities (e.g., a virus) present in the biological sample on a filter membrane.
- the filter membrane may be of any suitable material, non-limiting examples including nylon, cellulose, polyethersulfone (PES), polyvinylidene difluoride (PVDF), polycarbonate, borosilicate glass fiber and the like.
- the filter membrane is nylon.
- the filter membrane has an average pore size of about 0.2 ⁇ m to about 20 ⁇ m.
- the filter membrane may have an average pore size of about 0.2 ⁇ m, about 0.5 ⁇ m, about 1 ⁇ m, about 2 ⁇ m, about 3 ⁇ m, about 4 ⁇ m, about 5 ⁇ m, about 6 ⁇ m, about 7 ⁇ m, about 8 ⁇ m, about 9 ⁇ m, about 10 ⁇ m, about 11 ⁇ m , about 12 ⁇ m, about 13 ⁇ m, about 14 ⁇ m, about 15 ⁇ m, about 16 ⁇ m, about 17 ⁇ m, about 18 ⁇ m, about 19 ⁇ m, about 20 ⁇ m, or greater than 20 ⁇ m.
- the surface of the filter membrane may be chemically treated or coated in such a way as to improve the binding of a biological cell or entity to the membrane.
- the filter membrane may be treated with sodium polyphosphate.
- Clinical swab samples may contain mucus (or other substances) which can lead to clogging of the filter used in sample prep. If the filter is clogged then pressures may build up which may lead to leaks in the fluidic path of the sample prep device and/or tears or breaks in the capture filter itself.
- a second filter may be provided which sits next to a first filter.
- a mesh screen may be placed on the input side of the 5 micron nylon filter. This may reduce pressure from mucus samples and also prevent the 5 micron nylon filter from breaking.
- a mesh screen could also be placed on the exit side of the 5 micron nylon filter which would also prevent the 5 micron nylon filter from breaking, however this likely would not reduce the pressure required to push a sample (mucus) through.
- the mesh screen may be made from any plastic materials and may contain pore sizes from 1 micron to 1000 microns.
- the mesh screen may be a woven nylon mesh with 100 micron pores.
- the mesh screen is assembled into the housing that also contains the 5 micron nylon filter.
- the second filter may have a much larger pore size than the first filter and prevent clogging of the first filter.
- the first filter may have a pore size of about 0.1-20, 1-15, 1-10, 5-10, 1-5 or 0.1-1 ⁇ m while the second filter has a pore size of about 10-1000, 50-500, 100-500, 50-100, or 100-200 ⁇ m.
- the first filter has a pore size of 5 ⁇ m and the second filter has a pore size of 100 ⁇ m.
- the mesh filter may also be made from non-woven polypropylene.
- the mesh screen may have a thickness of about 150 ⁇ m, 200 ⁇ m or greater than 200 ⁇ m.
- the wash step may be utilized to, for example, remove any undesired material from the membrane.
- the wash step may involve pushing or forcing a fluid solution over or through the membrane (e.g., a buffer).
- the volume of wash solution may be from about 10 ⁇ L to about 50 mL.
- the volume of wash solution may be about 10 ⁇ L about 50 ⁇ L, about 100 ⁇ L, about 200 ⁇ L, about 300 ⁇ L, about 400 ⁇ L, about 500 ⁇ L, about 600 ⁇ L, about 700 ⁇ L, about 800 ⁇ L, about 900 ⁇ L, about 1 mL, about 5 mL, about 10 mL, about 15 mL, about 20 mL, about 25 mL, about 30 mL, about 35 mL, about 40 mL, about 45 about 50 mL or greater than 50 mL.
- the wash step may involve pushing or forcing air over or through the membrane. This step may be advantageous in decreasing the volume of sample buffer that is carried over into the lysis buffer.
- the volume of air wash may be from about 0.1 ⁇ L to about 100 L, or about 10 ⁇ L it to about 50 mL.
- the volume of air wash may be about 10 ⁇ L, about 50 ⁇ L, about 100 ⁇ L, about 200 ⁇ L, about 300 ⁇ L, about 400 ⁇ L, about 500 ⁇ L, about 600 ⁇ L, about 700 ⁇ L, about 800 ⁇ L, about 900 ⁇ L, about 1 mL, about 5 mL, about 10 mL, about 15 mL, about 20 mL, about 25 mL, about 30 mL, about 35 mL, about 40 mL, about 45 mL, about 50 mL or greater than 50 mL.
- an air wash volume of about 1-5 mL may be preferred, For example an air wash may be have a volume of about 1.5 mL. In cases where an air wash is used the subsequent liquid wash may be more effective and/or the final eluted sample may be cleaner than if no air wash were used.
- the wash step involves both a fluid wash step and an air wash step, performed in any order.
- the wash solution comprises bovine serum albumin and/or a detergent.
- the wash solution comprises about 0.1% to 5% bovine serum albumin.
- the wash solution comprises about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4%, or 5% bovine serum albumin.
- the wash solution comprises about 0.1% to 20% detergent. In some cases, the wash solution comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% detergent. In some cases, the detergent is Tween-20. In some embodiments, the bovine serum albumin and/or detergent increase the viscosity of the wash solution in manner which increases the surface area of the filter contacted with the wash solution during a wash step as compared to a wash solution lacking one or both of bovine serum albumin and detergent.
- the biological cells or entities captured on the membrane may be lysed or otherwise disrupted so as to release a plurality of nucleic acid molecules contained therein.
- the methods and devices of this disclosure may use chemical, enzymatic and/or thermal methods to lyse the sample. In some embodiments the methods and devices of this disclosure do not use ultrasound to lyse the sample.
- the cells may be lysed be heating the sample. For example the sample may be heated to greater than about 90° C. for longer than about 10 seconds. In some examples heating the sample to about 95° C. for about 20 seconds is seen to be sufficient to lyse the sample.
- lysis involves flowing a lysis buffer over the biological cells or entities captured on the membrane.
- the lysis buffer is flowed through the filter membrane.
- the lysis buffer is back-flowed through the filter membrane.
- the lysis buffer may be osmotically imbalanced so as to force fluid into the cells to rupture the cell membranes.
- the lysis buffer may include one or more surfactants or detergents.
- Non-limiting examples of surfactants or detergents that may be used include: nonionic sufactants including polyoxyethylene glycol alkyl ethers (sold as Brij® series detergents including Brij® 58, Brij® 52, Brij® L4 and Brij® L23), octaethvlene glycol monododecyl ether, pentaethylene glycol monododecyl ether, polyoxypropylene glycol alkyl ethers, glucoside alkyl ethers (e.g., decyl glucoside, laurel glucoside, octyl glucoside), polyoxyethylene glycol octylphenol ethers (e.g., Triton X-100), polyoxyethylene glycol alkylphenol ethers (e.g., nonoxynol-9), glycerol alkyl esters (e.g., glyceryl laurate), polyoxyethylene glycol sorbitan alky
- the lysis buffer may contain an antifoaming agent for preventing or minimizing foaming.
- antifoaming agents include Antifoam SE-15, Antifoam 204, Antifoam Y-30.
- the lysis buffer may contain a preservative, for example an antimicrobial agent.
- antimicrobials may include preservatives like ProClinTM 150, ProClinTM 200, ProClinTM 300, and ProClinTM 950.
- the lysis buffer may include one or more agents that prevent degradation of the RNA, such as, for example, an RNAse inhibitor.
- the volume of lysis buffer flowed over the membrane can be from about 10 ⁇ L to about 50 mL.
- the volume of lysis buffer may be about 10 ⁇ L, about 50 ⁇ L, about 100 ⁇ L, about 200 ⁇ L, about 300 ⁇ L, about 400 ⁇ L, about 500 ⁇ L, about 600 ⁇ L, about 700 ⁇ L, about 800 ⁇ L, about 900 ⁇ L, about 1 mL, about 5 mL, about 10 mL, about 15 mL, about 20 mL, about 25 mL, about 30 mL, about 35 mL, about 40 mL, about 45 mL, about 50 mL or greater than 50 mL.
- the lysis buffer contains one or more enzymes.
- the one or more enzymes comprise Proteinase K. Proteinase K may be present in the lysis buffer at a concentration of about 0.001 mg/mL, to about 10 mg/mL.
- the concentration of proteinase K in the lysis buffer may be about 0.001 mg/mL, about 0.005 mg/mL, about 0.01 mg/mL, about 0.05 mg/mL, about 0.1 mg/mL, about 0.5 mg/mL, about 1 mg/mL, about 2 mg/mL, about 3 mg/mL, about 4 mg/mL, about 5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL or greater than about 10 mg/mL.
- the one or more enzymes comprise lysozyme to process gram-positive organisms.
- Lysozyme may be present in the lysis buffer at a concentration of about 0.001 mg/mL to about 10 mg/mL.
- the concentration of lysozyme in the lysis buffer may be about 0.001 mg/mL, about 0.005 mg/mL, about 0.01 mg/mL, about 0.05 mg/mL, about 0.1 mg/mL, about 0.5 mg/mL, about 1 mg/mL, about 2 mg/mL, about 3 mg/mL, about 4 mg/mL, about 5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL or greater than about 10 mg/mL.
- the one or more enzymes comprise zymolyase to process yeast.
- Zymolase may be present in the lysis buffer at a concentration of about 0.001 mg/mL to about 10 mg/mL.
- the concentration of zymolase in the lysis buffer may be about 0.001 mg/mL, about 0.005 mg/mL, about 0.01 mg/mL, about 0.05 mg/mL, about 0.1 mg/mL, about 0.5 mg/mL, about 1 mg/mL, about 2 mg/mL, about 3 mg/mL, about 4 mg/mL, about 5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL or greater than about 10 mg/mL.
- Additional enzymes include, without limitation, lyticase, chitinase or gluculase, for e.g., the extraction of nucleic acids from yeast.
- the enzymes may be added in sequence. For example, lysozyme may be added first, followed by an incubation period, and subsequently followed by addition of proteinase K and an additional incubation period.
- the lysis buffer does not contain any enzymes.
- the methods may involve one or more incubation steps.
- the one or more incubation steps may be performed in the lysis buffer in order to ensure complete lysis or disruption of the biological cell or entity and/or to destroy any inhibitory protein that may be present.
- the incubation step may involve holding the biological cell or entity in the lysis buffer for a period of time. In sonic cases, the incubation step involves holding the biological cell or entity in the lysis buffer for a period of time at a specified temperature.
- the biological cell or entity is incubated in the lysis buffer from about 0.01 seconds to about 48 hours,
- the biological cell or entity is incubated in the lysis buffer from about 0.01 seconds, about 0.05 seconds, about 1 second, about 10 seconds, about 30 seconds, about 1 minute, about 5 minutes, about 10 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 48 hours, or greater than 48 hours,
- the biological cell or entity is incubated in the lysis buffer at a specified temperature, for example, from about 4° C.
- the biological cell or entity is incubated in the lysis buffer at a temperature of about 4° C., about 10° C., about 15° C., about 20° C., about 25° C., about 30° C., about 40° C. about 45° C., about 50° C., about 55° C., about 60° C., about 65° C., about 70° C., about 75° C. or greater than 75° C.
- the temperature conditions will be selected so as to promote disruption of the biological cell or entity.
- the lysis buffer contains an enzyme (e.g., Proteinase K)
- the temperature may be selected such that the enzyme retains catalytic activity.
- the temperature may be selected for optimal catalytic activity of the lysis enzyme.
- the temperature may also be selected to neutralize any inhibitory proteins within the sample, but should not destroy or disrupt the integrity of the nucleic acid molecules released therefrom.
- the lysis buffer does not contain any enzymes.
- an additional incubation step may be performed to, for example, destroy or inactivate the one or more interfering components (e.g., Proteinase K) used in the lysis step.
- the subsequent incubation step may be from about 0.01 seconds to about 48 hours.
- the biological cell or entity is incubated in the lysis buffer from about 0.01 seconds, about 0.05 seconds, about 1 second, about 10 seconds, about 30 seconds, about 1 minute, about 5 minutes, about 10 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 48 hours, or greater than 48 hours.
- the additional incubation step may occur at a temperature between about 57° C. and about 100° C.
- the additional incubation step may occur at a temperature of about 57° C., about 58° C., about 59° C., about 60° C., about 61° C., about 62° C., about 63° C., about 64° C., about 65° C., about 66° C., about 67° C., about 68° C., about 69° C., about 70° C., about 71° C., about 72° C., about 73° C., about 74° C., about 75° C., about 76° C., about 77° C., about 78° C., about 79° C., about 80° C., about 81° C., about 82° C., about 83° C., about 84° C., about 85° C., about 86° C., about 87° C., about 88° C., about 89° C., about 90° C., about 91° C., about 92
- the extracted nucleic acids may be utilized at this stage for any downstream processes, without any purification steps.
- the extracted nucleic acid molecules may be used in one or more amplification reactions.
- the extracted nucleic acid molecules may be used in one or more polymerase chain reactions (PCR), in the case where RNA is extracted, the RNA may be reverse transcribed (i.e., using a reverse transcriptase) prior to performing the downstream application. Any known method of PCR may be performed using the extracted nucleic acid molecules provided herein.
- the biological sample can be a tissue sample.
- the tissue sample is a blood sample.
- the biological sample comprises a bodily fluid taken from a subject.
- the bodily fluid comprises one or more cells comprising nucleic acids.
- the one or more cells comprise one or more microbial cells, including, but not limited to, bacteria, archaebacteria, protists, and fungi.
- the biological sample includes one or more virus particles.
- the biological sample comprises one or more microbes that causes a sexually-transmitted disease.
- a sample may comprise a sample from a subject, such as whole blood; blood products; red blood cells; white blood cells; buffy coat; swabs; urine; sputum; saliva; semen; lymphatic fluid; endolymph; perilymph; gastric, juice; bile; mucus; sebum; sweat; tears; vaginal secretion; vomit; feces; breast milk; cerumen; amniotic fluid; cerebrospinal fluid; peritoneal effusions; pleural effusions; biopsy samples; fluid from cysts; synovial fluid; vitreous humor; aqueous humor; bursa fluid; eye washes; eye aspirates; plasma; serum; pulmonary lavage; lung aspirates; animal, including human, tissues, including but not limited to, liver, spleen, kidney, lung, intestine, brain, heart, muscle, pancreas, cell cultures, as well as lysates, extracts, or materials and fractions obtained from the samples described above or any cells and
- a sample may comprise cells of a primary culture or a cell line.
- cell lines include, but are not limited to 293-T human kidney cells, A2870 human ovary cells, A431 human epithelium, B35 rat neuroblastoma cells, BHK-21 hamster kidney cells, BR293 human breast cells, CHO chinese hamster ovary cells, CORL23 human lung cells, HeLa cells, or Jurkat cells.
- the sample may comprise a homogeneous or mixed population of microbes, including one or more of viruses, bacteria, protists, monerans, chromalveolata, archaea, or fungi.
- the biological sample can be a urine sample, a vaginal swab, a cervical swab, an anal swab, or a cheek swab.
- the biological sample can be obtained from a hospital, laboratory, clinical or medical laboratory.
- the sample can be obtained from a subject.
- sample sources include environmental sources, industrial sources, one or more subjects, and one or more populations of microbes.
- environmental sources include, but are not limited to agricultural fields, lakes, rivers, water reservoirs, air vents, walls, roofs, soil samples, plants, and swimming pools.
- industrial sources include, but are not limited to clean rooms, hospitals, food processing areas, food production areas, food stuffs, medical laboratories, pharmacies, and pharmaceutical compounding centers.
- subjects from which polynucleotides may be isolated include multicellular organisms, such as fish, amphibians, reptiles, birds, and mammals.
- mammals examples include primates (e.g., apes, monkeys, gorillas), rodents (e.g., mice, rats), cows, pigs, sheep, horses, dogs, cats, or rabbits.
- rodents e.g., mice, rats
- cows, pigs, sheep, horses, dogs, cats, or rabbits examples include primates (e.g., mice, rats), cows, pigs, sheep, horses, dogs, cats, or rabbits.
- the mammal is a human.
- the sample is from an individual subject.
- the biological sample is provided in a sample buffer.
- the sample buffer comprises bovine serum albumin and/or a detergent.
- the sample buffer comprises about 0.1% to 5% bovine serum albumin.
- the sample buffer comprises about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4%, or 5% bovine serum albumin.
- the sample buffer comprises about 0.1% to 20% detergent.
- the sample buffer comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% detergent.
- the detergent is Tween-20.
- the choice of sample buffer to be used may depend on the intended method. For example the choice of sample buffer may different when a wash step will be used to when a wash step is not used. If a wash step will not be used then the sample buffer may be a buffer suitable for lysis and subsequent PCR reactions.
- Some commercial collection mediums or sample buffers contain chemicals for the preservation of microorganisms for future growth, or chemicals that lyse target organisms such as guanidinium thiocyanate. As such, these collection media are inhibitory to DNA polymerase and must be washed from a sample before PCR via, filtration or similar process. The methods described herein may not require the target organism to be kept in a viable state, or for the sample buffer to be able to lyse the cells.
- Some components which may be found in a sample buffer suitable for use with the methods and devices of this disclosure include: Tris HCL, Tween-80, BSA, Proclin and Antifoam SE-15.
- a sample buffer may have a composition of: 50 mM Tris pH 8.4, Tween-80, 2% (w/v), BSA, 0.25% (w/v), Proclin 300 0.03% (w/v), and Antifoam 0.002% (v/v) made up in purified water.
- Tris 1-ICL is a common buffer for PCR.
- the pH may drop, for example a Tris buffer with pH of 8.4 at a temperature of 25° C. may drop to a pH of about ⁇ 7.4 when heated to about 95° C.
- the range of concentrations could be from 0.1 mM to 1 M.
- the pH range could be from 6 to 10.
- Any other PCR compatible buffer could be used, for example HEPES.
- Tween-80 is a nonionic surfactant and emulsifier that may help to elute target organisms off of a swab.
- the range of concentrations could be from 0.01% (w/v) to 20% (w/v). Any other PCR compatible surfactant and/or emulsifier could be used.
- Proclin 300 is a broad spectrum antimicrobial used as a preservative to ensure a long shelf life of the collection media. It could be used from 0.01% (w/v) to 0.1% (w/v). Many other antimicrobials are known in the art and could be used in a sample buffer.
- Antifoam SE-15 is present to reduce foaming during manufacturing and fluidic movement through the device. It could be used from 0.001% (v/v) to 1% (v/v). Any other antifoam agent could also be used, for example Antifoam 204, Antifoam A, Antifoam B, Antifoam C, or Antifoam Y-30.
- the devices and methods provided herein may be utilized to prepare nucleic acids for downstream applications.
- the downstream applications may be utilized to, e.g., detect the presence or absence of a nucleic acid sequence present in the sample.
- the devices and methods can be utilized to detect the presence or absence of one or more microbes in a biological sample.
- the one or more microbes are pathogens (i.e., disease-causative).
- the one or more microbes are infectious.
- the one or more microbes cause disease in a subject.
- the disease is a sexually transmitted disease.
- the devices and methods can be utilized to detect the presence or absence of nucleic acids associated with one or more bacterial cells in the biological sample.
- one or more bacterial cells are pathogens.
- the one or more bacterial cells are infectious.
- Non-limiting examples of bacterial pathogens that can be detected include Mycobacteria (e.g. M. tuberculosis, M. bovis, M. ovium, M. leprae , and M. africanum ), rickettsia, mycoplasma, chlamydia, and legionella.
- bacterial infections include, but are not limited to, infections caused by Gram positive bacillus (e.g., Listeria, Bacillus such as Bacillus anthracia, Erysipelothrix species), Gram negative bacillus (e.g., Bartonella, Brucella, Campylobacter, Enterobacter, Escherichia, Francisella, Herophilus, Klebsiella, Morganella, Proteus, Providencia, Pseudomonas, Salmonella, Serratia, Shigella, Vibrio and Yersinia species), spirochete bacteria (e.g., Borrelia species including Borrelia burgdorferi that causes Lyme disease), anaerobic bacteria (e.g., Actinomyces and Clostridium species), Gram positive and negative coccal bacteria, Enterococcus species, Streptococcus species, Pneumococcus species, Staphylococcus species, and Neisseria species.
- infectious bacteria include, but are not limited to: Helicobacter pyloris, Legionella pneumophilia, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium kansaii, Mycobacterium gordonae, Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenes (Group A Streptococcus ), Streptococcus agalactiae , (Group B Streptococcus ), Streptococcus viridans, Streptococcus faecalis, Streptococcus bovis, Streptococcus pneumoniae, Haemophilus influenzae, Bacillus antracis, Erysipelothrix rhusiopathiae, Clostridium Enterobacter aerogene
- the devices and methods can be utilized to detect the presence or absence of nucleic acids associated with one or more viruses in the biological sample.
- viruses include the herpes virus (e.g., human cytomegalomous virus (HCMV), herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), varicella zoster virus (VZV), Epstein-Barr virus), influenza.
- HCMV human cytomegalomous virus
- HSV-1 herpes simplex virus 1
- HSV-2 herpes simplex virus 2
- VZV varicella zoster virus
- Epstein-Barr virus Epstein-Barr virus
- influenza e.g., Epstein-Barr virus
- HCVB3 Coxsackievirus B3
- viruses may include, but are not limited to, the hepatitis B virus, HIV, poxvirus, hepadavirus, retrovirus, and RNA viruses such as flavivirus, togavirus, coronavirus, Hepatitis D virus, orthomyxovirus, paramyxovirus, rhabdovirus, bunyavirus, filo virus, Adenovirus, Human herpesvirus, type 8, Human papillomavirus, BK virus, JC virus, Smallpox, Hepatitis B virus, Human bocavirus, Parvovirus B19, Human astrovirus, Norwalk virus, coxsackievirus, hepatitis A virus, poliovirus, rhinovirus, Severe acute respiratory syndrome virus, Hepatitis C virus, yellow fever virus, dengue virus, West Nile virus, Rubella virus, Hepatitis E virus, and Human immunodeficiency virus (HIV).
- flavivirus flavivirus
- togavirus coronavirus
- Hepatitis D virus ortho
- the virus is an enveloped virus.
- enveloped virus examples include, but are not limited to, viruses that are members of the hepadnavirus family, herpesvirus family, iridovirus family, poxvirus family, flavivirus family, togavirus family, retrovirus family, coronavirus family, filovirus family, rhabdovirus family, bunyavirus family, orthomyxovirus family, paramyxovirus family, and arenavirus family.
- HBV Hepadnavirus hepatitis B virus
- woodchuck hepatitis virus woodchuck hepatitis virus
- Hepadnaviridae Hepatitis virus
- duck hepatitis B virus heron hepatitis B virus
- Herpesvirus herpes simplex virus (HSV) types 1 and 2 varicella-zoster virus, cytomegalovirus (CMV), human cytomegalovirus (HCMV), mouse cytomegalovirus (MCMV), guinea pig cytomegalovirus (GPCMV), Epstein-Barr virus (EBV), human herpes virus 6 (HHV variants A and B), human herpes virus 7 (HHV-7), human herpes virus 8 (HHV-8).
- HBV Herpesvirus herpes simplex virus
- CMV cytomegalovirus
- HCMV human cytomegalovirus
- MCMV mouse cytomegalovirus
- GPCMV guinea pig cytomegal
- VEE Venezuelan equine encephalitis
- chikungunya virus Ross River virus, Mayaro virus, Sindbis virus, rubella virus
- Retrovirus human immunodeficiency virus HIV
- HTLV human T cell leukemia virus
- MMTV mouse mammary tumor virus
- RSV Rous sarcoma virus
- lentiviruses Coronavirus, severe acute respiratory syndrome (SARS) virus
- Filovirus Ebola virus Marburg virus
- Metapneumoviruses such as human metapneumovirus (HMPV), Rhabdovirus rabies virus, vesicular stomatitis virus, Bunyavirus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, La Crosse virus, Hanta
- the virus is a non-enveloped virus, examples of which include, but are not limited to, viruses that are members of the parvovirus family, circovirus family, polyoma virus family, papillomavirus family, adenovirus family, iridovirus family, reovirus family, bimavirus family, calicivirus family, and picornavirus family.
- BFDV Beak and Feather Disease virus, chicken anaemia virus, Polyomavirus, simian virus 40 (SV40), JC virus, BK virus, Budgerigar fledgling disease virus, human papillomavirus, bovine papillomavirus (BPV) type 1, cotton tail rabbit papillomavirus, human adenovirus (HAdV-A, HAdV-B, HAdV-C, HAdV-D, HAdV-E, and HAdV-F), fowl adenovirus A, bovine adenovirus D, frog adenovirus, Reovirus, human orbivirus, human cold virus, mammalian orthoreovirus, bluetongue virus, rotavirus A, rotaviruses (groups B to G).
- BFDV Beak and Feather Disease virus, chicken anaemia virus, Polyomavirus, simian virus 40 (SV40), JC virus, BK
- the virus may be phage.
- phages include, but are not limited to T4, T5, ⁇ phage, T7 phage, G4, P1, ⁇ 6, Thermoproteus tenax virus 1, M13, MS2, Q ⁇ , ⁇ X174, ⁇ 29, PZA, ⁇ 15, BS32, B103, M2Y (M2), Nf, GA-1, FWLBc1, FWLBc2, FWLLm3, B4.
- the reference database may comprise sequences for phage that are pathogenic, protective, or both.
- the virus is selected from a member of the Flaviviridae family (e.g., a member of the Flavivirus, Pestivirus, and Hepacivirus genera), which includes the hepatitis C virus, Yellow fever virus; Tick-borne viruses, such as the Gadgets Gully virus, Kadam virus, Kyasanur Forest disease virus, Langat virus, Omsk hemorrhagic fever virus, Powassan virus, Royal Farm virus, Karshi virus, tick-borne encephalitis virus, Neudoerti virus, Sofjin virus, Louping ill virus and the Negishi virus; seabird tick-borne viruses, such as the Meaban virus, Saumarez Reef virus, and the Tyuleniy virus; mosquito-borne viruses, such as the Aroa virus, dengue virus, Kedougou virus, Cacipacore virus, Koutango virus, Japanese encephalitis virus, Murray Valley encephalitis virus, St.
- Tick-borne viruses such as the Gadgets Gully virus, Ka
- the virus is selected from a member of the Arenaviridae family, which includes the Ippy virus, Lassa virus (e.g., the Josiah, LP, or GA391 strain), lymphocytic choriomeningitis virus (LCMV), Mobala virus, Mopeia virus, Amapari virus, Flexal virus, Guanarito virus, Junin virus, Latino virus, Machupo virus, Oliveros virus, Parana virus, Pichinde virus, Pirital virus, Sabia virus, Tacaribe virus, Tamiami virus, Whitewater Arroyo virus, Chapare virus, and Lujo virus.
- Lassa virus e.g., the Josiah, LP, or GA391 strain
- LCMV lymphocytic choriomeningitis virus
- Mobala virus Mopeia virus
- Amapari virus Flexal virus
- Guanarito virus Junin virus
- Latino virus Machupo virus
- Oliveros virus Parana virus
- the virus is selected from a member of the Bunyaviridae family (e.g., a member of the Hantavirus, Nairovirus, Orthobunyavirus , and Phlebovirus genera), which includes the Hantaan virus, Sin Nombre virus, Dugbe virus, Bunyamwera virus, Rift Valley fever virus, La Crosse virus, Punta Toro virus (PTV), California encephalitis virus, and Crimean-Congo hemorrhagic fever (CCHF) virus.
- Bunyaviridae family e.g., a member of the Hantavirus, Nairovirus, Orthobunyavirus , and Phlebovirus genera
- the devices and methods can be utilized to detect the presence or absence of nucleic acids associated with one or more fungi in the biological sample.
- infectious fungal agents include, without limitation Aspergillus, Blastomyces, Coccidioides, Cryptococcus, Histoplasma, Paracoccidioides, Sporothrix , and at least three genera of Zygomycetes .
- the above fungi, as well as many other fungi, can cause disease in pets and companion animals.
- the present teaching is inclusive of substrates that contact animals directly or indirectly.
- organisms that cause disease in animals include Mulassezia furfur, Epidermophpon floccosur, Trichophyton mentagrophytes, Trichophyton rubrum, Trichophyton tonsurans, Trichophyton equinum, Dermatophilus congolensis, Microsporum canis, Microsporu audouinii, Microsporum gypseum, Malassezia ovale, Pseudalleseheria, Seopulartopsis, Scedosporium , and Candida albicans .
- fungal infectious agent examples include, but are not limited to, Aspergillus, Blastomyces dermatitidis, Candida, Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum var. capsulatum, Paracoccidioides brasiliensis, Sporothrix schenckii, Zygomycetes spp., Absidia corymbifera, Rhizomucor pusillus , or Rhizopus arrhizus.
- the devices and methods can be utilized to detect the presence or absence of nucleic acids associated with one or more parasites in the biological sample.
- parasites include Plasmodium, Leishmania, Babesta, Treponema, Borrelia, Trypanosotna, Toxoplasma gondii, Plasniodium falciparum, P. vivax, P. ovale, P. malariae, Trypanosoma spp., or Legionella spp.
- the parasite is Trichomonas vaginalis.
- the biological sample can be an environmental sample comprising medium such as water, soil, air, and the like.
- the biological sample can be a forensic sample (e.g., hair, blood, semen, saliva, etc.).
- the biological sample can comprise an agent used in a bioterrorist attack (e.g., influenza, anthrax, smallpox).
- the biological sample comprises an infectious agent associated with a sexually-transmitted disease (STD) or a sexually-transmitted infection (STI).
- STDs or STIs and associated infectious agents that may be detected with the devices and methods provided herein may include, Bacterial Vaginosis; Chlamydia ( Chlamydia trachomatis ); Genital herpes (herpes virus); Gonorrhea ( Neisseria gonorrhoeae ); Hepatitis B (Hepatitis B virus); Hepatitis C (Hepatitis C virus); Genital Warts, Anal Warts, Cervical Cancer (Human Papillomavirus); Lymphogranuloma venereum ( Chlamydia trachomatis ); Syphilis ( Treponema pallidum ); Trichomoniasis ( Trichomonas vaginalis ); Yeast infection (Candida); and Acquired Immuno
- the devices and methods described herein may demonstrate improved performance when compared with traditional methods.
- the devices and methods may result in the extraction and preparation of nucleic acid molecules suitable for use in a polymerase chain reaction (PCR) in a shorter period of time when compared with other methods.
- the devices and methods may result in the extraction and preparation of nucleic acid molecules suitable for use in a PCR reaction in 20 minutes or less.
- the extraction and preparation of nucleic acid molecules as described herein may be achieved in about 20 minutes, 19 minutes, 18 minutes, 17 minutes, 16 minutes, 15 minutes.
- the extraction and preparation of nucleic acid molecules as described herein is achieved in about 5 minutes or less.
- the method extracts nucleic acid molecules in about 5 minutes or less at a quality sufficient to successfully run a polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- a quality of extracted nucleic acid sufficient to run a polymerase chain reaction refers to the quantity of extracted nucleic acid, the purity of the nucleic acid and the shearing of the nucleic acid (average length of nucleic acid molecules).
- a sufficient quantity of nucleic acid may refer to about 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1 ⁇ g.
- a sufficient quantity may also refer to the concentration of the nucleic acid in the eluted liquid. The concentration of the eluted nucleic acid may be about 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5.
- the nucleic acid produced may comprise nucleic acid fragments with an average length of at least about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more than 1000 base pairs.
- a quality of extracted nucleic acid sufficient to run a polymerase chain reaction may be a sample that produces at least 70% efficiency as determined by a qPCR standard curve.
- the efficiency of the PCR may be between 90-100% ( ⁇ 3.6 ⁇ slope ⁇ 3.3).
- Efficiency of qPCR may be quantified by calculating the cycle difference between a sample and 10-fold dilution of the sample. For example if the efficiency is 100%, the Ct values of a 10 fold dilution of input DNA will be 3.3 cycles apart (there is a 2-fold change for each change in Ct).
- the nucleic acid sample prepared using the devices and methods described herein have similar or improved purity as compared to nucleic acid samples prepared using other methods.
- the purity may be measured, for example, as a ratio of the absorbance at 260 nm and 280 nm A260/A280).
- a nucleic acid samples comprising DNA prepared using the devices and methods may have a A260/A280 ratio of about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0.
- the extracted nucleic acid molecules comprise DNA and the DNA has an A260/A280 ratio of at least 1.5.
- a nucleic acid sample comprising RNA prepared using the devices and methods may have an A260/A280 ratio of about 1.7, about 1.8, about 1.9, about 2.0, about 2.1, or about 2.2.
- the extracted nucleic acid molecules comprise RNA and the RNA has an A260/A280 ratio of at least 1.7.
- Downstream processes such as polymerase chain reaction (PCR) may be sensitive to certain molecules present in a sample.
- PCR polymerase chain reaction
- the presence of one or more lysis reagents e.g., Proteinase K
- the nucleic acid molecules described herein are extracted from the one or more biological cells or entities with a qualify that is sufficient to successfully perform one or more downstream processes.
- the extracted nucleic acid molecules may be of a quality sufficient to successfully perform a PCR.
- the extracted nucleic acid molecules may be of a quality sufficient to perform an amplification reaction on a target nucleic acid molecule present in the extracted nucleic acid molecules to generate amplified target nucleic molecules.
- a positive control may be used (e.g., a biological cell that is known to be positive for the target molecule) to confirm that the extraction process is performed successfully.
- the extracted nucleic acid molecules described herein are generally substantially free of molecules that inhibit downstream processes (e.g., Proteinase K).
- nucleic acid samples may have similar or improved yields as compared to nucleic acid samples prepared using other methods from the same amount of starting material.
- nucleic acid samples prepared using the methods and devices described herein may have about 5%, about 10% about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%. about 99% or greater yields than using other nucleic acid extraction methods from the same amount of starting material.
- 100831 Standard nucleic acid extraction methods may involve the use of centrifuges and vacuums. In some cases, the methods and devices herein do not involve the use of centrifuges or vacuums.
- FIG. 10 is a schematic illustration of a molecular diagnostic test device 1000 (also referred to as a “test device” or “device”, according to an embodiment.
- the schematic illustration describes the primary components of the test device 1000 as shown in FIG. 11 .
- the test device 1000 is an integrated device (i.e., the modules are contained within a single housing) that is suitable for use within a point-of-care setting (e.g., doctor's office, pharmacy or the like), decentralized test facility, or at the user's home.
- a point-of-care setting e.g., doctor's office, pharmacy or the like
- the device 1000 can have a size, shape and/or weight such that the device 1000 can be carried, held, used and/or manipulated in a user's hands (i.e., it can be a “handheld” device).
- a handheld device may have dimensions less than 15 cm ⁇ 15 cm ⁇ 15 cm, or less than 15 cm ⁇ 15 cm ⁇ 10 cm, or less than 12 cm ⁇ 12 cm ⁇ 6 cm .
- the test device 1000 can be a self-contained, single-use device.
- the test device 1000 can be configured with lock-outs or other mechanisms to prevent re-use or attempts to re-use the device.
- the device 1000 can be a CLIA-waived device and/or can operate in accordance with methods that are CLIA waived.
- the device 1000 (and any of the other devices shown and described herein) is configured to be operated in a sufficiently simple manner, and can produce results with sufficient accuracy to pose a limited likelihood of misuse and/or to pose a limited risk of harm if used improperly.
- the device 1000 (and any of the other devices shown and described herein), can be operated by a user with minimal (or no) scientific training, in accordance with methods that require little judgment of the user, and/or in which certain operational steps are easily and/or automatically controlled.
- the molecular diagnostic test device 1000 can be configured for long term storage in a manner that poses a limited likelihood of misuse (spoilage of the reagent(s), expiration of the reagents(s), leakage of the reagent(s), or the like). In some embodiments, the molecular diagnostic test device 1000 is configured to be stored for up to about 36 months, up to about 32 months, up to about 26 months, up to about 24 months, up to about 20 months, up to about 18 months, or any values there between.
- the test device 1000 is configured to manipulate a biological sample S 1 to produce one or more output signals associated with a target cell.
- the device 1000 includes a sample preparation module 1200 , an inactivation module 1300 (also referred to as a lysing module), a fluidic drive (or fluid transfer) module 1400 , a mixing chamber 1500 , an amplification module, a detection module and a power and control module (not shown).
- the test device and certain components therein can be similar to any of the molecular test devices shown and described herein or in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety. Accordingly, a detailed description of certain modules (e.g., the fluidic drive module 1400 ) is not provided herein. A description of each of the modules is provided below.
- FIG. 11 shows a perspective exploded view of the molecular diagnostic test device 1000 .
- the diagnostic test device 1000 includes a housing (including a top portion 1010 and a bottom portion 1030 ), within which the modules described herein are contained. Similarly stated, the housing (including the top portion 1010 and/or the bottom portion 1030 ) surround and/or enclose the modules. As shown, the top housing 1010 defines a detection opening 1011 that is aligned with the detection module 1800 such that the signal produced by and/or on each detection surface of the detection module 1800 is visible through the detection opening 1011 .
- the top housing 1010 and/or the portion of the top housing 1010 surrounding the detection opening 1011 is opaque (or semi-opaque), thereby “framing” or accentuating the detection openings.
- the top housing 1010 can include markings (e.g., thick lines, colors or the like) to highlight the detection opening 1011 .
- the top housing 1010 can include indicia identifying the detection opening to a specific disease (e.g., Chlamydia trachomatis (CT), Neisseria gonorrhea (NG) and Trichomonas vaginalis (TV)) or control.
- CT Chlamydia trachomatis
- NG Neisseria gonorrhea
- TV Trichomonas vaginalis
- the top housing 1010 can include a series of color spots having a range of colors associated with a range of colors that is likely produced by the signals produced during the test. In this manner, the housing design can contribute to reducing the amount of user judgment required to accurately read the test.
- the sample preparation module 1200 includes a sample input module 1170 , a wash module 1210 , an elution module 1260 , a filter assembly 1230 , and various fluidic conduits (e.g., tubes, lines, valves, etc.) connecting the various components.
- the device 1000 also includes the lysing module 1300 (see e.g., the lysing module 2300 shown in FIGS. 13-16 ), which, together with the sample preparation module 1200 , performs the nucleic acid extraction according to any of the methods described herein.
- sample preparation module 1200 and the inactivation module 1300 are described as two separate modules, in other embodiments, the structure and function of the sample preparation module 1200 can be included within or performed by the inactivation module 1300 and vice-versa.
- any of the sample preparation modules, inactivation modules and/or lysing modules described herein can include any of the structure and/or perform any of the functions of the other modules to perform any of the methods of sample preparation or nucleic acid extraction described herein.
- the device 1000 is suitable for use within a point-of-care setting (e.g., doctor's office, pharmacy or the like) or at the user's home, and can receive any suitable biological sample S 1 .
- the biological sample S 1 (and any of the input samples described herein) can be, for example, blood, urine, male urethral specimens, vaginal specimens, cervical swab specimens, and/or nasal swab specimens gathered using a commercially available sample collection kit.
- the sample input module 1170 is disposed within the housing 1010 , and is configured receive a biological sample S 1 containing a biological entity.
- the biological sample S 1 can be any of the sample types described herein, and the biological entity can be any of the entities described herein.
- the sample input module 1170 defines a sample volume 1174 that can be selectively covered by the cap 1152 .
- the cap 1152 can include seals or other locking members such that it can be securely fastened to the lower housing 1030 (or other portions of the device 1000 ) and/or can be closed during shipping, after delivery of a sample thereto, or the like.
- the input port cap 1152 can include an irreversible lock to prevent reuse of the device 1000 and/or the addition of supplemental sample fluids. In this manner, the device 1000 can be suitably used by untrained individuals.
- the wash module 1210 includes a housing that defines a wash volume containing any suitable wash composition.
- the wash module 1210 can include a gaseous first wash composition (e.g., nitrogen, air, or another inert gas) and a liquid second wash composition.
- the wash operation can include an “air purge” of the filter assembly 1230 .
- a gas (or air) wash i.e., the first wash composition
- the amount of liquid constituents from the input sample conveyed to the filter assembly 1230 indicated by the flow S 2 in FIG.
- the filter assembly 1230 will retain the desired sample cells (or organisms) and some amount of residual liquid.
- the filter i.e., an “air wash”
- the amount of residual liquid can be minimized.
- This arrangement can reduce the amount of liquid wash (e.g., the second wash composition) needed to sufficiently prepare the sample particles. Reducing the liquid volume contributes to the reduction size of the device 1000 , and also reduces the likelihood of potentially harmful shearing stress when the liquid wash is flowed through the filter assembly 1230 .
- the sample input module 1170 and any of the sample input modules described herein) and the wash module 1210 (and any of the wash modules described herein) can be actuated by any suitable mechanism to convey the biological sample SI towards the filter assembly 1230 and/or the lysing module 1300 to enable the nucleic acid extraction methods described herein,
- the sample input module 1170 and the wash module 1210 are actuated by the sample actuator (or button) 1050 .
- the sample actuator 1050 is movably coupled to the housing, and is aligned with and can move a piston or plunger (not shown) within the sample volume 1174 when the sample input module 1170 is actuated.
- the sample actuator 1050 is a non-electronic actuator that is manually depressed by a user to actuate the sample input module 1170 .
- the sample actuator 1050 can be an electronic actuator.
- the sample actuator 1050 can include a lock tab (not shown) that is fixedly received within the notch or opening of the housing 1010 to fix the sample actuator 1050 in its second or “actuated” position, as described above. In this manner, the device 1000 cannot be reused after the initial actuation.
- the sample within the sample volume 1174 is conveyed along with the wash solution(s) from the wash module 1210 towards the filter assembly 1230 .
- the flow of the biological sample S 1 towards the filter assembly 1230 is shown by the arrow S 2 in FIG. 10 .
- the filter assembly 1230 is configured to filter and prepare the biological sample S 1 (via the sample input operation and the sample wash operation), and to allow a back-flow elution operation to deliver captured particles from the filter membrane and deliver the eluted volume to lysing module 1300 .
- the filter assembly 1230 can be toggled between two configurations to allow the flow of the biological sample S 1 and wash solution in a first direction (towards the waste reservoir 1205 ), followed by a backflush of the elution reagent and the captured organisms (or cells) in a second direction (as indicated by the arrow S 3 towards the lysing/inactivation module 1300 ).
- the toggling mechanism can be any suitable mechanism, such as those shown and described in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety.
- the filter assembly 1230 can include any suitable filter membrane that captures the target organism/entity while allowing the bulk of the liquid within the biological sample S 1 , the first wash composition, and the second wash composition to flow therethrough and into the waste tank 1205 .
- the filter membrane 1254 (and any of the filter membranes described herein) can be any suitable membrane and or combination of membranes as described herein.
- the filter membrane 1254 is a woven nylon filter membrane with a pore size of about 1 ⁇ m (e.g., 0.8 ⁇ m, 1.0 ⁇ m, 1.2 ⁇ m) enclosed between various plates of the filter assembly 1230 such that there is minimal dead volume.
- the elution module (or assembly) 1260 of the sample preparation module 1200 is contained within the housing, and defines an elution volume within which an elution composition is stored.
- the elution composition can be any of the elution compositions described herein.
- the elution composition can include proteinase which allows for the release of any bound cells and/or nucleic acid molecules (e.g., DNA) from the filter membrane.
- the output from the elution module 1260 can be selectively placed in fluid communication with the filter assembly 1230 . when the filter assembly is toggled into its second (or backflow) configuration.
- the elution module 1230 can include any suitable flow control devices, such as check valves, duck-bill valves, or the like to prevent flow back towards and/or into the elution volume.
- the elution module 1210 is actuated by the elution actuator (or button) 1070 (see FIG. 1 ).
- the reagent actuator 1070 is movably coupled to the lower housing 1030 , and can exert force on a piston or other portion of the elution module 1210 to convey the elution composition back through the filter and towards the lysing module 1300 , as shown by the arrow S 3 .
- the elution actuator 1070 further includes a lock tab or other structure that is fixedly received within the notch or opening of the housing to fix the elution actuator 1070 in its second or “actuated” position. In this manner, the device 1000 cannot be reused after the actuation of the elution actuator.
- the filter assembly 1230 recovers the target organisms with a certain efficiency, from a given starting volume.
- the wash operation then removes undesired material, without removing the target organisms (which stay present on the filter membrane).
- the elution operation then removes the target organism from the filter membrane, diluting the total amount of captured organisms in the volume of the elution solution, thus comprising the eluent.
- a further dilution can be achieved, if desired, by mixing the eluent solution with another reagent after the initial sample preparation. Given a known volume of eluent, and a known volume of diluent, a correct dilution factor can be achieved, through to maintain the reliability of the system very high dilution factors are avoided.
- the elution solution and the captured cells and/or organisms are conveyed during the elution operation back through the filter assembly 1230 , and to the inactivation module (or lysing module) 1300 .
- the inactivation module 1300 is configured to be fluidically coupled to and receive the eluted sample S 3 from the sample preparation module 1200 .
- the inactivation module 1300 is configured for lysis of the received input fluid.
- the inactivation module 1300 is configured for de-activating the enzymes present in input fluid after lysis occurs.
- the inactivation module 1300 is configured for preventing cross-contamination between the output fluid and the input fluid.
- the inactivation module 1300 can include any of the inactivation (or lysing) modules as described herein, including the lysing module 3300 and the lysing module 4300 described herein,
- the mixing module 1500 mixes the output of inactivation module 1300 with the reagents to conduct a successful amplification reaction.
- the mixing module 1500 is configured to reconstitute the reagent in a predetermined input volume, while ensuring even local concentrations of reagents in the entirety of the volume.
- the mixing chamber module 1500 is configured to produce and/or convey a sufficient volume of liquid for the amplification module 1600 to provide sufficient volume output to the detection module 1800 .
- the mixing module 1500 can be any suitable mixing module, such as those shown and described in international Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety.
- the fluidic drive (or transfer) module 1400 can be a pump or series of pumps configured to produce a pressure differential and/or flow of the solutions within the diagnostic test device 1000 .
- the fluid transfer module 1400 is configured to generate fluid pressure, fluid flow and/or otherwise convey the biological sample S 1 , and the reagents through the various modules of the device 1000 .
- the fluid transfer module 1400 is configured to contact and/or receive the sample flow therein.
- the device 1000 is specifically configured for a single-use to eliminate the likelihood that contamination of the fluid transfer module 1400 and/or the sample preparation module 1200 will become contaminated from previous runs, thereby negatively impacting the accuracy of the results.
- the fluid transfer module 1500 can be any suitable fluid transfer module, such as those shown and described in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety.
- the amplification module 1600 includes a flow member 1610 and a heater 1630 .
- the flow member 1610 can be any suitable flow member that defines a volume or a series of volumes within which the that prepared solution S 3 can flow and/or be maintained to amplify the target nucleic acid molecules within the solution S 3 .
- the heater 1630 can be any suitable heater or group of heaters coupled to the flow member 1610 that can heat the prepared solution within the flow member 1610 to perform any of the amplification operations as described herein.
- the amplification module 1600 (or any of the amplification modules described herein) can be similar to the amplification modules shown and described in U.S. Patent Application No. 15/494,145, entitled “Printed Circuit Board Heater for an Amplification Module,” which is incorporated herein by reference in its entirety.
- the amplification module 1600 (or any of the amplification modules described herein) can be similar to the amplification modules shown and described in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety.
- the flow member 1610 defines a single volume within which the prepared solution is maintained and heated to amplify the nucleic acid molecules within the prepared solution.
- the flow member 1610 can define a “switchback” or serpentine flow path through which the prepared solution flows.
- the flow member 1610 defines a flow path that is curved such that the flow path intersects the heater 1630 at multiple locations. In this manner, the amplification module 1600 can perform a “flow through” amplification reaction where the prepared solution flows through multiple different temperature regions.
- the flow member 1610 (and any of the flow members described herein) can be constructed from any suitable material and can have any suitable dimensions to facilitate the desired amplification performance for the desired volume of sample.
- the amplification module 1600 (and any of the amplification modules described herein) can perform 1000 ⁇ or greater amplification in a time of less than 15 minutes.
- the flow member 1610 (and any of the flow members described herein) is constructed from at least one of a cyclic olefin copolymer or a graphite-based material. Such materials facilitate the desired heat transfer properties into the flow path.
- the flow member 1610 (and any of the flow members described herein) can have a thickness of less than about 0.5 mm. In some embodiments, the flow member 1610 (and any of the flow members described herein) can have a volume about 150 microliters or greater, and the flow can be such that at least 10 microliters of sample is amplified. In other embodiments, at least 20 microliters of sample are amplified by the methods and devices described herein. In other embodiments, at least 30 microliters of sample are amplified by the methods and devices described herein. In yet other embodiments, at least 50 microliters of sample are amplified by the methods and devices described herein.
- the heater 1630 can be any suitable heater or collection of heaters that can perform the functions described herein to amplify the prepared solution.
- the heater 1630 can establish multiple temperature zones through which the prepared solution flows and/or can define a desired number of amplification cycles to ensure the desired test sensitivity (e.g., at least 30 cycles, at least 34 cycles, at least 36 cycles, at least 38 cycles, or at least 40 cycles).
- the heater 1630 (and any of the heaters described herein) can be of any suitable design.
- the heater 1630 can be a resistance heater, a thermoelectric device (e.g. a Peltier device), or the like.
- the heater 1630 can be one or more linear “strip heaters” arranged such that the flow path crosses the heaters at multiple different points. In other embodiments, the heater 1630 can be one or more curved heaters having a geometry that corresponds to that of the flow member 1610 to produce multiple different temperature zones in the flow path.
- the amplification module 1600 can perform any suitable thermal reaction to amplify nucleic acids within the solution.
- the amplification module 1600 (and any of the amplification modules described herein) can perform any suitable type of isothermal amplification process, including, for example, Loop Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA), which can be useful to detect target RNA molecules, Strand Displacement Amplification (SDA), Multiple Displacement Amplification (MDA), Ramification Amplification Method (RAM), or any other type of isothermal process
- LAMP Loop Mediated Isothermal Amplification
- NASBA Nucleic Acid Sequence Based Amplification
- SDA Strand Displacement Amplification
- MDA Multiple Displacement Amplification
- RAM Ramification Amplification Method
- the detection methods enabled by the device 1000 include sequential delivery of the detection reagents and other substances within the device 1000 .
- the device 1000 is configured to be an “off-the-shelf” product for use in a point-of-care location (or other decentralized location), and is thus configured for long-term storage.
- the reagent storage module 1700 is configured for simple, non-empirical steps for the user to remove the reagents from their long-term storage containers, and for removing all the reagents from their storage containers using a single user action.
- the reagent storage module 1700 and the rotary selection valve 1340 are configured for allowing the reagents to be used in the detection module 1800 , one at a time, without user intervention.
- the device 1000 is configured such that the last step of the initial user operation (i.e., the depressing of the reagent actuator 1080 ) results in dispensing the stored reagents.
- This action crushes and/or opens the sealed reagent containers present in the assembly and relocates the liquid for delivery.
- the rotary venting selector valve 1340 allows the reagent module 1700 to be vented for this step, and thus allows for opening of the reagent containers, but closes the vents to the tanks once this process is concluded.
- the reagents remain in the reagent module 1700 until needed in the detection module 1800 .
- the rotary valve 1340 opens the appropriate vent path to the reagent module 1700 , and the fluidic drive module 1400 applies vacuum to the output port of the reagent module 1700 (via the detection module 1800 ), thus conveying the reagents from the reagent module 1700 .
- the reagent module 1700 and the valve 1340 can be similar to the reagent modules and valves shown and described in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety.
- the detection module 1800 is configured to receive output from the amplification module 1600 and reagents from the reagent module 1700 to produce a colorimetric change to indicate presence or absence of target organism in the initial input sample.
- the detection module 1800 also produces a colorimetric signal to indicate the general correct operation of the test (positive control and negative control). In some embodiments, color change induced by the reaction is easy to read and binary, with no requirement to interpret shade or hue.
- the detection module 1800 can be similar to the detection modules shown and described in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety.
- a device comprising: (a) an input port, configured to receive the biological sample comprising one or more biological cells or biological entities; (b) a filter assembly comprising a filter configured to capture the one or more biological cells or biological entities, wherein the input port is configured to relay the biological sample to the filter assembly; (c) one or more reservoirs comprising a wash solution, a lysis solution, or both, operably coupled to the filter assembly; (d) a waste chamber, operably coupled to the filter assembly and configured to receive waste from the filter assembly; and (e) an elution chamber, operably coupled to the filter assembly and configured to receive an eluent from the filter assembly.
- FIG. 12 depicts an example of a sample preparation device (or module) 2200 that may be used to perform the methods provided herein.
- the sample preparation module 2200 can be included in any of the molecular diagnostic test devices described herein, including the device 1000 described above. It should be understood that the invention is not limited to a particular arrangement or configuration of the sample preparation device, and any suitable arrangement or configuration may be used.
- the sample preparation device 2200 comprises an input port 2170 .
- the input port is configured to receive a sample (e.g., biological sample).
- the input port 2170 may be configured to receive about 50 ⁇ L to about 20 mL of a liquid sample.
- the input port 2170 may comprise a reservoir or chamber for holding or storing the sample.
- the input port 2170 may comprise a cap or lid (similar to the lid 1152 described above) that can be placed over the input port to contain the sample in the reservoir or chamber.
- the input port 2170 may be operably coupled to a filter assembly 2230 .
- the sample may be relayed (e.g., pushed or flowed) to the filter assembly 2230 in any manner as described herein.
- the filter assembly 2230 may contain one or more filter membranes for capturing biological cells or entities on the filter.
- the filter assembly 2230 (or any of the filter assemblies described herein) contains at least two filter membranes, one with a larger pore size and one with a smaller pore size.
- the two filter membranes may be arranged such that the sample first passes through the membrane with the larger pore size and then the membrane with the smaller pore size.
- the filter membrane may be of any suitable material as described herein, non-limiting examples including nylon, cellulose, polyethersulfone (PES), polyvinylidene difluoride (PVDF), polycarbonate, borosilicate glass fiber and the like.
- the filter membrane is nylon.
- the filter membrane has an average pore size of about 0.2 ⁇ m to about 20 ⁇ m.
- the filter membrane may have an average pore size of about 0.2 ⁇ m, about 0.5 ⁇ m, about 1 ⁇ m, about 2 ⁇ m, about 3 ⁇ m, about 4 ⁇ m, about 5 ⁇ m, about 6 ⁇ m, about 7 ⁇ m, about 8 ⁇ m, about 9 ⁇ m, about 10 ⁇ m, about 11 ⁇ m , about 12 ⁇ m, about 13 ⁇ m, about 14 ⁇ m, about 15 ⁇ m, about 16 ⁇ m, about 17 ⁇ m, about 18 ⁇ m, about 19 ⁇ m, about 20 ⁇ m, or greater than 20 ⁇ m.
- the surface of the filter membrane may be chemically treated or coated in such a way as to improve the binding of a biological cell or entity to the membrane,
- the biological cells or entities may be captured on the membrane while the majority of the liquid (“flow-through”) is flowed through the filter membrane.
- the flow-through is substantially devoid of biological cells or entities.
- the flow-through is disposed of by relaying the flow-through to one or more waste chambers operably coupled to the filter assembly. In other cases, the flow-through is relayed to a collection chamber for further downstream processing.
- the sample preparation device 2200 further comprises one or more chambers 2210 or reservoirs for housing a wash solution
- the one or more chambers or reservoirs (also referred to as wash modules) housing the wash solution may be operably coupled to the filter assembly such that actuation of the wash chamber or reservoir 2210 relays the wash solution to the filter assembly 2230 .
- the wash solution is provided as a lyophilized pellet or bead that sits within the chamber or reservoir. The lyophilized pellet or bead can be reconstituted in one or more solutions.
- the wash solution may be flowed through the filter assembly 2230 and the majority of the liquid can be collected in the one or more waste chambers 2205 .
- wash solutions suitable for use with the sample preparation device have been described above.
- the sample preparation device further comprises one or more chambers or reservoirs for housing a lysis solution.
- the chamber or reservoir housing the lysis solution may be operably coupled to the filter assembly such that actuation of the chamber or reservoir relays the lysis solution to the filter assembly.
- the lysis solution may be flowed through the filter assembly.
- the lysis solution may cause the lysis or disruption of the biological cells or entities on the filter membrane.
- the reagents of the lysis solution are provided as a lyophilized pellet or bead that sits within the chamber or reservoir (e.g., within a lysing module, similar to the lysing modules 1300 , 3300 and 4300 described herein).
- the lyophilized pellet or bead can be reconstituted in one or more solutions.
- the lysis enzyme is stored separately as a lyophilized bead or pellet within the device.
- the lyophilized lysis enzyme may be reconstituted in the lysis buffer prior to addition to the cells.
- the cells are eluted from the filter membrane and relayed into the elution chamber 2260 which contains the lyophilized lysis enzyme, thereby reconstituting the enzyme.
- the enzyme is stable in the device at ambient temperatures for long periods of time.
- the enzyme may be stable in the device at ambient temperature for at least one day, at least two days, at least three days, at least four days, at least five days, at least six days, at least one week, at least two weeks, at least three weeks, at least four weeks, at least a month, at least two months, at least three months, at least four months, at least five months, at least six months, at least seven months, at least eight months, at least nine months, at least ten months, at least eleven months, at least one year, at least two years, at least three years, at least four years, at least five years, at least six years, at least seven years, at least eight years, at least nine years, at least ten years or longer.
- the lysis solution containing the lysed cells (“eluent”) may be collected in an elution chamber.
- the lysis solution may be back-flowed through the filter assembly.
- the biological cells or entities on the filter membrane may be pushed or washed from the membrane and collected in an elution chamber with the lysis solution.
- the cells or entities (or lysed or otherwise disrupted cells or entities) diluted in the lysis solution may be referred to as the “eluent.”
- the sample preparation device 2200 may further comprise one or more heating modules (not shown).
- the one or more heating modules may be operably coupled to the elution chamber 2260 .
- the one or more heating modules may heat the elution chamber to a temperature sufficient for lysis of the biological cells or entities to occur.
- the lysis solution comprises one or more enzymes (e.g., Proteinase K).
- the one or more heating modules heats the elution chamber to a temperature sufficient for optimal performance of the lysis enzyme.
- the heating module heats the elution chamber (and the fluid contained therein) to a temperature of about 4° C., about 10° C., about 15° C., about 20° C., about 25° C., about 30° C., about 40° C., about 45° C., about 50° C., about 55° C., about 60° C., about 65° C., about 70° C. about 75° C. or greater than 75° C.
- the sample preparation device 2200 and/or any of the molecular diagnostic devices described herein further comprises an inactivation chamber (also referred to as an inactivation module or a lysing module).
- the inactivation chamber may be operably coupled to the elution chamber.
- the eluent may be relayed from the elution chamber to the inactivation chamber.
- the elution chamber and the inactivation chamber are the same chamber and are coupled to a heating element that can heat the chamber to an optimal lysis temperature, and can further heat the chamber to an optimal inactivation temperature (e.g., from about 56° C. to about 95° C.).
- the inactivation chamber comprises a chamber body 3310 , a bottom lid 3318 , and a heater 3330 .
- the chamber body 3310 may defines an input port 3312 , a holding tank (or first volume) 3311 , a permanent vent 3314 , an inactivation segment (or second volume) 3321 , and an output port 3313 .
- the input port 3312 may be configured to receive the eluent from the elution chamber and/or directly from a filter assembly (e.g., the filter assembly 1230 ).
- the input port 3312 can be fluidically coupled to a sample input module without the biological input being conveyed through a filter.
- the eluent may flow into the inactivation chamber (or lysing module 3300 ) and be collected in the holding tank 3311 .
- the holding tank may have a capacity of about 1 ⁇ L to about 100 mL, about 100 ⁇ L, to about 10 mL, about 300 ⁇ L to 1 mL, or about 300 ⁇ L, to about 650 ⁇ L.
- the holding tank may be used to lyse the sample.
- the eluent containing the target organisms can be heated by the heater 3330 to maintain the eluent at or above a target lysing temperature.
- the heater 3330 can be coupled to the chamber body 3310 and/or the bottom lid 3318 such that the heater 3330 can convey thermal energy into the lysing module 3300 to produce a lysing temperature zone within the holding tank (or first volume) 3311 .
- the lysing temperature zone can maintain the eluent at any of the temperatures and for any of the time periods described herein.
- the vent 3314 may be a hole which allows air to flow into or out of the lysing module 3300 (including the first volume 3311 and the second volume 3321 ) as sample is brought in or out.
- the vent 3314 can also relieve pressure within either of the first volume 3311 or the second volume 3321 when the eluent is heated.
- the lysing module 3300 can have an active vent,
- the lysing module 3300 can include a valve that controls the venting of pressure and/or air from within the lysing module 3300 .
- the eluent may flow from the holding tank 3311 through the inactivation segment of the lysing module 3300 . More specifically, the holding tank 3311 is in fluid communication with the inactivation segment 3321 such that when a pressure gradient is applied across the input port 3312 and the output port 3313 , the eluent can flow from the holding tank 3311 (first volume) through the inactivation segment 3321 (second volume).
- the pressure gradient can be applied by any suitable mechanism, such as for example, a pump (e.g., the fluidic drive module 1400 ).
- the inactivation segment 3321 may be a small, shallow channel that allows efficient and rapid heating of the eluent as it leaves the holding tank.
- the inactivation segment 3321 is configured in a serpentine pattern.
- the serpentine pattern may allow for rapid inactivation of the lysis enzymes in the eluent.
- the eluent after being flowed through the inactivation segment, may be flowed into the output port 3313 to be collected.
- the volume of liquid passed through the heated channel could be from about 1 ⁇ L to about 100 mL, about 10 ⁇ L to about 10 mL, about 100 ⁇ L to about 5 mL, or about 250 ⁇ L to about 750 ⁇ L.
- the inactivation module 3300 may be in contact with a heating element 3330 , which can be, for example, a printed circuit board (PCB) heater.
- the heating element 3330 may function to heat the eluent as it flows through the inactivation segment at a high temperature sufficient to inactivate the one or more lysis enzymes contained within the eluent.
- the heating element may heat the eluent to about 57° C., about 58° C., about 59° C., about 60° C., about 61° C., about 62° C., about 63° C., about 64° C., about 65° C., about 66° C., about 67° C., about 68° C., about 69° C., about 70° C., about 71° C., about 72° C., about 73° C., about 74° C., about 75° C., about 76° C., about 77′′ C, about 78° C., about 79′′ C, about 80° C., about 81′′ C, about 82° C., about 83° C., about 84° C.
- the lysis enzymes as well as any other enzymes present can be deactivated.
- the sample can be heated to about 95 C for about 3 minutes.
- the serpentine path 3321 may be preceded by a check valve (not shown) to maintain a back pressure such that fluid does not enter the serpentine path 3321 before the desired temperature has been achieved.
- the serpentine area may be preheated to the desired temperature (50° C. to 99° C. or more) before fluid is drawn through the serpentine channel. If fluid were to flow into the serpentine channel prematurely without controlled flow, large bubbles may form in the channel as the heater warms up which could result in portions of the fluid to pass through the channel without receiving the proper temperature treatment.
- a certain amount of “cracking pressure” must be achieved. If the holding tank of the inactivation chamber is well vented from a vent port, the liquid that is placed into the holding tank will not flow into the serpentine channel due to the cracking pressure of the check valve at the exit of the serpentine channel.
- the cracking pressure may be from 0.05 to 50 psi.
- the check valves used may have a cracking pressure of approximately 0.5 psi.
- the lysing module 3300 and/or the formulation of the input solution can collectively reduce the likelihood that the liquid portion of the input solution will boil at a temperature of 99 degrees Celsius or higher, 98 degrees Celsius or higher, 96 degrees Celsius or higher, 94 degrees Celsius or higher, 92 degrees Celsius or higher, 90 degrees Celsius or higher, or 88 degrees Celsius or higher.
- the input solution can include salts and/or sugars to raise the boiling temperature of the input solution.
- the lysing module 3300 can include one or more vent openings into either the first volume 3311 or the second volume 3321 or both (to limit pressure build-up during heating).
- the output from the lysing module 3300 can be conveyed into an (e.g., the amplification module 1600 or any other amplification modules described herein). Similarly stated, the output from the lysing module 3300 , which contains the extracted nucleic acid molecules, can be conveyed to an amplification module.
- the amplification module can then perform a thermal reaction (e.g., an amplification reaction) on the prepared solution containing target nucleic acid mixed with required reagents.
- the amplification module is configured to conduct rapid amplification of an input target.
- the amplification module is configured to generate an output copy number that reaches or exceeds the threshold of the sensitivity of an associated detection module (e.g., the detection module 1800 ).
- FIGS. 17-22 show various views of a lysing module 4300 (also referred to as an inactivation module), according to an embodiment.
- the lysing module 4300 includes a chamber body 4310 , a bottom lid 4318 , a heater 4330 , and an electrode assembly.
- the chamber body 4310 and the bottom lid 4318 can be referred to as a flow member.
- the flow member is shown as being constructed from two pieces (the body 4310 and the bottom lid 4318 ) that are coupled together, in other embodiments, the flow member can be monolithically constructed.
- the chamber body 4310 and the bottom lid 4318 define an input port 4312 , a first (or holding) volume 4311 , a vent 4314 , a second (or inactivation) volume 4321 , and an output port 4313 .
- the input port 4312 can receive the eluent from the elution chamber and/or directly from a filter assembly (e.g., the filter assembly 1230 ).
- the input port 4312 can be fluidically coupled to a sample input module without the biological input being conveyed through a filter.
- the eluent can flow into the lysing module 4300 and be collected in the holding volume 4311 .
- the sample can be lysed within the holding volume 4311 .
- the eluent containing the target organisms can be heated by the heater 4330 to maintain the eluent at or above a target lysing temperature.
- the heater 4330 can be coupled to the chamber body 4310 and/or the bottom lid 4318 such that the heater 4330 can convey thermal energy into the lysing module 4300 to produce a lysing temperature zone within the holding volume 4311 .
- the lysing temperature zone can maintain the eluent at any of the temperatures and for any of the time periods described herein.
- the vent opening 4314 is in fluid communication with the first volume 4311 , and thus allows air to flow into or out of the lysing module 4300 (including the first volume 4311 and the second volume 4321 ) as sample is conveyed into and/or out of the lysing module 4300 .
- the vent 4314 can also relieve pressure within either of the first volume 4311 or the second volume 4321 when the eluent is heated.
- the lysing module 4300 can have an active vent.
- the lysing module 4300 (or any of the lysing modules described herein) can include a valve that controls the venting of pressure and/or air from within the lysing module 4300 .
- the first volume 4311 is in fluid communication with the second volume 4322 .
- the eluent can flow from the first (or holding) volume 4311 through the second (or inactivation) volume 4321 of the lysing module 4300 .
- the pressure gradient can be applied by any suitable mechanism, such as for example, a pump (e.g., the fluidic drive module 1400 ).
- the second volume 4321 is a serpentine channel that provides a high surface area to volume ratio.
- the eluent after being flowed through the inactivation segment, may be flowed into the output port 4313 to be collected and/or conveyed to an amplification module (not shown).
- the flow member is in contact with a heating element 4330 , which can be, for example, a printed circuit board (PCB) heater.
- the heating element 4330 may function to heat the eluent as it flows through the second volume 4311 at a high temperature sufficient to inactivate the one or more lysis enzymes contained within the eluent.
- the heating element may heat the eluent to about 57° C., about 58° C., about 59° C., about 60° C., about 61° C., about 62° C., about 63° C., about 64° C., about 65° C., about 66° C., about 67° C., about 68° C., about 69° C., about 70° C., about 71° C., about 72° C., about 73° C., about 74° C., about 75° C., about 76° C., about 77° C., about 78° C., about 79° C., about 80° C., about 81° C., about 82° C., about 83° C., about 84° C., about 85° C., about 86° C., about 87° C., about 88° C., about 89° C., about 90° C., about 91° C., about 92°
- the lysis enzymes as well as any other enzymes present can be deactivated.
- the sample can be heated to about 95 C for about 4 minutes.
- the heater on the PCB 4330 is specifically designed to heat the serpentine portion of the lysing module 4300 (i.e., the second volume 4321 ) while not heating the holding volume 4311 . Because the lid 4318 of the lysing module 4300 is thick, the heater surface may be heated well above the desired temperature of the fluid. Since the electrodes 1971 , 1972 (described in more detail below) are thermally conductive and come into direct contact with the fluid, the fluid surrounding the electrodes 1971 , 1972 will experience the same temperature as the heater surface, which may cause evaporation.
- a slot may be cut in the PCB 4330 to isolate the heater from the portion of the PCB adjacent and/or in contact with the holding volume 4311 .
- the heater 4330 can include a series of slots and/or openings as described in U.S. Patent Application No. 15/494,145, entitled “Printed Circuit Board Heater for an Amplification Module,” which is incorporated herein by reference in its entirety.
- the heating element of the heater 4330 is located on an internal layer so the top copper pour (not shown) can be used as a heat spreader to minimize temperature variation along the serpentine path.
- the six wires soldered to the PCB 4330 may remove heat from the surrounding area, creating temperature gradients across the heater surface. To minimize this effect, wires may be soldered on both sides of the heater surface so the temperature roll off is symmetrical.
- the lysing module 4300 can determine whether there is liquid in the first volume 4311 and/or the second volume 4321 . Specifically, the lysing module 4300 includes electrical probes to determine electrical resistance of the fluid within the first volume.
- the molecular diagnostic device e.g., the device 1000
- the molecular diagnostic device can include an electronic controller configured to determine when the user has actuated the elution module (e.g., by pressing an elution actuator, similar to the button 1070 described above) by detecting the presence of liquid in the first volume 4311 . In this manner, the introduction of liquid into the first volume 4311 can trigger the start of the device.
- the control system and/or the lysing module 4300 includes two electrodes 4971 , 4972 inside the first volume 4311 .
- the electrodes 4971 , 4972 are connected to circuitry (e.g., a controller, not shown) that detects a resistance change between the two electrodes 4971 , 4972 .
- Fluid may be reliably detected between the electrodes 4971 , 4972 due to the high gain of the circuit, which may easily differentiate between an open circuit condition (no fluid) and a non-negligible resistance across the electrodes 4971 , 4972 (fluid detected).
- Use of a sample matrix with high salt concentration increases the conductivity of the fluid, which may make the fluid easily detectable even with variation across samples.
- the electrodes 4971 , 4972 and the circuitry are designed to detect fluid without impacting the biological processes that take place in the device.
- the electrodes 4971 , 4972 are specifically chosen so as not inhibit PCR reactions.
- the electrodes 4971 , 4972 are gold plated.
- Both DNA and cells have a net charge so they may migrate in the presence of an electric field. Because the resistance change between the electrodes 4971 , 4972 is determined by measuring a change in electric potential, precautions may be taken to minimize the impact of this electromotive force. For example, once fluid is detected voltage may be removed from the electrodes 4971 , 4972 and they may be electrically shorted together. This ensures there is no potential difference between the electrodes 4971 , 4972 and the charged particles (DNA, cells, salts, etc.) will not bind to the electrodes, which would prevent them from entering the amplification module (not shown).
- the output from the lysing module 4300 can be conveyed into an (e.g., the amplification module 1600 or any other amplification modules described herein). Similarly stated, the output from the lysing module 4300 , which contains the extracted nucleic acid molecules, can be conveyed to an amplification module.
- the amplification module can then perform a thermal reaction (e.g., an amplification reaction) on the prepared solution containing target nucleic acid mixed with required reagents.
- the amplification module is configured to conduct rapid amplification of an input target.
- the amplification module is configured to generate an output copy number that reaches or exceeds the threshold of the sensitivity of an associated detection module (e.g., the detection module 1800 ).
- a sample preparation device need not include a filter or filter assembly.
- the sample input may be directly linked to an inactivation chamber, as shown schematically in FIG. 23 .
- Advantages of a device without a filter assembly include lower pressures in the device, no risk of breaking a filter, fewer parts, fewer reagents required, higher recovery of target organisms from the clinical sample matrix and higher recovery of DNA from target organisms.
- FIG. 23 shows a portion of a molecular test device 5000 that includes a sample input module 5170 and an inactivation (or lysing) module 5300 .
- the device 5000 can be similar to the device 1000 described above, and can include an amplification module, a detection module or the like. In this case, the device 5000 differs from the device 1000 in that the sample is flowed from the input module 5170 into the holding tank of the inactivation module 5300 .
- the sample may be lysed either in the holding tank 5311 or in the inactivation segment 5321 . In this case the sample may be lysed by heating without need for a specialized lysis buffer or lysis enzymes. Any proteases or nucleases released from the cells of the sample will be inactivated by heating.
- a sample may be flowed into the holding tank and held until the inactivation segment 5321 reaches a se temperature (for example greater than 90 C) and then flowed through the inactivation segment.
- a se temperature for example greater than 90 C
- the sample is rapidly heated to 95 C causing the cells in the sample to lyse and proteins from within the cells to be inactivated.
- the housing 6010 can be any structure within which the sample input module 6170 , the lysing module 6300 , and the amplification module 6600 are contained, in some embodiments, the test device 6000 can have a size, shape and/or weight such that the device can be carried, held, used and/or manipulated in a user's hands (i.e., it can be a “handheld” device). In other embodiments, the test device 6000 can be a self-contained., single-use device of the types shown and described herein (e.g., the device 1000 ) or in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety.
- the sample input module 6170 is disposed within the housing 6010 , and is configured receive a biological sample Si containing a biological entity.
- the biological sample S 1 can be any of the sample types described herein, and the biological entity can be any of the entities described herein.
- the sample input module 6170 defines a sample volume 6174 , and includes a piston 6180 that is movably disposed within the sample volume 6174 . In use the biological sample S 1 can be conveyed into the sample volume 6174 by any suitable mechanism, such as, for example, via a pipette, a dropper, or the like.
- the sample input module 6170 (and any of the sample input modules described herein) can be actuated by any suitable mechanism to convey the biological sample S 1 towards the lysing module 6300 to enable the nucleic acid extraction methods described herein.
- the sample input module 6170 is actuated by the sample actuator (or button) 6050 .
- the sample actuator 6050 is movably coupled to the housing 6010 , and is aligned with and can move the piston 6180 when the sample input module 6170 is actuated.
- the sample actuator 6050 is a non-electronic actuator that is manually depressed by a user to actuate the sample input module 6170 . In other embodiments, however, the sample actuator 6050 can be an electronic actuator.
- the sample actuator 6050 can include a lock tab (not shown) that is fixedly received within the notch or opening of the housing 6010 to fix the sample actuator 6050 in its second or “actuated” position, as described above. In this manner, the device 6000 cannot be reused after the initial actuation.
- the piston 6180 is moved downward within the sample volume 6174 , as shown by the arrow AA, the sample within the sample volume 6174 is conveyed towards the lysing module 6300 .
- the flow of the biological sample S 1 towards the lysing module 6300 is shown by the arrow S 2 in FIG. 24 .
- the lysing module 6300 (also referred to as the inactivation module), which can be a portion of a sample preparation module, is configured to process the biological sample S 1 to facilitate detection of an organism therein that is associated with a disease. Specifically, the lysing module 6300 is configured to concentrate and lyse cells in the biological sample S 1 , thereby allowing subsequent extraction of a nucleic acid to facilitate amplification (e.g., via the amplification module 6600 ) and/or detection (e.g., via a detection module, not shown).
- amplification e.g., via the amplification module 6600
- detection e.g., via a detection module, not shown.
- the processed/lysed sample (e.g., the sample S 3 ) is pushed and/or otherwise transferred from the lysing module 6300 to other modules within the device 6000 (e.g., the amplification module 6600 ).
- the device 6000 is suitable for use within a point-of-care setting (e.g., doctor's office, pharmacy or the like) or at the user's home, and can receive any suitable biological sample S 1 .
- the lysing module includes a flow member 6310 and a heater 6330 .
- the flow member 6310 includes an input port 6312 and an output port 6313 , and defines a first volume 6311 and a second volume 6321 .
- the first volume 6311 can receive an input solution (identified as S 2 ) containing at least the biological sample S 1 and a lysis buffer.
- the lysis buffer can be any of the lysis buffers described herein.
- the lysis buffer can be mixed with the biological sample S 1 to form the input solution S 2 in any suitable manner or at any suitable location within the device 6000 .
- the lysis buffer can be stored within the sample input module 6170 , and can be mixed with the biological sample S 1 when the biological sample S 1 is conveyed into the volume 6174 .
- the lysis buffer can be stored in a reagent module (not shown) and can be mixed with the biological sample S 1 when the sample input module 6170 is actuated (e.g., via the actuator 6050 ).
- the lysis buffer can be stored in the lysing module 6300 (e.g., the first volume 6311 ).
- the heater 6330 is coupled to the flow member 6310 and is configured to produce thermal energy that is conveyed into the first volume 6311 , the second volume 6321 , or both the first volume 6311 and the second volume 6321 to lyse organisms within the biological sample S 1 and/or the input solution S 2 .
- the lysing module 6300 can release one or more nucleic acid molecules from within the cells and/or organisms within the biological sample S 1 and/or the input solution S 2 .
- the heater 6330 and the flow member 6310 are collectively configured to maintain the input solution S 2 at a desired lysing temperature for a predetermined amount of time to facilitate and/or promote lysing of the organisms therein.
- the heater 6330 and the flow member 6310 are configured to heat the first volume 6311 , the second volume 6321 , or both the first volume 6311 and the second volume 6321 to inactivate enzymes present within the biological sample S 1 and/or the input solution S 2 .
- the lysing module 6300 can denature certain proteins and/or inactivate certain enzymes present within organisms that are within the input solution S 2 . Such proteins and/or enzymes can, in certain instances, limit the efficiency or effectiveness of the desired amplification operation.
- the lysing and the inactivation can be performed by a single heating operation.
- the input solution S 2 can be heated to the desired temperature range to both lyse the organisms and inactivate the enzymes as the input solution S 2 flows through the first volume 6311 and/or the second volume 6321 .
- the lysing module 6300 can perform “flow through” inactivation and lysing operations.
- either of the first volume 6311 or the second volume 6321 (or both) can define a tortuous flow path through which the input solution S 2 flows during the lysing/inactivation operation.
- the surface area-to-volume ratio of the first volume 6311 and/or the second volume 6321 can be high enough such that the heat transfer into the input solution S 2 occurs rapidly as it flows through the lysing module.
- the first volume 6311 and/or the second volume 6321 can define a serpentine flow path.
- a ratio of the surface area of the second volume 6321 to the volume of the second. volume 6321 is 20 cm ⁇ 1 .
- the flow member 6310 (and any of the flow members described herein) can have a volume about 650 microliters or greater, and the flow can be such that at least 60 microliters of the input solution S 2 is prepared for amplification (i.e., has nucleic acids extracted therefrom). In other embodiments, at least 20 microliters of the input solution S 2 is prepared for amplification by the methods and devices described herein. In other embodiments, at least 30 microliters of the input solution S 2 is prepared for amplification by the methods and devices described herein. In yet other embodiments, at least 50 microliters of the input solution S 2 is prepared for amplification by the methods and devices described herein.
- the input solution S 2 is rapidly heated to temperatures of up to about 100 degrees Celsius.
- the lysing module 6300 and/or the formulation of the input solution S 2 can collectively reduce the likelihood that the liquid portion of the input solution S 2 will boil during the lysing/inactivation operations. Such boiling can produce undesirable bubbles and/or air pockets and can reduce the repeatability of the lysing and/or inactivation operations.
- the lysing module 6300 and/or the formulation of the input solution S 2 can collectively reduce the likelihood that the liquid portion of the input solution S 2 will boil at a temperature of 99 degrees Celsius or higher, 98 degrees Celsius or higher, 96 degrees Celsius or higher, 94 degrees Celsius or higher, 92 degrees Celsius or higher, 90 degrees Celsius or higher, or 88 degrees Celsius or higher.
- the input solution S 2 can include salts and/or sugars to raise the boiling temperature of the input solution S 2 .
- the lysing module 6300 can include one or more vent openings into either the first volume 6311 or the second volume 6321 or both (to limit pressure build-up during heating). In such embodiments, the vent opening can be such that a limited amount of pressure is allowed within the first volume 6311 or the second volume 6321 to raise the boiling temperature of the input solution S 2 .
- the output from the lysing module 6300 can be conveyed into the amplification module 6600 .
- the output from the lysing module 6300 which is identified as the prepared solution S 3 , and which contains the extracted nucleic acid molecules, can be conveyed to the amplification module 6600 .
- the amplification module 6600 can then perform a thermal reaction (e.g., an amplification reaction) on the prepared solution S 3 containing target nucleic acid mixed with required reagents.
- the amplification module 6600 is configured to conduct rapid amplification of an input target.
- the amplification module 6600 is configured to generate an output copy number that reaches or exceeds the threshold of the sensitivity of an associated detection module.
- the amplification module 6600 includes a flow member 6610 and a heater 6630 .
- the flow member 6610 can be any suitable flow member that defines a volume or a series of volumes within which the that prepared solution S 3 can flow and/or be maintained to amplify the target nucleic acid molecules within the solution S 3 .
- the heater 6630 can be any suitable heater or group of heaters coupled to the flow member 6610 that can heat the prepared solution S 3 within the flow member 6610 to perform any of the amplification operations as described herein.
- the amplification module 6600 (or any of the amplification modules described herein) can be similar to the amplification modules shown and described in U.S. Patent Application No. 65/494,145, entitled “Printed Circuit Board Heater for an Amplification Module,” which is incorporated herein by reference in its entirety.
- the flow member 6610 defines a single volume within which the prepared solution S 3 is maintained and heated to amplify the nucleic acid molecules within the prepared solution S 3 .
- the flow member 6610 can define a “switchback” or serpentine flow path through which the prepared solution S 3 flows.
- the flow member 6610 defines a flow path that is curved such that the flow path 6618 intersects the heater 6630 at multiple locations. In this manner, the amplification module 6600 can perform a “flow through” PCR where the prepared solution S 3 flows through multiple different temperature regions.
- the flow member 6610 (and any of the flow members described herein) can be constructed from any suitable material and can have any suitable dimensions to facilitate the desired amplification performance for the desired volume of sample.
- the amplification module 6600 (and any of the amplification modules described herein) can perform 6000 ⁇ or greater amplification in a time of less than 65 minutes.
- the flow member 6610 (and any of the flow members described herein) is constructed from at least one of a cyclic olefin copolymer or a graphite-based material. Such materials facilitate the desired heat transfer properties into the flow path 6620 .
- the flow member 6610 (and any of the flow members described herein) can have a thickness of less than about 0.5 mm. In some embodiments, the flow member 6610 (and any of the flow members described herein) can have a volume about 150 microliters or greater, and the flow can be such that at least 10 microliters of sample is amplified. In other embodiments, at least 20 microliters of sample are amplified by the methods and devices described herein. In other embodiments, at least 30 microliters of sample are amplified by the methods and devices described herein. In yet other embodiments, at least 50 microliters of sample are amplified by the methods and devices described herein.
- the heater 6630 can be any suitable heater or collection of heaters that can perform the functions described herein to amplify the prepared solution S 3 .
- the heater 6630 can establish multiple temperature zones through which the prepared solution S 3 flows and/or can define a desired number of amplification cycles to ensure the desired test sensitivity (e.g., at least 30 cycles, at least 34 cycles, at least 36 cycles, at least 38 cycles, or at least 40 cycles).
- the heater 6630 (and any of the heaters described herein) can be of any suitable design.
- the heater 6630 can be a resistance heater, a thermoelectric device (e.g. a Peltier device), or the like.
- the heater 6630 can be one or more linear “strip heaters” arranged such that the flow path crosses the heaters at multiple different points. In other embodiments, the heater 6630 can be one or more curved heaters having a geometry that corresponds to that of the flow member 6610 to produce multiple different temperature zones in the flow path.
- the amplification module 6600 can perform any suitable thermal reaction to amplify nucleic acids within the solution S 3 .
- the amplification module 6600 (and any of the amplification modules described herein) can perform any suitable type of isothermal amplification process, including, for example, Loop Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA), which can be useful to detect target RNA molecules, Strand Displacement Amplification (SDA), Multiple Displacement Amplification (MDA), Ramification Amplification Method (RAM), or any other type of isothermal process.
- LAMP Loop Mediated Isothermal Amplification
- NASBA Nucleic Acid Sequence Based Amplification
- SDA Strand Displacement Amplification
- MDA Multiple Displacement Amplification
- RAM Ramification Amplification Method
- FIG. 25 is a photograph of a molecular diagnostic test device that can perform any of the methods described herein.
- the devices described herein may be contained with a housing.
- the device is self-contained.
- the device is a handheld device.
- the device is configured for one-time use (e.g., disposable).
- the devices may generate a nucleic acid sample that may be collected prior to performing one or more downstream applications.
- the sample can be held in a chamber or reservoir within the housing of the device or can be relayed to a chamber or reservoir that sits outside of the housing of the device.
- the device is coupled to one or more additional devices that can perform the one or more downstream applications, for example, a device that can perform a polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- DNA was extracted from clinical samples using either a standard DNA extraction protocol or a DNA extraction protocol using the methods described herein.
- Clinical samples that were positive for Neisseria gonorrhoeae and/or Chlamydia trachomatis (Samples 101, 105, 108, 117 and 122) were obtained and screened for the presence of these bacteria (See Table 1).
- These samples were processed utilizing two different methods for DNA extraction. For the first method, 500 ⁇ L of each of these samples were taken for DNA extraction utilizing the Qiagen QIAmp® DNA Mini Kit according to the manufacturer's recommendations for isolation of bacterial DNA from bodily fluids (“standard method”).
- 500 ⁇ L of each of the samples were taken for DNA extraction utilizing an embodiment of the methods provided herein. Briefly, 500 ⁇ L of the sample was preloaded into a clean syringe and 1 mL of air was aspirated into the same syringe. The syringe containing both the sample and air was connected to the filter housing and the entire volume was pushed through (i.e., liquid followed by air). A new syringe was preloaded with 600 ⁇ L of wash solution, then the wash solution was pushed through the filter housing. The orientation of the filter was flipped and a female luer lug was attached to the end.
- TT buffer Tris Acid, Tris Base, a non-iconic surfactant Tween® 80, Antifoam SE-15, a preservative ProClinTM300 and molecular grade water
- TT buffer Tris Acid, Tris Base, a non-iconic surfactant Tween® 80, Antifoam SE-15, a preservative ProClinTM300 and molecular grade water
- the 1.5 mL tube was preloaded with a lyophilized proteinase K pellet.
- the tube was incubated in a heat block at 56° C. for 1 minute to allow for optimal proteinase K activity.
- the proteinase K was heat inactivated by placing the tube in a heat block at 95° C. for 10 minutes.
- PCR reagents Each sample was mixed with PCR reagents. Primer/probe sets designed to amplify sequences from several different organisms were added to each sample. 1 ⁇ L of N. subflava DNA (1,000 copies/rxn) were added to the sample/PCR mix designated for the NS assay. The mixtures were divided into two wells of 20 ⁇ L each on a LightCycler® plate. The plate was loaded onto the LightCycler® Real-Time PCR System (Roche) and run under the following PCR conditions:
- Stage 1 95 C for 20 seconds
- Stage 2 40 cycles of: 95 C for 1 second, 60 C for 6 seconds
- FIGS. 5 and 6 depict a comparison of data generated from real-time PCR reactions performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122), and clinical samples positive for C. trachomatis (Samples 101 and 108) utilizing the methods provided herein versus standard DNA extraction methods.
- Both standard (“Qiagen”) and new methods (“Click”) of DNA extraction did not detect the presence of C. trachomatis in Sample 105 using either Primer Set #3 or Primer Set #4.
- Primer Set #3 was able to detect the presence of C. trachomatis in Samples 108, 122 and 101 using either sample preparation method ( FIG. 5 ).
- Primer Set #4 was able to detect the presence of C. trachomatis in Sample 101 for both sample preparation methods, and only Sample 122 for the standard method, and only Sample 108 for the new method ( FIG. 6 ).
- FIGS. 7 and 8 depict a comparison of data generated from real-time PCR reactions performed on N. gonorrhoeae positive control DNA or C. trachomatis positive control DNA, respectively, utilizing different sets of primers.
- FIG. 9 depicts data generated from a real-time PCR reaction performed on N. gonorrhoeae DNA spiked into a sample and PCR mixture to test for sample inhibition.
- DNA was purified from a range of samples using the no filter method described herein. Briefly samples are flowed into the holding chamber of the inactivation module. the heat-treated fluid is flowed through the serpentine path and into a mixing chamber containing PCR reagents, PCR is performed and PCR products are detected. In this example, purified DNA is subjected to PCR using the probe sets of example 1.
- FIG. 25 shows successful PCR amplification from DNA isolated from 19 different clinical samples, shown in Table 2, using this method.
- FIG. 26 shows the results of PCR amplification on DNA extracted from the samples in Table 3.
- Samples in Table 2 were purified in buffer comprising 50 mM Tris pH 8.4, Tween-80, 2% (w/v), BSA, 0.25% (w/v), Proclin 300 0.03% (w/v), and Antifoam SE-15, 0002% (v/v) made up in purified water, (TT buffer).
- Amplification was seen in every sample indicating that the PCR reaction possesses high tolerance to inhibitors.
- FIG. 26 depicts the result of an experiment comparing different sample buffers.
- the sample buffers used were the TT buffer described above, MSwab buffer (MS; Copan Diagnostics, CA), and Liquid Amies Buffer (LA; Copan Diagnostics, CA).
- PCR products were run on 4% agarose gels to determine the success of the PCR reaction. Samples rehydrated in TT buffer amplified as expected, equal to the controls. The other two medias MS and LA showed varying results, suggesting variable inhibition of the PCR by contaminants from the sample buffer.
- the devices and methods described herein are not limited to performing a molecular diagnostic test on human samples. In some embodiments, any of the devices and methods described herein can be used with veterinary samples, food samples, and/or environmental samples.
- any suitable pump can be used.
- any of the fluid transfer assemblies described herein can include any suitable positive-displacement fluid transfer device, such as a gear pump, a vane pump, and/or the like.
Abstract
Description
- This application is a divisional of U.S. application Ser. No. 16/186,240, filed Nov. 9, 2018, which is a continuation of International Patent Application No. PCT/US2017/032035, filed May 10, 2017, Which claims the benefit of U.S. Provisional Application No. 62/334,982, filed May 11, 2016, U.S. Provisional Application No. 62/356,451, filed Jun. 29, 2016, and U.S. Provisional Application No. 62/356,596. filed Jun. 30, 2016, which applications are incorporated herein by reference.
- Sample preparation methods involving the extraction of nucleic acid molecules from biological cells are widely used. Oftentimes, the nucleic acid molecules are to be used in downstream applications, for example, amplification (e.g., PCR) or sequencing methods. These methods, however, can be sensitive to additional components found in the sample mixture. These additional components may be residual components carried over from the sample preparation method. Thus, the sample preparation method should be able to generate a nucleic acid sample of sufficient quality to perform the intended downstream application. Furthermore, standard sample preparation methods may be time-consuming, ranging on the order of hours to be complete.
- In one aspect, a method is provided for nucleic acid extraction, comprising: (a) obtaining a biological sample comprising one or more biological entities; (b) capturing the one or more biological entities on a filter; (c) washing the filter; (d) eluting the one or more biological entities from the filter; and (e) lysing the one or more biological entities, thereby releasing a plurality of nucleic acid molecules therefrom, wherein the method extracts the nucleic acid molecules from the one or more biological entities within 5 minutes or less at a quality sufficient to successfully perform a polymerase chain reaction (PCR). In some cases, the one or more biological entities comprise one or more biological cells. In some cases, the one or more biological cells comprise one or more bacterial cells, fungal cells, mammalian cells or a combination thereof. In some cases, the one or more biological entities comprise one or more viruses. In some cases, the nucleic acid molecules comprise RNA. In some cases, the nucleic acid molecules comprise DNA. In some cases, the lysing further comprises flowing a lysis solution over the one or more biological entities on the filter. In some cases, the lysis solution comprises a lysis enzyme. In some cases, the lysis enzyme is proteinase K. In some cases, the proteinase K is present in the lysis solution at a concentration of about 0.001 mg/ML to about 10 mg/mL. In some cases, about 10 μL to about 50 mL of lysis solution is flowed over the filter. In some cases, the washing further comprises, (i) pushing a wash solution through the filter; (ii) pushing air through the filter; (iii) or a combination of both. In some cases, the lysis solution is back-flushed over the filter. In some cases, the wash solution comprises bovine serum albumin and/or a detergent. In some cases, the wash solution comprises about 0.1% to 5% bovine serum albumin. In some cases, the wash solution comprises about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 1.5%. 2%, 2.5%, 3%, 4%, or 5% bovine serum albumin. In some cases, the wash solution comprises about 0.1% to 20% detergent. In some cases, the wash solution comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% detergent. In some cases, the detergent is Tween-20. In some cases, the biological sample comprises urine, a vaginal swab, a cervical swab, or blood. In some cases, the filter comprises cellulose, polyethersulfone (PES), nylon, polyvinylidene fluoride (PVDF), polycarbonate or borosilicate glass fiber. In some cases, the filter has a pore size of about 0.2 μm to about 20 μm. In some cases, the lysing further comprises incubating the biological sample in the lysis solution for a period of time at a specified temperature. In some cases, the period of time comprises from about 0.01 seconds to about 48 hours. In some cases, the specified temperature comprises from about 4° C. to about 75° C. In some cases, the method further comprises inactivating said lysis solution. In some cases, the inactivating comprises incubating said lysis solution at a temperature of about 57° C. to about 100° C. at a time period from about 0.01 seconds to about 48 hours. In some cases, the nucleic acid molecules comprise DNA and the DNA is extracted from the one or more biological entities with a A260/A280 ratio of at least 1.5. In some cases, the nucleic acid molecules comprise RNA and the RNA is extracted from the one or more biological entities with a A260/A280 ratio of at least 1.7. In some cases, the method further comprises performing a polymerase chain reaction on the extracted nucleic acid molecules. In some cases, the polymerase chain reaction successfully amplifies a target nucleic acid sequence present in the extracted nucleic acid molecules.
- In another aspect, a device is provided. In some cases, the device is configured to perform a method of the disclosure. In some cases, the device comprises: (a) an input port, configured to receive the biological sample comprising one or more biological entities; (b) a filter assembly comprising a filter configured to capture the one or more biological entities, wherein the input port is configured to relay the biological sample to the filter assembly; (c) one or more reservoirs comprising a wash solution, a lysis solution, or both, operably coupled to the filter assembly; (d) a waste chamber, operably coupled to the filter assembly and configured to receive waste from the filter assembly; and (e) an elution chamber, operably coupled to the filter assembly and configured to receive an eluent from the filter assembly. In some cases, the elution chamber further comprises a heating element in contact with the elution chamber. In some cases, the device further comprises an inactivation chamber, operably coupled to the elution chamber. In some cases, the inactivation chamber further comprises a heating element. In some cases, the inactivation chamber comprises a serpentine flow path in contact with the heating element. In some cases, the input port, the filter assembly, the one or more reservoirs, the waste chamber, and the elution chamber are contained within a housing. In some cases, the device is handheld. In some cases, the device is configured for one-time use. In some cases, the device is configured to extract said nucleic acid molecules from the biological entities in 5 minutes or less at a quality sufficient to successfully perform a polymerase chain reaction. In some cases, the device further comprises one or more additional elements for performing a polymerase chain reaction.
- In one aspect a method is provided for nucleic acid extraction, comprising: obtaining a biological sample comprising one or more biological entities; capturing said one or more biological entities on a filter; eluting said one or more biological entities front said filter; and lysing said one or more biological entities, thereby releasing a plurality of nucleic acid molecules therefrom, wherein said method extracts said nucleic acid molecules from said one or more biological entities within 5 minutes or less at a quality sufficient to successfully perform a polymerase chain reaction (PCR). In some cases the method further comprises that the filter consists of two filter membranes, a first filter membrane and a second filter membrane with a smaller pore size than the first filter membrane. In some cases the method further comprises a wash step, whereby once the biological entities are captured on the filter the filter and biological entities are washed with an air wash.
- In one aspect a method is provided for nucleic acid extraction, comprising: obtaining a biological sample comprising one or more biological entities; and lysing said one or more biological entities, thereby releasing a plurality of nucleic acid molecules therefrom, wherein said method extracts said nucleic acid molecules from said one or more biological entities within 5 minutes or less art a quality sufficient to successfully perform a polymerase chain reaction (PCR). In some cases the method is performed by a handheld device. In some cases a quality sufficient to successfully perform a polymerase chain reaction comprises nucleic acid molecules which amplify with at least 70% efficiency as determined by a qPCR standard curve. In some cases the method produces at least 100 μL of a solution containing the nucleic acid molecules. In some cases the method produces at least 300 μL of a solution containing the nucleic acid molecules. In some cases the method produces at least 500 μL of a solution containing the nucleic acid molecules. In some cases the method further comprises catching biological entities on a filter and subjecting the biological entities and filter to an air wash. In some cases the biological entities are washed with a volume of air sufficient to dry the filter. In some cases the biological entities are washed with at least about 1.5 mL of air.
- In another aspect a device is provided. In some cases the device comprises: an input port, configured to receive said biological sample comprising one or more biological entities; a holding tank, operably coupled to said input port, an inactivation section, and containing a heating element; and an output port. In some cases the device further comprises a permanent vent. In some cases the holding tank further comprises an electrical probe which can sense the presence of liquid in the holding tank. In some cases the inactivation chamber comprises a serpentine path.
- In a further aspect a method of nucleic acid extraction comprises: conveying a biological sample into a sample input module of a. molecular diagnostic test device; and actuating the molecular diagnostic test device to: convey the biological sample from the sample input module to a lysing module, the lysing module including a heater and defining a first reaction volume and a second reaction volume; maintain an input solution containing the biological sample and a lysis buffer within the first reaction module to lyse at least a portion of the biological sample thereby releasing a plurality of nucleic acid molecules; activate the heater to heat a portion of the lysing module to produce an inactivation temperature zone within the second reaction volume; and produce a flow of the input solution within the second reaction volume such that a volume of the input solution is heated within the inactivation temperature In some cases the volume of the input solution is at least 10 microliters. In some cases the volume of the input solution is produced within five minutes or less. In some cases the second reaction volume is a serpentine flow path. In some cases a wall of the lysing module that defines the second reaction volume has a surface area, a ratio of the surface area to the second reaction volume being greater than about 10 cm −1. In one example, a ratio of the surface area to the second reaction volume is about 20 cm−1. In some cases the volume of the input solution is heated to an inactivation temperature of between about 57 degrees Celsius and about 100 degrees Celsius for a time period from about 15 seconds. In some cases the flow of the input solution is such that the volume of the input solution is heated to an inactivation temperature of between about 92 degrees Celsius and about 98 degrees Celsius for a time period of at least about 25 seconds. In some cases the first reaction volume is in fluid communication with the second reaction volume; and the lysing module defines a vent opening into the first reaction volume. In some cases the volume of the input solution is heated to an inactivation temperature of at least about 95 degrees Celsius; and the input solution within the first reaction module contains at least one of a salt or a sugar formulated to raise a boiling temperature of the input solution. In some cases the portion of the lysing module is a second portion, the actuating the molecular diagnostic test device further causes the molecular diagnostic test device to: heat a first portion of the lysing module to produce a lysing temperature zone within the second reaction volume, the flow of the input solution within the second reaction volume being such that the volume of the input solution is heated within the lysing temperature zone to lyse a biological entity within the volume of the input solution.
- In some cases the plurality of nucleic acid molecules includes DNA, the DNA being extracted from said one or more biological entities with a A260/A280 ratio of at least 1.5.
- In some cases the actuating the molecular diagnostic test device causes the molecular diagnostic test device to: convey the biological sample from the sample input module through a filter to retain a biological entity with the biological sample on the filter; and produce a flow of an elution butler through the filter to produce the input solution and convey the input solution to the lysing module. In some cases the actuating the molecular diagnostic test device includes moving a sample actuator to produce a pressure within the sample input module to convey the biological sample from the sample input module towards the lysing module. In some cases the sample actuator is a non-electronic actuator. In some cases the actuating the molecular diagnostic test device further causes the molecular diagnostic test device to: receive an electronic signal from a sensor within the lysing module, the electronic signal indicating the presence of the input solution within the first reaction module; and activate the heater in response to the electronic signal.
- In some cases the actuating the molecular diagnostic test device further causes the molecular diagnostic test device to: heat a portion of an amplification module within the molecular diagnostic test device to amplify a nucleic acid from the plurality of nucleic acid molecules to produce an output containing a target amplicon; and convey the Output to a detection module of the molecular diagnostic test device.
- In some cases a method described herein further comprises viewing a visible signal indicating a presence of the target amplicon; and discarding, after the viewing, the molecular diagnostic test device.
- In an aspect an apparatus is provided. The apparatus comprises a housing; a sample input module defining an input reservoir configured to receive a biological sample, the biological sample containing a biological entity; a lysing module disposed within the housing, the lysing module including a heater and first flow member, the first flow member defining a first volume and a second volume, the first volume configured to receive an input solution containing at least the biological sample and a lysis buffer, the heater coupled to the first flow member and configured to convey thermal energy into the second volume to A) lyse at least a portion of the biological sample thereby releasing a plurality of nucleic acid molecules and B) inactivate an enzyme within the input solution when a volume of the input solution flows through the second volume; and an amplification module disposed within the housing, the amplification module including a second flow member configured to receive the volume of the input solution from the lysing module, the amplification module configured to amplify a nucleic acid molecule from the plurality of nucleic acid molecules within the volume of the input solution to produce an output containing a target amplicon. In some cases the second volume is a serpentine flow path. In some cases a wall of the lysing module that defines the second volume has a surface area, a ratio of the surface area to the second reaction volume being greater than about 20 cm−1. In one example, a ratio of the surface area to the second reaction volume is about 20 cm−1.
- In some cases the first volume is in fluid communication with the second reaction volume; and the lysing module defines a vent opening into the first volume. In some cases the lysing module includes a sensor disposed within the first volume, the sensor configured to produce an electronic signal indicating the presence of the input solution within the first module, the heater activated in response to the electronic signal. In some cases the heater is a first heater; the second flow member defines an amplification flow path; and the amplification module includes a second heater different from the first heater, the second heater coupled to the second flow member and configured to convey thermal energy into the amplification flow path to amplify the nucleic acid molecule from the plurality of nucleic acid molecules.
- In some cases an apparatus further comprises a non-electronic sample actuator to produce a pressure within the sample input module to convey the biological sample from the sample input module towards the lysing module; and a fluid pump disposed within the housing, the fluid pump configured to produce a flow of the input solution from the lysing module to the amplification module. In some cases the flow of the input solution from the lysing module to the amplification module is in a first direction; and the lysing module includes a check valve to configured to prevent a flow of the input solution in a second direction.
- In an aspect a device is provided. The device comprises a holding tank which contains two electrical probes which may be used to determine the electrical resistance of the fluid within the holding tank, thus determining whether liquid has entered the holding tank.
- All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
- The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
-
FIG. 1 depicts data generated from a real-time PCR reaction performed on DNA extracted from clinical samples utilizing the methods provided herein. -
FIG. 2 depicts data generated from a real-time PCR reaction performed on DNA extracted from clinical samples utilizing standard DNA extraction methods. -
FIG. 3 depicts a comparison of data generated from a real-time PCR reaction performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122) and a clinical sample positive for N. gonorrhoeae (Sample 117) utilizing the methods provided herein versus standard DNA extraction methods. -
FIG. 4 depicts a comparison of data generated from a real-time PCR reaction performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122) and a clinical sample positive for N. gonorrhoeae (Sample 117) utilizing the methods provided herein versus standard DNA extraction methods. -
FIG. 5 depicts a comparison of data generated from a real-time PCR reaction performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122), a clinical samples positive for C. trachomatis (Samples 101 and 108) utilizing the methods provided herein versus standard DNA extraction methods. -
FIG. 6 depicts a comparison of data generated from a real-time PCR reaction performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122) and clinical samples positive for C. trachomatis (Samples 101 and 108) utilizing the methods provided herein versus standard DNA extraction methods. -
FIG. 7 depicts a comparison of data generated from a real-time PCR reaction performed on N. gonorrhoeae DNA utilizing different sets of primers. -
FIG. 8 depicts a comparison of data generated from a real-time PCR reaction performed on C. trachomatis DNA utilizing different sets of primers. -
FIG. 9 depicts data generated from a real-time PCR reaction performed on N. gonorrhoeae DNA spiked into a sample and PCR mixture to test for sample inhibition. -
FIG. 10 is a schematic illustration of a molecular diagnostic test device, according to an embodiment, which can perform the methods described herein. -
FIG. 11 is an exploded view of the molecular diagnostic test device shown schematically inFIG. 10 . -
FIG. 12 depicts an example of a sample preparation device amenable to performing the methods as described herein. -
FIG. 13 is a perspective view of a lysing module according to an embodiment, which is amenable to performing the methods as described herein. -
FIG. 14 is an exploded view of the lysing module shown inFIG. 13 . -
FIG. 15 is a top view of a portion of the lysing module shown inFIG. 13 . -
FIG. 16 is a cross-sectional view of the lysing module shown inFIG. 13 . -
FIGS. 17 and 18 is are perspective views of a lysing module according to an embodiment, which can perform any of the methods described herein. -
FIG. 19 is a bottom view of the lysing module shown inFIGS. 17 and 18 . -
FIG. 20 is a cross-sectional view of the lysing module shown inFIGS. 17 and 18 taken along line X1-X1 inFIG. 19 . -
FIG. 21 is a cross-sectional view of the lysing module shown inFIGS. 17 and 18 taken along line X2-X2 inFIG. 19 . -
FIG. 22 is a perspective view of a portion of the lysing module shown inFIGS. 17 and 18 . -
FIG. 23 is a schematic illustration of a portion of a molecular diagnostic test device, according to an embodiment, which can perform the methods described herein. -
FIG. 24 is a schematic illustration of a molecular diagnostic test device, according to an embodiment, which can perform the methods described herein. -
FIG. 25 illustrates the results of a PCR reaction performed upon DNA extracted using the methods of this disclosure. -
FIG. 26 illustrates the results of a PCR reaction performed upon DNA extracted using the methods of this disclosure. -
FIG. 27 illustrates the results of a PCR reaction performed upon DNA extracted using the methods of this disclosure. - Disclosed herein are devices and methods for the preparation of nucleic acid molecules for downstream applications. In some cases, the devices and methods are utilized for the extraction of nucleic acid molecules from a biological sample. In some cases, the devices and methods are utilized for the purification of nucleic acid molecules from a biological sample. The devices described herein may include self-contained, handheld devices. The devices described herein may include one or more components that aid in the extraction, purification, and/or processing of a biological sample and the nucleic acids contained therein. In some cases, the methods include the use of a device that includes one or more components that aid in the extraction, purification, and/or processing of a biological sample and the nucleic acids contained therein.
- In one aspect, a method is provided for nucleic acid extraction. The method may include one or more steps including: (a) obtaining a biological sample comprising one or more biological entities; (b) capturing the one or more biological entities on a filter; (b) washing the filter with a wash solution and/or air; (c) eluting the one or more biological entities from the filter; and (d) lysing the one or more biological entities, thereby releasing a plurality of nucleic acid molecules therefrom. In some cases, the wash solution comprises bovine serum albumin and/or a detergent. In some cases, the wash solution comprises about 0.1% to 5% bovine serum albumin. In some cases, the wash solution comprises about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4%, or 5% bovine serum albumin. In some cases, the wash solution comprises about 0.1% to 20% detergent. In some cases, the wash solution comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% detergent. In some cases, the detergent is Tween-20. In some embodiments the method may not require use of a filter. In other embodiments the method may use a filter but not require a wash solution.
- In some cases, the method involves obtaining or providing a biological sample. The biological sample can be derived from a non-cellular entity comprising polynucleotides (e.g., a virus) or from a cell-based organism (e.g., member of archaea, bacteria, or eukarya domains).
- Generally, the biological sample will contain one or more biological entities that comprise one or more polynucleotides or nucleic acid molecules. A “nucleic acid molecule”, “nucleic acid” or “polynucleotide” may be used interchangeably throughout and may refer to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) including known analogs or a combination thereof unless otherwise indicated. Nucleic acid molecules to be profiled herein can be obtained from any source of nucleic acid, The nucleic acid molecule can be single-stranded or double-stranded. In some cases, the nucleic acid molecules are DNA. The DNA can be mitochondrial DNA, complementary DNA (cDNA), or genomic DNA. In sonic cases, the nucleic acid molecules are genomic DNA (gDNA). The DNA can be plasmid DNA, cosmid DNA, bacterial artificial chromosome (BAC), or yeast artificial chromosome (YAC). The DNA can be derived from one or more chromosomes. For example, if the DNA is from a human, the DNA can derived from one or more of
chromosomes - In some aspects, the methods involve capturing one or more biological cells or biological entities (e.g., a virus) present in the biological sample on a filter membrane. The filter membrane may be of any suitable material, non-limiting examples including nylon, cellulose, polyethersulfone (PES), polyvinylidene difluoride (PVDF), polycarbonate, borosilicate glass fiber and the like. In some examples, the filter membrane is nylon. In some cases, the filter membrane has an average pore size of about 0.2 μm to about 20 μm. For example, the filter membrane may have an average pore size of about 0.2 μm, about 0.5 μm, about 1 μm, about 2 μm, about 3 μm, about 4 μm, about 5 μm, about 6 μm, about 7 μm, about 8 μm, about 9 μm, about 10 μm, about 11 μm , about 12 μm, about 13 μm, about 14 μm, about 15 μm, about 16 μm, about 17 μm, about 18 μm, about 19 μm, about 20 μm, or greater than 20 μm. In some examples, the surface of the filter membrane may be chemically treated or coated in such a way as to improve the binding of a biological cell or entity to the membrane. For example, without limitation, the filter membrane may be treated with sodium polyphosphate.
- Clinical swab samples may contain mucus (or other substances) which can lead to clogging of the filter used in sample prep. If the filter is clogged then pressures may build up which may lead to leaks in the fluidic path of the sample prep device and/or tears or breaks in the capture filter itself. In some examples a second filter may be provided which sits next to a first filter. For example, a mesh screen may be placed on the input side of the 5 micron nylon filter. This may reduce pressure from mucus samples and also prevent the 5 micron nylon filter from breaking. A mesh screen could also be placed on the exit side of the 5 micron nylon filter which would also prevent the 5 micron nylon filter from breaking, however this likely would not reduce the pressure required to push a sample (mucus) through.
- The mesh screen may be made from any plastic materials and may contain pore sizes from 1 micron to 1000 microns. In some embodiments the mesh screen may be a woven nylon mesh with 100 micron pores. The mesh screen is assembled into the housing that also contains the 5 micron nylon filter. The second filter may have a much larger pore size than the first filter and prevent clogging of the first filter. For example the first filter may have a pore size of about 0.1-20, 1-15, 1-10, 5-10, 1-5 or 0.1-1 μm while the second filter has a pore size of about 10-1000, 50-500, 100-500, 50-100, or 100-200 μm. In one example the first filter has a pore size of 5 μm and the second filter has a pore size of 100 μm. The mesh filter may also be made from non-woven polypropylene. The mesh screen may have a thickness of about 150 μm, 200 μm or greater than 200 μm. After the biological cells or biological entities are captured on the filter membrane, the filter membrane may be optionally washed with one or more wash steps. The wash step may be utilized to, for example, remove any undesired material from the membrane. In some cases, the wash step may involve pushing or forcing a fluid solution over or through the membrane (e.g., a buffer). The volume of wash solution may be from about 10 μL to about 50 mL. For example, the volume of wash solution may be about 10 μL about 50 μL, about 100 μL, about 200 μL, about 300 μL, about 400 μL, about 500 μL, about 600 μL, about 700 μL, about 800 μL, about 900 μL, about 1 mL, about 5 mL, about 10 mL, about 15 mL, about 20 mL, about 25 mL, about 30 mL, about 35 mL, about 40 mL, about 45 about 50 mL or greater than 50 mL. In other cases, the wash step may involve pushing or forcing air over or through the membrane. This step may be advantageous in decreasing the volume of sample buffer that is carried over into the lysis buffer. The volume of air wash may be from about 0.1 μL to about 100 L, or about 10 μL it to about 50 mL. For example, the volume of air wash may be about 10 μL, about 50 μL, about 100 μL, about 200 μL, about 300 μL, about 400 μL, about 500 μL, about 600 μL, about 700 μL, about 800 μL, about 900 μL, about 1 mL, about 5 mL, about 10 mL, about 15 mL, about 20 mL, about 25 mL, about 30 mL, about 35 mL, about 40 mL, about 45 mL, about 50 mL or greater than 50 mL. In some cases, an air wash volume of about 1-5 mL, may be preferred, For example an air wash may be have a volume of about 1.5 mL. In cases where an air wash is used the subsequent liquid wash may be more effective and/or the final eluted sample may be cleaner than if no air wash were used. In some cases, the wash step involves both a fluid wash step and an air wash step, performed in any order. In some cases, the wash solution comprises bovine serum albumin and/or a detergent. In some cases, the wash solution comprises about 0.1% to 5% bovine serum albumin. In some cases, the wash solution comprises about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4%, or 5% bovine serum albumin. In some cases, the wash solution comprises about 0.1% to 20% detergent. In some cases, the wash solution comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% detergent. In some cases, the detergent is Tween-20. In some embodiments, the bovine serum albumin and/or detergent increase the viscosity of the wash solution in manner which increases the surface area of the filter contacted with the wash solution during a wash step as compared to a wash solution lacking one or both of bovine serum albumin and detergent.
- After the membrane is washed, the biological cells or entities captured on the membrane may be lysed or otherwise disrupted so as to release a plurality of nucleic acid molecules contained therein. The methods and devices of this disclosure may use chemical, enzymatic and/or thermal methods to lyse the sample. In some embodiments the methods and devices of this disclosure do not use ultrasound to lyse the sample. In some cases, the cells may be lysed be heating the sample. For example the sample may be heated to greater than about 90° C. for longer than about 10 seconds. In some examples heating the sample to about 95° C. for about 20 seconds is seen to be sufficient to lyse the sample.
- In some cases, lysis involves flowing a lysis buffer over the biological cells or entities captured on the membrane. In some cases, the lysis buffer is flowed through the filter membrane. In other cases, the lysis buffer is back-flowed through the filter membrane. The lysis buffer may be osmotically imbalanced so as to force fluid into the cells to rupture the cell membranes. In some cases, the lysis buffer may include one or more surfactants or detergents. Non-limiting examples of surfactants or detergents that may be used include: nonionic sufactants including polyoxyethylene glycol alkyl ethers (sold as Brij® series detergents including Brij® 58, Brij® 52, Brij® L4 and Brij® L23), octaethvlene glycol monododecyl ether, pentaethylene glycol monododecyl ether, polyoxypropylene glycol alkyl ethers, glucoside alkyl ethers (e.g., decyl glucoside, laurel glucoside, octyl glucoside), polyoxyethylene glycol octylphenol ethers (e.g., Triton X-100), polyoxyethylene glycol alkylphenol ethers (e.g., nonoxynol-9), glycerol alkyl esters (e.g., glyceryl laurate), polyoxyethylene glycol sorbitan alkyl esters (e.g., polyoxyethylene glycol (20) sorbitan monolaurate, polyoxyethylene glycol (40) sorbitan monolaurate, polyoxyethylene glycol (20) sorbitan monopalmitate, polyoxyethylene glycol (20) sorbitan monostearate, polyoxyethylene glycol (4) sorbitan monostearate, polyoxyethylene glycol (20) sorbitan tristearate, polyoxyethylene glycol (20) sorbitan monooleate)), sorbitan alkyl esters (e.g., sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan sesquioleate, sorbitan trioleate, sorbitan isostearate), cocamide monoethanolamine, cocamide diethanolamine, dodecyldimethylamine oxide, poloxamers including those sold under the Pluronic®, Synperonic® and Kolliphor® tradenames, and polyethoxylated tallow amine (POEA); anionic surfactants including ammonium lauryl sulfate, ammonium perfluorononanoate, docusate, perfluorobutanesulfonic acid, perfluorononanoic acid, perfluorooctanesulfonic acid, perfluorooctanoic acid, potassium lauryl sulfate, sodium alkyl sulfate, sodium dodecyl sulfate, sodium dodecylbenzenesulfonate, sodium laurate, sodium lauryl ether sulfate, sodium lauroyl sarcosinate, sodium myreth sulfate, sodium pareth sulfate, sodium stearate; cationic surfactants including benzalkonium chloride, benzethonium chloride, bronidox, cetrimonium bromide, cetrimonium chloride, distearyldimethylammonium chloride, lauryl methyl gluceth-10 hydroxypropyl dimonium chloride, octenidine dihydrochloride, olaflur, and tetramethylammonium hydroxide; and Zwitterionic surfactants including CHAPS detergent, cocamidopropyl betaine, cocamidopropyl hydroxysultaine, dipalmitoylphosphatidylcholine, lecithin, hydroxysultaine, and sodium lauroamphoacetate.
- In some cases, the lysis buffer may contain an antifoaming agent for preventing or minimizing foaming. Non-limiting examples of antifoaming agents include Antifoam SE-15, Antifoam 204, Antifoam Y-30. In some cases, the lysis buffer may contain a preservative, for example an antimicrobial agent. Non-limiting examples of antimicrobials may include preservatives like ProClin™ 150, ProClin™ 200, ProClin™ 300, and ProClin™ 950.
- In cases where the desired nucleic acid molecules are RNA, the lysis buffer may include one or more agents that prevent degradation of the RNA, such as, for example, an RNAse inhibitor. The volume of lysis buffer flowed over the membrane can be from about 10 μL to about 50 mL. For example, the volume of lysis buffer may be about 10 μL, about 50 μL, about 100 μL, about 200 μL, about 300 μL, about 400 μL, about 500 μL, about 600 μL, about 700 μL, about 800 μL, about 900 μL, about 1 mL, about 5 mL, about 10 mL, about 15 mL, about 20 mL, about 25 mL, about 30 mL, about 35 mL, about 40 mL, about 45 mL, about 50 mL or greater than 50 mL.
- In some cases, the lysis buffer contains one or more enzymes. In some cases, the one or more enzymes comprise Proteinase K. Proteinase K may be present in the lysis buffer at a concentration of about 0.001 mg/mL, to about 10 mg/mL. For example, the concentration of proteinase K in the lysis buffer may be about 0.001 mg/mL, about 0.005 mg/mL, about 0.01 mg/mL, about 0.05 mg/mL, about 0.1 mg/mL, about 0.5 mg/mL, about 1 mg/mL, about 2 mg/mL, about 3 mg/mL, about 4 mg/mL, about 5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL or greater than about 10 mg/mL. In some cases, the one or more enzymes comprise lysozyme to process gram-positive organisms. Lysozyme may be present in the lysis buffer at a concentration of about 0.001 mg/mL to about 10 mg/mL. For example, the concentration of lysozyme in the lysis buffer may be about 0.001 mg/mL, about 0.005 mg/mL, about 0.01 mg/mL, about 0.05 mg/mL, about 0.1 mg/mL, about 0.5 mg/mL, about 1 mg/mL, about 2 mg/mL, about 3 mg/mL, about 4 mg/mL, about 5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL or greater than about 10 mg/mL. In some cases, the one or more enzymes comprise zymolyase to process yeast. Zymolase may be present in the lysis buffer at a concentration of about 0.001 mg/mL to about 10 mg/mL. For example, the concentration of zymolase in the lysis buffer may be about 0.001 mg/mL, about 0.005 mg/mL, about 0.01 mg/mL, about 0.05 mg/mL, about 0.1 mg/mL, about 0.5 mg/mL, about 1 mg/mL, about 2 mg/mL, about 3 mg/mL, about 4 mg/mL, about 5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL or greater than about 10 mg/mL. Additional enzymes that may be used include, without limitation, lyticase, chitinase or gluculase, for e.g., the extraction of nucleic acids from yeast. In some examples, if more than one lysis enzyme is used, the enzymes may be added in sequence. For example, lysozyme may be added first, followed by an incubation period, and subsequently followed by addition of proteinase K and an additional incubation period. In some cases, the lysis buffer does not contain any enzymes.
- In some aspects, the methods may involve one or more incubation steps. The one or more incubation steps may be performed in the lysis buffer in order to ensure complete lysis or disruption of the biological cell or entity and/or to destroy any inhibitory protein that may be present. The incubation step may involve holding the biological cell or entity in the lysis buffer for a period of time. In sonic cases, the incubation step involves holding the biological cell or entity in the lysis buffer for a period of time at a specified temperature. In a non-limiting example, the biological cell or entity is incubated in the lysis buffer from about 0.01 seconds to about 48 hours, For example, the biological cell or entity is incubated in the lysis buffer from about 0.01 seconds, about 0.05 seconds, about 1 second, about 10 seconds, about 30 seconds, about 1 minute, about 5 minutes, about 10 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 48 hours, or greater than 48 hours, In some examples, the biological cell or entity is incubated in the lysis buffer at a specified temperature, for example, from about 4° C. to about 75° C. For example, the biological cell or entity is incubated in the lysis buffer at a temperature of about 4° C., about 10° C., about 15° C., about 20° C., about 25° C., about 30° C., about 40° C. about 45° C., about 50° C., about 55° C., about 60° C., about 65° C., about 70° C., about 75° C. or greater than 75° C. Generally, the temperature conditions will be selected so as to promote disruption of the biological cell or entity. For example, if the lysis buffer contains an enzyme (e.g., Proteinase K), the temperature may be selected such that the enzyme retains catalytic activity. In some cases, the temperature may be selected for optimal catalytic activity of the lysis enzyme. The temperature may also be selected to neutralize any inhibitory proteins within the sample, but should not destroy or disrupt the integrity of the nucleic acid molecules released therefrom. In some cases, the lysis buffer does not contain any enzymes.
- The presence of one or more components (e.g., Proteinase K) in the lysis buffer may affect or interfere with downstream applications. In some cases, an additional incubation step may be performed to, for example, destroy or inactivate the one or more interfering components (e.g., Proteinase K) used in the lysis step. The subsequent incubation step may be from about 0.01 seconds to about 48 hours. For example, the biological cell or entity is incubated in the lysis buffer from about 0.01 seconds, about 0.05 seconds, about 1 second, about 10 seconds, about 30 seconds, about 1 minute, about 5 minutes, about 10 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 48 hours, or greater than 48 hours. In some examples, the additional incubation step may occur at a temperature between about 57° C. and about 100° C. For example, the additional incubation step may occur at a temperature of about 57° C., about 58° C., about 59° C., about 60° C., about 61° C., about 62° C., about 63° C., about 64° C., about 65° C., about 66° C., about 67° C., about 68° C., about 69° C., about 70° C., about 71° C., about 72° C., about 73° C., about 74° C., about 75° C., about 76° C., about 77° C., about 78° C., about 79° C., about 80° C., about 81° C., about 82° C., about 83° C., about 84° C., about 85° C., about 86° C., about 87° C., about 88° C., about 89° C., about 90° C., about 91° C., about 92° C., about 93° C., about 94° C. , about 95° C., about 96° C., about 97° C., about 98° C., about 99° C., about 100° C. or greater than 100° C.,
- In some aspects, the extracted nucleic acids may be utilized at this stage for any downstream processes, without any purification steps. In some cases, the extracted nucleic acid molecules may be used in one or more amplification reactions. For example, the extracted nucleic acid molecules may be used in one or more polymerase chain reactions (PCR), in the case where RNA is extracted, the RNA may be reverse transcribed (i.e., using a reverse transcriptase) prior to performing the downstream application. Any known method of PCR may be performed using the extracted nucleic acid molecules provided herein.
- In some cases, the biological sample can be a tissue sample. In some cases, the tissue sample is a blood sample. In some cases, the biological sample comprises a bodily fluid taken from a subject. In some cases, the bodily fluid comprises one or more cells comprising nucleic acids. In some cases, the one or more cells comprise one or more microbial cells, including, but not limited to, bacteria, archaebacteria, protists, and fungi. In some cases, the biological sample includes one or more virus particles. In some cases, the biological sample comprises one or more microbes that causes a sexually-transmitted disease. A sample may comprise a sample from a subject, such as whole blood; blood products; red blood cells; white blood cells; buffy coat; swabs; urine; sputum; saliva; semen; lymphatic fluid; endolymph; perilymph; gastric, juice; bile; mucus; sebum; sweat; tears; vaginal secretion; vomit; feces; breast milk; cerumen; amniotic fluid; cerebrospinal fluid; peritoneal effusions; pleural effusions; biopsy samples; fluid from cysts; synovial fluid; vitreous humor; aqueous humor; bursa fluid; eye washes; eye aspirates; plasma; serum; pulmonary lavage; lung aspirates; animal, including human, tissues, including but not limited to, liver, spleen, kidney, lung, intestine, brain, heart, muscle, pancreas, cell cultures, as well as lysates, extracts, or materials and fractions obtained from the samples described above or any cells and microorganisms and viruses that may be present on or in a sample. A sample may comprise cells of a primary culture or a cell line. Examples of cell lines include, but are not limited to 293-T human kidney cells, A2870 human ovary cells, A431 human epithelium, B35 rat neuroblastoma cells, BHK-21 hamster kidney cells, BR293 human breast cells, CHO chinese hamster ovary cells, CORL23 human lung cells, HeLa cells, or Jurkat cells. The sample may comprise a homogeneous or mixed population of microbes, including one or more of viruses, bacteria, protists, monerans, chromalveolata, archaea, or fungi. The biological sample can be a urine sample, a vaginal swab, a cervical swab, an anal swab, or a cheek swab. The biological sample can be obtained from a hospital, laboratory, clinical or medical laboratory. The sample can be obtained from a subject.
- Non-limiting examples of sample sources include environmental sources, industrial sources, one or more subjects, and one or more populations of microbes. Examples of environmental sources include, but are not limited to agricultural fields, lakes, rivers, water reservoirs, air vents, walls, roofs, soil samples, plants, and swimming pools. Examples of industrial sources include, but are not limited to clean rooms, hospitals, food processing areas, food production areas, food stuffs, medical laboratories, pharmacies, and pharmaceutical compounding centers. Examples of subjects from which polynucleotides may be isolated include multicellular organisms, such as fish, amphibians, reptiles, birds, and mammals. Examples of mammals include primates (e.g., apes, monkeys, gorillas), rodents (e.g., mice, rats), cows, pigs, sheep, horses, dogs, cats, or rabbits. In some examples, the mammal is a human. In some cases, the sample is from an individual subject.
- In some cases, the biological sample is provided in a sample buffer. In some cases, the sample buffer comprises bovine serum albumin and/or a detergent. In some cases, the sample buffer comprises about 0.1% to 5% bovine serum albumin. In some cases, the sample buffer comprises about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4%, or 5% bovine serum albumin. In some cases, the sample buffer comprises about 0.1% to 20% detergent. In some cases, the sample buffer comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% detergent. In some cases, the detergent is Tween-20. The choice of sample buffer to be used may depend on the intended method. For example the choice of sample buffer may different when a wash step will be used to when a wash step is not used. If a wash step will not be used then the sample buffer may be a buffer suitable for lysis and subsequent PCR reactions.
- Some commercial collection mediums or sample buffers contain chemicals for the preservation of microorganisms for future growth, or chemicals that lyse target organisms such as guanidinium thiocyanate. As such, these collection media are inhibitory to DNA polymerase and must be washed from a sample before PCR via, filtration or similar process. The methods described herein may not require the target organism to be kept in a viable state, or for the sample buffer to be able to lyse the cells. Some components which may be found in a sample buffer suitable for use with the methods and devices of this disclosure include: Tris HCL, Tween-80, BSA, Proclin and Antifoam SE-15. In one embodiment a sample buffer may have a composition of: 50 mM Tris pH 8.4, Tween-80, 2% (w/v), BSA, 0.25% (w/v), Proclin 300 0.03% (w/v), and Antifoam 0.002% (v/v) made up in purified water.
- Tris 1-ICL is a common buffer for PCR. When it is heated during thermocycling, the pH may drop, for example a Tris buffer with pH of 8.4 at a temperature of 25° C. may drop to a pH of about ˜7.4 when heated to about 95° C. The range of concentrations could be from 0.1 mM to 1 M. The pH range could be from 6 to 10. Any other PCR compatible buffer could be used, for example HEPES.
- Tween-80 is a nonionic surfactant and emulsifier that may help to elute target organisms off of a swab. The range of concentrations could be from 0.01% (w/v) to 20% (w/v). Any other PCR compatible surfactant and/or emulsifier could be used.
- Proclin 300 is a broad spectrum antimicrobial used as a preservative to ensure a long shelf life of the collection media. It could be used from 0.01% (w/v) to 0.1% (w/v). Many other antimicrobials are known in the art and could be used in a sample buffer.
- Antifoam SE-15 is present to reduce foaming during manufacturing and fluidic movement through the device. It could be used from 0.001% (v/v) to 1% (v/v). Any other antifoam agent could also be used, for example Antifoam 204, Antifoam A, Antifoam B, Antifoam C, or Antifoam Y-30.
- The devices and methods provided herein may be utilized to prepare nucleic acids for downstream applications. The downstream applications may be utilized to, e.g., detect the presence or absence of a nucleic acid sequence present in the sample. In some instances, the devices and methods can be utilized to detect the presence or absence of one or more microbes in a biological sample. In some cases, the one or more microbes are pathogens (i.e., disease-causative). In some cases, the one or more microbes are infectious. In some cases, the one or more microbes cause disease in a subject. In some cases, the disease is a sexually transmitted disease.
- In some aspects, the devices and methods can be utilized to detect the presence or absence of nucleic acids associated with one or more bacterial cells in the biological sample. In some cases, one or more bacterial cells are pathogens. In some cases, the one or more bacterial cells are infectious. Non-limiting examples of bacterial pathogens that can be detected include Mycobacteria (e.g. M. tuberculosis, M. bovis, M. ovium, M. leprae, and M. africanum), rickettsia, mycoplasma, chlamydia, and legionella. Some examples of bacterial infections include, but are not limited to, infections caused by Gram positive bacillus (e.g., Listeria, Bacillus such as Bacillus anthracia, Erysipelothrix species), Gram negative bacillus (e.g., Bartonella, Brucella, Campylobacter, Enterobacter, Escherichia, Francisella, Herophilus, Klebsiella, Morganella, Proteus, Providencia, Pseudomonas, Salmonella, Serratia, Shigella, Vibrio and Yersinia species), spirochete bacteria (e.g., Borrelia species including Borrelia burgdorferi that causes Lyme disease), anaerobic bacteria (e.g., Actinomyces and Clostridium species), Gram positive and negative coccal bacteria, Enterococcus species, Streptococcus species, Pneumococcus species, Staphylococcus species, and Neisseria species. Specific examples of infectious bacteria include, but are not limited to: Helicobacter pyloris, Legionella pneumophilia, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium kansaii, Mycobacterium gordonae, Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenes (Group A Streptococcus), Streptococcus agalactiae, (Group B Streptococcus), Streptococcus viridans, Streptococcus faecalis, Streptococcus bovis, Streptococcus pneumoniae, Haemophilus influenzae, Bacillus antracis, Erysipelothrix rhusiopathiae, Clostridium Enterobacter aerogenes, Klebsiella pneumoniae, Pasturella multocida, Fusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidium, Treponema pertenue, Leptospira, Rickettsia, and Actinomyces israelii, Acinetobacter, Bacillus, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Haemophilus, Helicobacter, Mycobacterium, Mycoplasma, Stenotrophomonas, Treponema, Vibrio, Yersinia, Acinetobacter baumanii, Bordetella pertussis, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Corynebacterium diphtheriae, Enterobacter sazakii, Enterobacter agglomerans, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Francisella tularensis, Helicobacter Legionella pneurnophila, Leptospira interrogans, Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium ulcerans, Mycoplasma pneumoniae, Pseudomonas aeruginosa, Rickettsia rickettsii, Salmonella typhi, Salmonella typhimurium, Salmonella enterica, Shigella sonnei, Staphylococcus epidermidis, Staphylococcus saprophyticus, Stenotrophomonas Vibrio cholerae, Yersinia pestis, and the like. In some instances, the infectious bacteria is Neisseria gonorrhoeae or Chlamydia trachomatis.
- In some aspects, the devices and methods can be utilized to detect the presence or absence of nucleic acids associated with one or more viruses in the biological sample. Non-limiting examples of viruses include the herpes virus (e.g., human cytomegalomous virus (HCMV), herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), varicella zoster virus (VZV), Epstein-Barr virus), influenza. A virus and Hepatitis C virus (HCV) or a picornavirus such as Coxsackievirus B3 (CVB3). Other viruses may include, but are not limited to, the hepatitis B virus, HIV, poxvirus, hepadavirus, retrovirus, and RNA viruses such as flavivirus, togavirus, coronavirus, Hepatitis D virus, orthomyxovirus, paramyxovirus, rhabdovirus, bunyavirus, filo virus, Adenovirus, Human herpesvirus,
type 8, Human papillomavirus, BK virus, JC virus, Smallpox, Hepatitis B virus, Human bocavirus, Parvovirus B19, Human astrovirus, Norwalk virus, coxsackievirus, hepatitis A virus, poliovirus, rhinovirus, Severe acute respiratory syndrome virus, Hepatitis C virus, yellow fever virus, dengue virus, West Nile virus, Rubella virus, Hepatitis E virus, and Human immunodeficiency virus (HIV). In some cases, the virus is an enveloped virus. Examples include, but are not limited to, viruses that are members of the hepadnavirus family, herpesvirus family, iridovirus family, poxvirus family, flavivirus family, togavirus family, retrovirus family, coronavirus family, filovirus family, rhabdovirus family, bunyavirus family, orthomyxovirus family, paramyxovirus family, and arenavirus family. Other examples include, but are not limited to, Hepadnavirus hepatitis B virus (HBV), woodchuck hepatitis virus, ground squirrel (Hepadnaviridae) hepatitis virus, duck hepatitis B virus, heron hepatitis B virus, Herpesvirus herpes simplex virus (HSV)types porcine circovirus type type 1, cotton tail rabbit papillomavirus, human adenovirus (HAdV-A, HAdV-B, HAdV-C, HAdV-D, HAdV-E, and HAdV-F), fowl adenovirus A, bovine adenovirus D, frog adenovirus, Reovirus, human orbivirus, human cold virus, mammalian orthoreovirus, bluetongue virus, rotavirus A, rotaviruses (groups B to G). Colorado tick fever virus, aquareovirus A,cypovirus 1, Fiji disease virus, rice dwarf virus, rice ragged stunt virus,idnoreovirus 1,mycoreovirus 1, Birnavirus, bursal disease virus, pancreatic necrosis virus, Calici virus, swine vesicular exanthema virus, rabbit hemorrhagic disease virus, Norwalk virus, Sapporo virus, Picornavirus, human polioviruses (1-3), human coxsackieviruses Al-22, 24 (CAI-22 and CA24, CA23 (echovirus 9)), human coxsackieviruses (BI-6 (CBI-6)), human echoviruses 1-7, 9, 11-27, 29-33, vilyuish virus, simian enteroviruses 1-18 (SEV1-18), porcine enteroviruses 1-11 (PEV1-11), bovine enteroviruses 1-2 (BEV1-2), hepatitis A virus, rhinoviruses, hepatoviruses, cardio viruses, aphthoviruses and echoviruses. The virus may be phage. Examples of phages include, but are not limited to T4, T5, λ phage, T7 phage, G4, P1, φ6,Thermoproteus tenax virus 1, M13, MS2, Qβ, φX174, Φ29, PZA, Φ15, BS32, B103, M2Y (M2), Nf, GA-1, FWLBc1, FWLBc2, FWLLm3, B4. The reference database may comprise sequences for phage that are pathogenic, protective, or both. In some cases, the virus is selected from a member of the Flaviviridae family (e.g., a member of the Flavivirus, Pestivirus, and Hepacivirus genera), which includes the hepatitis C virus, Yellow fever virus; Tick-borne viruses, such as the Gadgets Gully virus, Kadam virus, Kyasanur Forest disease virus, Langat virus, Omsk hemorrhagic fever virus, Powassan virus, Royal Farm virus, Karshi virus, tick-borne encephalitis virus, Neudoerti virus, Sofjin virus, Louping ill virus and the Negishi virus; seabird tick-borne viruses, such as the Meaban virus, Saumarez Reef virus, and the Tyuleniy virus; mosquito-borne viruses, such as the Aroa virus, dengue virus, Kedougou virus, Cacipacore virus, Koutango virus, Japanese encephalitis virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Usutu virus, West Nile virus, Yaounde virus, Kokobera virus, Bagaza virus, Ilheus virus, Israel turkey meningoencephalo-myelitis virus, Ntaya virus, Tembusu virus, Zika virus, Banzi virus, Bouboui virus, Edge Hill virus, Jugra virus, Saboya virus, Sepik virus, Uganda S virus, Wesselsbron virus, yellow fever virus; and viruses with no known arthropod vector, such as the Entebbe bat virus, Yokose virus, Apoi virus, Cowbone Ridge virus, Jutiapa virus, Modoc virus, Sal Vieja virus, San Perlita virus, Bukalasa bat virus, Carey Island virus, Dakar bat virus, Montana myotis leukoencephalitis virus, Phnom Penh bat virus, Rio Bravo virus, Tamana bat virus, and the Cell fusing agent virus. In some cases, the virus is selected from a member of the Arenaviridae family, which includes the Ippy virus, Lassa virus (e.g., the Josiah, LP, or GA391 strain), lymphocytic choriomeningitis virus (LCMV), Mobala virus, Mopeia virus, Amapari virus, Flexal virus, Guanarito virus, Junin virus, Latino virus, Machupo virus, Oliveros virus, Parana virus, Pichinde virus, Pirital virus, Sabia virus, Tacaribe virus, Tamiami virus, Whitewater Arroyo virus, Chapare virus, and Lujo virus. In some cases, the virus is selected from a member of the Bunyaviridae family (e.g., a member of the Hantavirus, Nairovirus, Orthobunyavirus, and Phlebovirus genera), which includes the Hantaan virus, Sin Nombre virus, Dugbe virus, Bunyamwera virus, Rift Valley fever virus, La Crosse virus, Punta Toro virus (PTV), California encephalitis virus, and Crimean-Congo hemorrhagic fever (CCHF) virus. In some cases, the virus is selected from a member of the Filoviridae family, which includes the Ebola virus (e.g., the Zaire, Sudan, Ivory Coast, Reston, and Uganda strains) and the Marburg virus (e.g., the Angola, Ci67, Musoke, Popp, Ravn and Lake Victoria strains); a member of the Togaviridae family (e.g., a member of the Alphavirus genus), which includes the Venezuelan equine encephalitis virus (VEE), Eastern equine encephalitis virus (EEE), Western equine encephalitis virus (WEE), Sindbis virus, rubella virus, Semliki Forest virus, Ross River virus, Barmah Forest virus, O'nyong'nyong virus, and the chikungunya virus; a member of the Poxyiridae family (e.g., a member of the Orthopoxvirus genus), which includes the smallpox virus, monkeypox virus, and vaccinia virus; a member of the Herpesviridae family, which includes the herpes simplex virus (HSV; types 1, 2, and 6), human herpes virus (e.g., types 7 and 8), cytomegalovirus (CMV), Epstein-Barr virus (EBV), Varicella-Zoster virus, and Kaposi's sarcoma associated-herpesvirus (KSHV); a member of the Orthomyxoviridae family, which includes the influenza virus (A, B, and C), such as the H5N1 avian influenza virus or H1N1 swine flu; a member of the Coronaviridae family, which includes the severe acute respiratory syndrome (SARS) virus; a member of the Rhabdoviridae family, which includes the rabies virus and vesicular stomatitis virus (VSV); a member of the Paramyxoviridae family, which includes the human respiratory syncytial virus (RSV), Newcastle disease virus, hendravirus, nipahvirus, measles virus, rinderpest virus, canine distemper virus, Sendai virus, human parainfluenza virus (e.g., 1, 2, 3, and 4), rhinovirus, and mumps virus; a member of the Picornaviridae family, which includes the poliovirus, human enterovirus (A, B, C, and D), hepatitis A virus, and the coxsackievirus; a member of the Hepadnaviridae family, which includes the hepatitis B virus; a member of the Papillainoviridae family, which includes the human papilloma virus; a member of the Parvoviridae family, which includes the adeno-associated virus; a member of the Astroviridae family, which includes the astrovirus; a member of the Polyomaviridae family, which includes the JC virus, BK virus, and SV40 virus; a member of the Calciviridae family, which includes the Norwalk virus; a member of the Reoviridae family, which includes the rotavirus; and a member of the Retroviridae family, which includes the human immunodeficiency virus (HIV; e.g., types 1 and 2), and human T-lymphotropic virus Types I and II (HTLV-1 and HTLV-2, respectively). - In some aspects, the devices and methods can be utilized to detect the presence or absence of nucleic acids associated with one or more fungi in the biological sample. Examples of infectious fungal agents include, without limitation Aspergillus, Blastomyces, Coccidioides, Cryptococcus, Histoplasma, Paracoccidioides, Sporothrix, and at least three genera of Zygomycetes. The above fungi, as well as many other fungi, can cause disease in pets and companion animals. The present teaching is inclusive of substrates that contact animals directly or indirectly. Examples of organisms that cause disease in animals include Mulassezia furfur, Epidermophpon floccosur, Trichophyton mentagrophytes, Trichophyton rubrum, Trichophyton tonsurans, Trichophyton equinum, Dermatophilus congolensis, Microsporum canis, Microsporu audouinii, Microsporum gypseum, Malassezia ovale, Pseudalleseheria, Seopulartopsis, Scedosporium, and Candida albicans. Further examples of fungal infectious agent include, but are not limited to, Aspergillus, Blastomyces dermatitidis, Candida, Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum var. capsulatum, Paracoccidioides brasiliensis, Sporothrix schenckii, Zygomycetes spp., Absidia corymbifera, Rhizomucor pusillus, or Rhizopus arrhizus.
- In some aspects, the devices and methods can be utilized to detect the presence or absence of nucleic acids associated with one or more parasites in the biological sample. Non-limiting examples of parasites include Plasmodium, Leishmania, Babesta, Treponema, Borrelia, Trypanosotna, Toxoplasma gondii, Plasniodium falciparum, P. vivax, P. ovale, P. malariae, Trypanosoma spp., or Legionella spp. In some cases, the parasite is Trichomonas vaginalis.
- In some cases, the biological sample can be an environmental sample comprising medium such as water, soil, air, and the like. In some cases, the biological sample can be a forensic sample (e.g., hair, blood, semen, saliva, etc.). In some cases, the biological sample can comprise an agent used in a bioterrorist attack (e.g., influenza, anthrax, smallpox).
- In some aspects, the biological sample comprises an infectious agent associated with a sexually-transmitted disease (STD) or a sexually-transmitted infection (STI). Non-limiting examples of STDs or STIs and associated infectious agents that may be detected with the devices and methods provided herein may include, Bacterial Vaginosis; Chlamydia (Chlamydia trachomatis); Genital herpes (herpes virus); Gonorrhea (Neisseria gonorrhoeae); Hepatitis B (Hepatitis B virus); Hepatitis C (Hepatitis C virus); Genital Warts, Anal Warts, Cervical Cancer (Human Papillomavirus); Lymphogranuloma venereum (Chlamydia trachomatis); Syphilis (Treponema pallidum); Trichomoniasis (Trichomonas vaginalis); Yeast infection (Candida); and Acquired Immunodeficiency Syndrome (Human Immunodeficiency Virus).
- In some cases, the devices and methods described herein may demonstrate improved performance when compared with traditional methods. For example, in some cases, the devices and methods may result in the extraction and preparation of nucleic acid molecules suitable for use in a polymerase chain reaction (PCR) in a shorter period of time when compared with other methods. In some cases, the devices and methods may result in the extraction and preparation of nucleic acid molecules suitable for use in a PCR reaction in 20 minutes or less. For example, the extraction and preparation of nucleic acid molecules as described herein may be achieved in about 20 minutes, 19 minutes, 18 minutes, 17 minutes, 16 minutes, 15 minutes. 14 minutes, 13 minutes, 12 minutes, 11 minutes, 10 minutes, 9 minutes, 8 minutes, 7 minutes, 6 minutes, 5 minutes, 4 minutes, 3 minutes, 2 minutes, 1 minute or less than 1 minute. In some cases, the extraction and preparation of nucleic acid molecules as described herein is achieved in about 5 minutes or less. In some cases, the method extracts nucleic acid molecules in about 5 minutes or less at a quality sufficient to successfully run a polymerase chain reaction (PCR).
- A quality of extracted nucleic acid sufficient to run a polymerase chain reaction refers to the quantity of extracted nucleic acid, the purity of the nucleic acid and the shearing of the nucleic acid (average length of nucleic acid molecules). A sufficient quantity of nucleic acid may refer to about 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1 μg. A sufficient quantity may also refer to the concentration of the nucleic acid in the eluted liquid. The concentration of the eluted nucleic acid may be about 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5. 0.6, 0.7, 0.8, 0.9 or 1 μg/μL. The nucleic acid produced may comprise nucleic acid fragments with an average length of at least about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more than 1000 base pairs.
- A quality of extracted nucleic acid sufficient to run a polymerase chain reaction may be a sample that produces at least 70% efficiency as determined by a qPCR standard curve. The efficiency of the PCR may be between 90-100% (−3.6≥slope≥−3.3). Efficiency of qPCR may be quantified by calculating the cycle difference between a sample and 10-fold dilution of the sample. For example if the efficiency is 100%, the Ct values of a 10 fold dilution of input DNA will be 3.3 cycles apart (there is a 2-fold change for each change in Ct).
- In some cases, the nucleic acid sample prepared using the devices and methods described herein have similar or improved purity as compared to nucleic acid samples prepared using other methods. The purity may be measured, for example, as a ratio of the absorbance at 260 nm and 280 nm A260/A280). For example, a nucleic acid samples comprising DNA prepared using the devices and methods may have a A260/A280 ratio of about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0. in some cases, the extracted nucleic acid molecules comprise DNA and the DNA has an A260/A280 ratio of at least 1.5. In another example, a nucleic acid sample comprising RNA prepared using the devices and methods may have an A260/A280 ratio of about 1.7, about 1.8, about 1.9, about 2.0, about 2.1, or about 2.2. In some cases, the extracted nucleic acid molecules comprise RNA and the RNA has an A260/A280 ratio of at least 1.7.
- Downstream processes such as polymerase chain reaction (PCR) may be sensitive to certain molecules present in a sample. For example, the presence of one or more lysis reagents (e.g., Proteinase K) may hinder or inhibit downstream processes. In some cases, the nucleic acid molecules described herein are extracted from the one or more biological cells or entities with a qualify that is sufficient to successfully perform one or more downstream processes. In some cases, the extracted nucleic acid molecules may be of a quality sufficient to successfully perform a PCR. For example, the extracted nucleic acid molecules may be of a quality sufficient to perform an amplification reaction on a target nucleic acid molecule present in the extracted nucleic acid molecules to generate amplified target nucleic molecules. In some cases, a positive control may be used (e.g., a biological cell that is known to be positive for the target molecule) to confirm that the extraction process is performed successfully. The extracted nucleic acid molecules described herein are generally substantially free of molecules that inhibit downstream processes (e.g., Proteinase K).
- In some cases, the nucleic acid samples may have similar or improved yields as compared to nucleic acid samples prepared using other methods from the same amount of starting material. For example, nucleic acid samples prepared using the methods and devices described herein may have about 5%, about 10% about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%. about 99% or greater yields than using other nucleic acid extraction methods from the same amount of starting material. 100831 Standard nucleic acid extraction methods may involve the use of centrifuges and vacuums. In some cases, the methods and devices herein do not involve the use of centrifuges or vacuums.
- In some aspects, devices are provided for performing any of the methods described herein. For example,
FIG. 10 is a schematic illustration of a molecular diagnostic test device 1000 (also referred to as a “test device” or “device”, according to an embodiment. The schematic illustration describes the primary components of thetest device 1000 as shown inFIG. 11 . Thetest device 1000 is an integrated device (i.e., the modules are contained within a single housing) that is suitable for use within a point-of-care setting (e.g., doctor's office, pharmacy or the like), decentralized test facility, or at the user's home. In some embodiments, thedevice 1000 can have a size, shape and/or weight such that thedevice 1000 can be carried, held, used and/or manipulated in a user's hands (i.e., it can be a “handheld” device). A handheld device may have dimensions less than 15 cm×15 cm×15 cm, or less than 15 cm×15 cm×10 cm, or less than 12 cm×12 cm×6 cm . In other embodiments, thetest device 1000 can be a self-contained, single-use device. In some embodiments, thetest device 1000 can be configured with lock-outs or other mechanisms to prevent re-use or attempts to re-use the device. - Further, in some embodiments, the
device 1000 can be a CLIA-waived device and/or can operate in accordance with methods that are CLIA waived. Similarly stated, in some embodiments, the device 1000 (and any of the other devices shown and described herein) is configured to be operated in a sufficiently simple manner, and can produce results with sufficient accuracy to pose a limited likelihood of misuse and/or to pose a limited risk of harm if used improperly. In some embodiments, the device 1000 (and any of the other devices shown and described herein), can be operated by a user with minimal (or no) scientific training, in accordance with methods that require little judgment of the user, and/or in which certain operational steps are easily and/or automatically controlled. In some embodiments, the moleculardiagnostic test device 1000 can be configured for long term storage in a manner that poses a limited likelihood of misuse (spoilage of the reagent(s), expiration of the reagents(s), leakage of the reagent(s), or the like). In some embodiments, the moleculardiagnostic test device 1000 is configured to be stored for up to about 36 months, up to about 32 months, up to about 26 months, up to about 24 months, up to about 20 months, up to about 18 months, or any values there between. - The
test device 1000 is configured to manipulate a biological sample S1 to produce one or more output signals associated with a target cell. Specifically, thedevice 1000 includes asample preparation module 1200, an inactivation module 1300 (also referred to as a lysing module), a fluidic drive (or fluid transfer)module 1400, amixing chamber 1500, an amplification module, a detection module and a power and control module (not shown). The test device and certain components therein can be similar to any of the molecular test devices shown and described herein or in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety. Accordingly, a detailed description of certain modules (e.g., the fluidic drive module 1400) is not provided herein. A description of each of the modules is provided below. -
FIG. 11 shows a perspective exploded view of the moleculardiagnostic test device 1000. Thediagnostic test device 1000 includes a housing (including atop portion 1010 and a bottom portion 1030), within which the modules described herein are contained. Similarly stated, the housing (including thetop portion 1010 and/or the bottom portion 1030) surround and/or enclose the modules. As shown, thetop housing 1010 defines adetection opening 1011 that is aligned with thedetection module 1800 such that the signal produced by and/or on each detection surface of thedetection module 1800 is visible through thedetection opening 1011. In some embodiments, thetop housing 1010 and/or the portion of thetop housing 1010 surrounding thedetection opening 1011 is opaque (or semi-opaque), thereby “framing” or accentuating the detection openings. In some embodiments, for example, thetop housing 1010 can include markings (e.g., thick lines, colors or the like) to highlight thedetection opening 1011. For example, in some embodiments, thetop housing 1010 can include indicia identifying the detection opening to a specific disease (e.g., Chlamydia trachomatis (CT), Neisseria gonorrhea (NG) and Trichomonas vaginalis (TV)) or control. In other embodiments, thetop housing 1010 can include a series of color spots having a range of colors associated with a range of colors that is likely produced by the signals produced during the test. In this manner, the housing design can contribute to reducing the amount of user judgment required to accurately read the test. - Referring to
FIG. 11 , thesample preparation module 1200 includes asample input module 1170, awash module 1210, anelution module 1260, afilter assembly 1230, and various fluidic conduits (e.g., tubes, lines, valves, etc.) connecting the various components. Thedevice 1000 also includes the lysing module 1300 (see e.g., the lysing module 2300 shown inFIGS. 13-16 ), which, together with thesample preparation module 1200, performs the nucleic acid extraction according to any of the methods described herein. Thus, although thesample preparation module 1200 and theinactivation module 1300 are described as two separate modules, in other embodiments, the structure and function of thesample preparation module 1200 can be included within or performed by theinactivation module 1300 and vice-versa. Similarly stated, any of the sample preparation modules, inactivation modules and/or lysing modules described herein can include any of the structure and/or perform any of the functions of the other modules to perform any of the methods of sample preparation or nucleic acid extraction described herein. By eliminating the need for external sample preparation and a cumbersome instrument, thedevice 1000 is suitable for use within a point-of-care setting (e.g., doctor's office, pharmacy or the like) or at the user's home, and can receive any suitable biological sample S1. The biological sample S1 (and any of the input samples described herein) can be, for example, blood, urine, male urethral specimens, vaginal specimens, cervical swab specimens, and/or nasal swab specimens gathered using a commercially available sample collection kit. - The
sample input module 1170 is disposed within thehousing 1010, and is configured receive a biological sample S1 containing a biological entity. The biological sample S1 can be any of the sample types described herein, and the biological entity can be any of the entities described herein. Thesample input module 1170 defines asample volume 1174 that can be selectively covered by thecap 1152. Thecap 1152 can include seals or other locking members such that it can be securely fastened to the lower housing 1030 (or other portions of the device 1000) and/or can be closed during shipping, after delivery of a sample thereto, or the like. In some embodiments, theinput port cap 1152 can include an irreversible lock to prevent reuse of thedevice 1000 and/or the addition of supplemental sample fluids. In this manner, thedevice 1000 can be suitably used by untrained individuals. - The
wash module 1210 includes a housing that defines a wash volume containing any suitable wash composition. For example, in some embodiments, thewash module 1210 can include a gaseous first wash composition (e.g., nitrogen, air, or another inert gas) and a liquid second wash composition. In this manner, the wash operation can include an “air purge” of thefilter assembly 1230. Specifically, when thesample input module 1170 and/or thewash module 1210 is actuated, a serial flow of the first wash composition (gas) followed by the second wash composition (liquid). By first including a gas (or air) wash (i.e., the first wash composition), the amount of liquid constituents from the input sample conveyed to the filter assembly 1230 (indicated by the flow S2 inFIG. 10 ) can be reduced. Said another way, after delivery of the input sample, thefilter assembly 1230 will retain the desired sample cells (or organisms) and some amount of residual liquid. By forcing the first, gaseous wash composition through the filter (i.e., an “air wash”), the amount of residual liquid can be minimized, This arrangement can reduce the amount of liquid wash (e.g., the second wash composition) needed to sufficiently prepare the sample particles. Reducing the liquid volume contributes to the reduction size of thedevice 1000, and also reduces the likelihood of potentially harmful shearing stress when the liquid wash is flowed through thefilter assembly 1230. - The sample input module 1170 (and any of the sample input modules described herein) and the wash module 1210 (and any of the wash modules described herein) can be actuated by any suitable mechanism to convey the biological sample SI towards the
filter assembly 1230 and/or thelysing module 1300 to enable the nucleic acid extraction methods described herein, For example, in the embodiment shown, thesample input module 1170 and thewash module 1210 are actuated by the sample actuator (or button) 1050. Thesample actuator 1050 is movably coupled to the housing, and is aligned with and can move a piston or plunger (not shown) within thesample volume 1174 when thesample input module 1170 is actuated. Thus, thesample actuator 1050 is a non-electronic actuator that is manually depressed by a user to actuate thesample input module 1170. In other embodiments, however, thesample actuator 1050 can be an electronic actuator. In some embodiments, thesample actuator 1050 can include a lock tab (not shown) that is fixedly received within the notch or opening of thehousing 1010 to fix thesample actuator 1050 in its second or “actuated” position, as described above. In this manner, thedevice 1000 cannot be reused after the initial actuation. - When actuated, the sample within the
sample volume 1174 is conveyed along with the wash solution(s) from thewash module 1210 towards thefilter assembly 1230. The flow of the biological sample S1 towards thefilter assembly 1230 is shown by the arrow S2 inFIG. 10 . Thefilter assembly 1230 is configured to filter and prepare the biological sample S1 (via the sample input operation and the sample wash operation), and to allow a back-flow elution operation to deliver captured particles from the filter membrane and deliver the eluted volume to lysingmodule 1300. Thefilter assembly 1230 can be toggled between two configurations to allow the flow of the biological sample S1 and wash solution in a first direction (towards the waste reservoir 1205), followed by a backflush of the elution reagent and the captured organisms (or cells) in a second direction (as indicated by the arrow S3 towards the lysing/inactivation module 1300). The toggling mechanism can be any suitable mechanism, such as those shown and described in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety. - The
filter assembly 1230 can include any suitable filter membrane that captures the target organism/entity while allowing the bulk of the liquid within the biological sample S1, the first wash composition, and the second wash composition to flow therethrough and into thewaste tank 1205. The filter membrane 1254 (and any of the filter membranes described herein) can be any suitable membrane and or combination of membranes as described herein. For example, in some embodiments, the filter membrane 1254 is a woven nylon filter membrane with a pore size of about 1 μm (e.g., 0.8 μm, 1.0 μm, 1.2 μm) enclosed between various plates of thefilter assembly 1230 such that there is minimal dead volume. - The elution module (or assembly) 1260 of the
sample preparation module 1200 is contained within the housing, and defines an elution volume within which an elution composition is stored. The elution composition can be any of the elution compositions described herein. In some embodiments, the elution composition can include proteinase which allows for the release of any bound cells and/or nucleic acid molecules (e.g., DNA) from the filter membrane. The output from theelution module 1260 can be selectively placed in fluid communication with thefilter assembly 1230. when the filter assembly is toggled into its second (or backflow) configuration. Thus, theelution module 1230 can include any suitable flow control devices, such as check valves, duck-bill valves, or the like to prevent flow back towards and/or into the elution volume. - The
elution module 1210 is actuated by the elution actuator (or button) 1070 (seeFIG. 1 ). Thereagent actuator 1070 is movably coupled to thelower housing 1030, and can exert force on a piston or other portion of theelution module 1210 to convey the elution composition back through the filter and towards the lysingmodule 1300, as shown by the arrow S3. In some embodiments, theelution actuator 1070 further includes a lock tab or other structure that is fixedly received within the notch or opening of the housing to fix theelution actuator 1070 in its second or “actuated” position. In this manner, thedevice 1000 cannot be reused after the actuation of the elution actuator. - In use, the
filter assembly 1230 recovers the target organisms with a certain efficiency, from a given starting volume. The wash operation then removes undesired material, without removing the target organisms (which stay present on the filter membrane). The elution operation then removes the target organism from the filter membrane, diluting the total amount of captured organisms in the volume of the elution solution, thus comprising the eluent. By modifying the total output volume of eluent, a higher or lower concentration of both target organism and any potential inhibiting matter can be achieved. In some embodiments, a further dilution can be achieved, if desired, by mixing the eluent solution with another reagent after the initial sample preparation. Given a known volume of eluent, and a known volume of diluent, a correct dilution factor can be achieved, through to maintain the reliability of the system very high dilution factors are avoided. - As shown by the arrow S3 in
FIG. 10 , the elution solution and the captured cells and/or organisms are conveyed during the elution operation back through thefilter assembly 1230, and to the inactivation module (or lysing module) 1300. Theinactivation module 1300 is configured to be fluidically coupled to and receive the eluted sample S3 from thesample preparation module 1200. In some embodiments, theinactivation module 1300 is configured for lysis of the received input fluid. In some embodiments, theinactivation module 1300 is configured for de-activating the enzymes present in input fluid after lysis occurs. In some embodiments, theinactivation module 1300 is configured for preventing cross-contamination between the output fluid and the input fluid. Theinactivation module 1300 can include any of the inactivation (or lysing) modules as described herein, including thelysing module 3300 and thelysing module 4300 described herein, - The mixing module (also referred to as simply the mixing chamber) 1500 mixes the output of
inactivation module 1300 with the reagents to conduct a successful amplification reaction. Similarly stated, themixing module 1500 is configured to reconstitute the reagent in a predetermined input volume, while ensuring even local concentrations of reagents in the entirety of the volume. In some embodiments, the mixingchamber module 1500 is configured to produce and/or convey a sufficient volume of liquid for theamplification module 1600 to provide sufficient volume output to thedetection module 1800. Themixing module 1500 can be any suitable mixing module, such as those shown and described in international Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety. - The fluidic drive (or transfer)
module 1400 can be a pump or series of pumps configured to produce a pressure differential and/or flow of the solutions within thediagnostic test device 1000. Similarly stated, thefluid transfer module 1400 is configured to generate fluid pressure, fluid flow and/or otherwise convey the biological sample S1, and the reagents through the various modules of thedevice 1000. Thefluid transfer module 1400 is configured to contact and/or receive the sample flow therein. Thus, in some embodiments, thedevice 1000 is specifically configured for a single-use to eliminate the likelihood that contamination of thefluid transfer module 1400 and/or thesample preparation module 1200 will become contaminated from previous runs, thereby negatively impacting the accuracy of the results. Thefluid transfer module 1500 can be any suitable fluid transfer module, such as those shown and described in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety. - After being mixed within the
mixing module 1500, the prepared sample is then conveyed to the amplification module 1600 (as shown by the arrow CC inFIG. 10 ). Theamplification module 1600 includes a flow member 1610 and aheater 1630. The flow member 1610 can be any suitable flow member that defines a volume or a series of volumes within which the that prepared solution S3 can flow and/or be maintained to amplify the target nucleic acid molecules within the solution S3. Theheater 1630 can be any suitable heater or group of heaters coupled to the flow member 1610 that can heat the prepared solution within the flow member 1610 to perform any of the amplification operations as described herein. For example, in some embodiments, the amplification module 1600 (or any of the amplification modules described herein) can be similar to the amplification modules shown and described in U.S. Patent Application No. 15/494,145, entitled “Printed Circuit Board Heater for an Amplification Module,” which is incorporated herein by reference in its entirety. In other embodiments, the amplification module 1600 (or any of the amplification modules described herein) can be similar to the amplification modules shown and described in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety. - In some embodiments, the flow member 1610 defines a single volume within which the prepared solution is maintained and heated to amplify the nucleic acid molecules within the prepared solution. In other embodiments, the flow member 1610 can define a “switchback” or serpentine flow path through which the prepared solution flows. Similarly stated, the flow member 1610 defines a flow path that is curved such that the flow path intersects the
heater 1630 at multiple locations. In this manner, theamplification module 1600 can perform a “flow through” amplification reaction where the prepared solution flows through multiple different temperature regions. - The flow member 1610 (and any of the flow members described herein) can be constructed from any suitable material and can have any suitable dimensions to facilitate the desired amplification performance for the desired volume of sample. For example, in some embodiments, the amplification module 1600 (and any of the amplification modules described herein) can perform 1000× or greater amplification in a time of less than 15 minutes. For example, in some embodiments, the flow member 1610 (and any of the flow members described herein) is constructed from at least one of a cyclic olefin copolymer or a graphite-based material. Such materials facilitate the desired heat transfer properties into the flow path. Moreover, in some embodiments, the flow member 1610 (and any of the flow members described herein) can have a thickness of less than about 0.5 mm. In some embodiments, the flow member 1610 (and any of the flow members described herein) can have a volume about 150 microliters or greater, and the flow can be such that at least 10 microliters of sample is amplified. In other embodiments, at least 20 microliters of sample are amplified by the methods and devices described herein. In other embodiments, at least 30 microliters of sample are amplified by the methods and devices described herein. In yet other embodiments, at least 50 microliters of sample are amplified by the methods and devices described herein.
- The
heater 1630 can be any suitable heater or collection of heaters that can perform the functions described herein to amplify the prepared solution. In some embodiments, theheater 1630 can establish multiple temperature zones through which the prepared solution flows and/or can define a desired number of amplification cycles to ensure the desired test sensitivity (e.g., at least 30 cycles, at least 34 cycles, at least 36 cycles, at least 38 cycles, or at least 40 cycles). The heater 1630 (and any of the heaters described herein) can be of any suitable design. For example, in some embodiments, theheater 1630 can be a resistance heater, a thermoelectric device (e.g. a Peltier device), or the like. In some embodiments, theheater 1630 can be one or more linear “strip heaters” arranged such that the flow path crosses the heaters at multiple different points. In other embodiments, theheater 1630 can be one or more curved heaters having a geometry that corresponds to that of the flow member 1610 to produce multiple different temperature zones in the flow path. - Although the
amplification module 1600 is generally described as performing a thermal cycling operation on the prepared solution, in other embodiment, theamplification module 1600 can perform any suitable thermal reaction to amplify nucleic acids within the solution. In some embodiments, the amplification module 1600 (and any of the amplification modules described herein) can perform any suitable type of isothermal amplification process, including, for example, Loop Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA), which can be useful to detect target RNA molecules, Strand Displacement Amplification (SDA), Multiple Displacement Amplification (MDA), Ramification Amplification Method (RAM), or any other type of isothermal process - The detection methods enabled by the
device 1000 include sequential delivery of the detection reagents and other substances within thedevice 1000, Further, thedevice 1000 is configured to be an “off-the-shelf” product for use in a point-of-care location (or other decentralized location), and is thus configured for long-term storage. Accordingly, thereagent storage module 1700 is configured for simple, non-empirical steps for the user to remove the reagents from their long-term storage containers, and for removing all the reagents from their storage containers using a single user action. In some embodiments, thereagent storage module 1700 and therotary selection valve 1340 are configured for allowing the reagents to be used in thedetection module 1800, one at a time, without user intervention. - Specifically, the
device 1000 is configured such that the last step of the initial user operation (i.e., the depressing of the reagent actuator 1080) results in dispensing the stored reagents. This action crushes and/or opens the sealed reagent containers present in the assembly and relocates the liquid for delivery. The rotary ventingselector valve 1340 allows thereagent module 1700 to be vented for this step, and thus allows for opening of the reagent containers, but closes the vents to the tanks once this process is concluded. Thus, the reagents remain in thereagent module 1700 until needed in thedetection module 1800. When a desired reagent is needed, therotary valve 1340 opens the appropriate vent path to thereagent module 1700, and thefluidic drive module 1400 applies vacuum to the output port of the reagent module 1700 (via the detection module 1800), thus conveying the reagents from thereagent module 1700. Thereagent module 1700 and thevalve 1340 can be similar to the reagent modules and valves shown and described in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety. - The
detection module 1800 is configured to receive output from theamplification module 1600 and reagents from thereagent module 1700 to produce a colorimetric change to indicate presence or absence of target organism in the initial input sample. Thedetection module 1800 also produces a colorimetric signal to indicate the general correct operation of the test (positive control and negative control). In some embodiments, color change induced by the reaction is easy to read and binary, with no requirement to interpret shade or hue. Thedetection module 1800 can be similar to the detection modules shown and described in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety. - In one aspect, a device is provided comprising: (a) an input port, configured to receive the biological sample comprising one or more biological cells or biological entities; (b) a filter assembly comprising a filter configured to capture the one or more biological cells or biological entities, wherein the input port is configured to relay the biological sample to the filter assembly; (c) one or more reservoirs comprising a wash solution, a lysis solution, or both, operably coupled to the filter assembly; (d) a waste chamber, operably coupled to the filter assembly and configured to receive waste from the filter assembly; and (e) an elution chamber, operably coupled to the filter assembly and configured to receive an eluent from the filter assembly.
- For example,
FIG. 12 depicts an example of a sample preparation device (or module) 2200 that may be used to perform the methods provided herein. Thesample preparation module 2200 can be included in any of the molecular diagnostic test devices described herein, including thedevice 1000 described above. It should be understood that the invention is not limited to a particular arrangement or configuration of the sample preparation device, and any suitable arrangement or configuration may be used. In some cases, thesample preparation device 2200 comprises aninput port 2170. The input port is configured to receive a sample (e.g., biological sample). For example, theinput port 2170 may be configured to receive about 50 μL to about 20 mL of a liquid sample. Theinput port 2170 may comprise a reservoir or chamber for holding or storing the sample. Theinput port 2170 may comprise a cap or lid (similar to thelid 1152 described above) that can be placed over the input port to contain the sample in the reservoir or chamber. Theinput port 2170 may be operably coupled to afilter assembly 2230. In use, the sample may be relayed (e.g., pushed or flowed) to thefilter assembly 2230 in any manner as described herein. Thefilter assembly 2230 may contain one or more filter membranes for capturing biological cells or entities on the filter. In some instances, the filter assembly 2230 (or any of the filter assemblies described herein) contains at least two filter membranes, one with a larger pore size and one with a smaller pore size. The two filter membranes may be arranged such that the sample first passes through the membrane with the larger pore size and then the membrane with the smaller pore size. The filter membrane may be of any suitable material as described herein, non-limiting examples including nylon, cellulose, polyethersulfone (PES), polyvinylidene difluoride (PVDF), polycarbonate, borosilicate glass fiber and the like. In some examples, the filter membrane is nylon. In some cases, the filter membrane has an average pore size of about 0.2 μm to about 20 μm. For example, the filter membrane may have an average pore size of about 0.2 μm, about 0.5 μm, about 1 μm, about 2 μm, about 3 μm, about 4 μm, about 5 μm, about 6 μm, about 7 μm, about 8 μm, about 9 μm, about 10 μm, about 11 μm , about 12 μm, about 13 μm, about 14 μm, about 15 μm, about 16 μm, about 17 μm, about 18 μm, about 19 μm, about 20 μm, or greater than 20 μm. In some examples, the surface of the filter membrane may be chemically treated or coated in such a way as to improve the binding of a biological cell or entity to the membrane, The biological cells or entities may be captured on the membrane while the majority of the liquid (“flow-through”) is flowed through the filter membrane. In some cases, the flow-through is substantially devoid of biological cells or entities. In some cases, the flow-through is disposed of by relaying the flow-through to one or more waste chambers operably coupled to the filter assembly. In other cases, the flow-through is relayed to a collection chamber for further downstream processing. - In some aspects, the
sample preparation device 2200 further comprises one ormore chambers 2210 or reservoirs for housing a wash solution, The one or more chambers or reservoirs (also referred to as wash modules) housing the wash solution may be operably coupled to the filter assembly such that actuation of the wash chamber orreservoir 2210 relays the wash solution to thefilter assembly 2230. In some cases, the wash solution is provided as a lyophilized pellet or bead that sits within the chamber or reservoir. The lyophilized pellet or bead can be reconstituted in one or more solutions. The wash solution may be flowed through thefilter assembly 2230 and the majority of the liquid can be collected in the one ormore waste chambers 2205. Non-limiting examples of wash solutions suitable for use with the sample preparation device have been described above. - In certain aspects, the sample preparation device further comprises one or more chambers or reservoirs for housing a lysis solution. The chamber or reservoir housing the lysis solution may be operably coupled to the filter assembly such that actuation of the chamber or reservoir relays the lysis solution to the filter assembly. In some cases, the lysis solution may be flowed through the filter assembly. The lysis solution may cause the lysis or disruption of the biological cells or entities on the filter membrane. In some cases, the reagents of the lysis solution are provided as a lyophilized pellet or bead that sits within the chamber or reservoir (e.g., within a lysing module, similar to the lysing
modules elution chamber 2260 which contains the lyophilized lysis enzyme, thereby reconstituting the enzyme. In cases where a lysis enzyme is used, the enzyme is stable in the device at ambient temperatures for long periods of time. For example, the enzyme may be stable in the device at ambient temperature for at least one day, at least two days, at least three days, at least four days, at least five days, at least six days, at least one week, at least two weeks, at least three weeks, at least four weeks, at least a month, at least two months, at least three months, at least four months, at least five months, at least six months, at least seven months, at least eight months, at least nine months, at least ten months, at least eleven months, at least one year, at least two years, at least three years, at least four years, at least five years, at least six years, at least seven years, at least eight years, at least nine years, at least ten years or longer. The lysis solution containing the lysed cells (“eluent”) may be collected in an elution chamber. In some cases, the lysis solution may be back-flowed through the filter assembly. In this instance, the biological cells or entities on the filter membrane may be pushed or washed from the membrane and collected in an elution chamber with the lysis solution. The cells or entities (or lysed or otherwise disrupted cells or entities) diluted in the lysis solution may be referred to as the “eluent.” - In some aspects, the
sample preparation device 2200 may further comprise one or more heating modules (not shown). The one or more heating modules may be operably coupled to theelution chamber 2260. The one or more heating modules may heat the elution chamber to a temperature sufficient for lysis of the biological cells or entities to occur. In some cases, the lysis solution comprises one or more enzymes (e.g., Proteinase K). In some cases, the one or more heating modules heats the elution chamber to a temperature sufficient for optimal performance of the lysis enzyme. In some examples, the heating module heats the elution chamber (and the fluid contained therein) to a temperature of about 4° C., about 10° C., about 15° C., about 20° C., about 25° C., about 30° C., about 40° C., about 45° C., about 50° C., about 55° C., about 60° C., about 65° C., about 70° C. about 75° C. or greater than 75° C. - In some aspects, the
sample preparation device 2200 and/or any of the molecular diagnostic devices described herein further comprises an inactivation chamber (also referred to as an inactivation module or a lysing module). The inactivation chamber may be operably coupled to the elution chamber. The eluent may be relayed from the elution chamber to the inactivation chamber. In some instances, the elution chamber and the inactivation chamber are the same chamber and are coupled to a heating element that can heat the chamber to an optimal lysis temperature, and can further heat the chamber to an optimal inactivation temperature (e.g., from about 56° C. to about 95° C.). - For example, a non-limiting example of an
inactivation chamber 3300 is depicted inFIGS. 13-16 . In this example, the inactivation chamber comprises achamber body 3310, abottom lid 3318, and aheater 3330. As depicted inFIG. 12 , thechamber body 3310 may defines aninput port 3312, a holding tank (or first volume) 3311, apermanent vent 3314, an inactivation segment (or second volume) 3321, and anoutput port 3313. Theinput port 3312 may be configured to receive the eluent from the elution chamber and/or directly from a filter assembly (e.g., the filter assembly 1230). In other embodiments, as described herein, theinput port 3312 can be fluidically coupled to a sample input module without the biological input being conveyed through a filter. The eluent may flow into the inactivation chamber (or lysing module 3300) and be collected in theholding tank 3311. The holding tank may have a capacity of about 1 μL to about 100 mL, about 100 μL, to about 10 mL, about 300 μL to 1 mL, or about 300 μL, to about 650 μL. The holding tank may be used to lyse the sample. For example, in some embodiments, the eluent containing the target organisms can be heated by theheater 3330 to maintain the eluent at or above a target lysing temperature. Similarly stated, in some embodiments, theheater 3330 can be coupled to thechamber body 3310 and/or thebottom lid 3318 such that theheater 3330 can convey thermal energy into thelysing module 3300 to produce a lysing temperature zone within the holding tank (or first volume) 3311. The lysing temperature zone can maintain the eluent at any of the temperatures and for any of the time periods described herein. - The
vent 3314 may be a hole which allows air to flow into or out of the lysing module 3300 (including thefirst volume 3311 and the second volume 3321) as sample is brought in or out. Thevent 3314 can also relieve pressure within either of thefirst volume 3311 or thesecond volume 3321 when the eluent is heated. Although described as being a permanent vent (i.e., a vent having a fixed opening), in some embodiments, the lysing module 3300 (or any of the lysing modules described herein) can have an active vent, For example, in some embodiments, the lysing module 3300 (or any of the lysing modules described herein) can include a valve that controls the venting of pressure and/or air from within thelysing module 3300. - The eluent may flow from the
holding tank 3311 through the inactivation segment of thelysing module 3300. More specifically, theholding tank 3311 is in fluid communication with theinactivation segment 3321 such that when a pressure gradient is applied across theinput port 3312 and theoutput port 3313, the eluent can flow from the holding tank 3311 (first volume) through the inactivation segment 3321 (second volume). The pressure gradient can be applied by any suitable mechanism, such as for example, a pump (e.g., the fluidic drive module 1400). Theinactivation segment 3321 may be a small, shallow channel that allows efficient and rapid heating of the eluent as it leaves the holding tank. In a non-limiting example, theinactivation segment 3321 is configured in a serpentine pattern. The serpentine pattern may allow for rapid inactivation of the lysis enzymes in the eluent. The eluent, after being flowed through the inactivation segment, may be flowed into theoutput port 3313 to be collected. The volume of liquid passed through the heated channel could be from about 1 μL to about 100 mL, about 10 μL to about 10 mL, about 100 μL to about 5 mL, or about 250 μL to about 750 μL. - As described above, the
inactivation module 3300 may be in contact with aheating element 3330, which can be, for example, a printed circuit board (PCB) heater. Theheating element 3330 may function to heat the eluent as it flows through the inactivation segment at a high temperature sufficient to inactivate the one or more lysis enzymes contained within the eluent. For example, the heating element may heat the eluent to about 57° C., about 58° C., about 59° C., about 60° C., about 61° C., about 62° C., about 63° C., about 64° C., about 65° C., about 66° C., about 67° C., about 68° C., about 69° C., about 70° C., about 71° C., about 72° C., about 73° C., about 74° C., about 75° C., about 76° C., about 77″ C, about 78° C., about 79″ C, about 80° C., about 81″ C, about 82° C., about 83° C., about 84° C. about 85° C., about 86° C., about 87° C., about 88° C., about 89° C., about 90° C., about 91° C., about 92° C., about 93° C., about 94° C. , about 95° C., about 96° C., about 97° C., about 98° C., about 99° C., about 100° C. or greater than 100° C. By heating the liquid eluent to a high temperature, the lysis enzymes as well as any other enzymes present can be deactivated. In some embodiments, the sample can be heated to about 95 C for about 3 minutes. In some embodiments, theserpentine path 3321 may be preceded by a check valve (not shown) to maintain a back pressure such that fluid does not enter theserpentine path 3321 before the desired temperature has been achieved. The serpentine area may be preheated to the desired temperature (50° C. to 99° C. or more) before fluid is drawn through the serpentine channel. If fluid were to flow into the serpentine channel prematurely without controlled flow, large bubbles may form in the channel as the heater warms up which could result in portions of the fluid to pass through the channel without receiving the proper temperature treatment. - In some embodiments there may be a one-way check valve that allows flow between the inactivation chamber and the mixing chamber (and prevents reverse flow). However, before flow can occur a certain amount of “cracking pressure” must be achieved. If the holding tank of the inactivation chamber is well vented from a vent port, the liquid that is placed into the holding tank will not flow into the serpentine channel due to the cracking pressure of the check valve at the exit of the serpentine channel. The cracking pressure may be from 0.05 to 50 psi. In some examples, the check valves used may have a cracking pressure of approximately 0.5 psi.
- As described, the solution within the
second volume 3321 is rapidly heated to temperatures of up to about 100 degrees Celsius. Thelysing module 3300 and/or the formulation of the input solution (e.g., the eluent), however, can collectively reduce the likelihood that the liquid portion of the input solution will boil during the lysing/inactivation operations. Such boiling can produce undesirable bubbles and/or air pockets and can reduce the repeatability of the lysing and/or inactivation operations. Moreover, to facilitate use of the device at a variety of different altitudes, thelysing module 3300 and/or the formulation of the input solution can collectively reduce the likelihood that the liquid portion of the input solution will boil at a temperature of 99 degrees Celsius or higher, 98 degrees Celsius or higher, 96 degrees Celsius or higher, 94 degrees Celsius or higher, 92 degrees Celsius or higher, 90 degrees Celsius or higher, or 88 degrees Celsius or higher. For example, in some embodiments, the input solution can include salts and/or sugars to raise the boiling temperature of the input solution. In other embodiments, thelysing module 3300 can include one or more vent openings into either thefirst volume 3311 or thesecond volume 3321 or both (to limit pressure build-up during heating). - After the lysing and inactivation operations, the output from the
lysing module 3300 can be conveyed into an (e.g., theamplification module 1600 or any other amplification modules described herein). Similarly stated, the output from thelysing module 3300, which contains the extracted nucleic acid molecules, can be conveyed to an amplification module. The amplification module can then perform a thermal reaction (e.g., an amplification reaction) on the prepared solution containing target nucleic acid mixed with required reagents. In some embodiments, the amplification module is configured to conduct rapid amplification of an input target. In some embodiments, the amplification module is configured to generate an output copy number that reaches or exceeds the threshold of the sensitivity of an associated detection module (e.g., the detection module 1800). -
FIGS. 17-22 show various views of a lysing module 4300 (also referred to as an inactivation module), according to an embodiment. Thelysing module 4300 includes achamber body 4310, abottom lid 4318, aheater 4330, and an electrode assembly. Thechamber body 4310 and thebottom lid 4318 can be referred to as a flow member. Although the flow member is shown as being constructed from two pieces (thebody 4310 and the bottom lid 4318) that are coupled together, in other embodiments, the flow member can be monolithically constructed. Thechamber body 4310 and thebottom lid 4318 define aninput port 4312, a first (or holding)volume 4311, avent 4314, a second (or inactivation)volume 4321, and anoutput port 4313. Theinput port 4312 can receive the eluent from the elution chamber and/or directly from a filter assembly (e.g., the filter assembly 1230). In other embodiments, as described herein, theinput port 4312 can be fluidically coupled to a sample input module without the biological input being conveyed through a filter. In use, the eluent can flow into thelysing module 4300 and be collected in the holdingvolume 4311. The sample can be lysed within the holdingvolume 4311. For example, in some embodiments, the eluent containing the target organisms can be heated by theheater 4330 to maintain the eluent at or above a target lysing temperature. Similarly stated, in some embodiments, theheater 4330 can be coupled to thechamber body 4310 and/or thebottom lid 4318 such that theheater 4330 can convey thermal energy into thelysing module 4300 to produce a lysing temperature zone within the holdingvolume 4311. The lysing temperature zone can maintain the eluent at any of the temperatures and for any of the time periods described herein. - The
vent opening 4314 is in fluid communication with thefirst volume 4311, and thus allows air to flow into or out of the lysing module 4300 (including thefirst volume 4311 and the second volume 4321) as sample is conveyed into and/or out of thelysing module 4300. Thevent 4314 can also relieve pressure within either of thefirst volume 4311 or thesecond volume 4321 when the eluent is heated. Although shown as being a permanent vent (i.e., a vent having a fixed opening), in some embodiments, the lysing module 4300 (or any of the lysing modules described herein) can have an active vent. For example, in some embodiments, the lysing module 4300 (or any of the lysing modules described herein) can include a valve that controls the venting of pressure and/or air from within thelysing module 4300. - The
first volume 4311 is in fluid communication with the second volume 4322. In this manner, the eluent can flow from the first (or holding)volume 4311 through the second (or inactivation)volume 4321 of thelysing module 4300. More specifically, when a pressure gradient is applied across theinput port 4312 and theoutput port 4313, the eluent can flow from the holding volume 4311 (first volume) through the second volume 4322. The pressure gradient can be applied by any suitable mechanism, such as for example, a pump (e.g., the fluidic drive module 1400). As shown, thesecond volume 4321 is a serpentine channel that provides a high surface area to volume ratio. This arrangement allows for rapid inactivation of the lysis enzymes in the eluent. The eluent, after being flowed through the inactivation segment, may be flowed into theoutput port 4313 to be collected and/or conveyed to an amplification module (not shown). - As described above, the flow member is in contact with a
heating element 4330, which can be, for example, a printed circuit board (PCB) heater. Theheating element 4330 may function to heat the eluent as it flows through thesecond volume 4311 at a high temperature sufficient to inactivate the one or more lysis enzymes contained within the eluent. For example, the heating element may heat the eluent to about 57° C., about 58° C., about 59° C., about 60° C., about 61° C., about 62° C., about 63° C., about 64° C., about 65° C., about 66° C., about 67° C., about 68° C., about 69° C., about 70° C., about 71° C., about 72° C., about 73° C., about 74° C., about 75° C., about 76° C., about 77° C., about 78° C., about 79° C., about 80° C., about 81° C., about 82° C., about 83° C., about 84° C., about 85° C., about 86° C., about 87° C., about 88° C., about 89° C., about 90° C., about 91° C., about 92° C., about 93° C., about 94° C. , about 95° C., about 96° C., about 97° C., about 98° C., about 99° C., about 100° C. or greater than 100° C. By heating the liquid eluent to a high temperature, the lysis enzymes as well as any other enzymes present can be deactivated. In some embodiments, the sample can be heated to about 95 C for about 4 minutes. - In some embodiments the heater on the
PCB 4330 is specifically designed to heat the serpentine portion of the lysing module 4300 (i.e., the second volume 4321) while not heating theholding volume 4311. Because thelid 4318 of thelysing module 4300 is thick, the heater surface may be heated well above the desired temperature of the fluid. Since the electrodes 1971, 1972 (described in more detail below) are thermally conductive and come into direct contact with the fluid, the fluid surrounding the electrodes 1971, 1972 will experience the same temperature as the heater surface, which may cause evaporation. To minimize the heating of the holdingvolume 4311, a slot (not shown) may be cut in thePCB 4330 to isolate the heater from the portion of the PCB adjacent and/or in contact with the holdingvolume 4311. For example, in some embodiments, theheater 4330 can include a series of slots and/or openings as described in U.S. Patent Application No. 15/494,145, entitled “Printed Circuit Board Heater for an Amplification Module,” which is incorporated herein by reference in its entirety. Moreover, in some embodiments, the heating element of theheater 4330 is located on an internal layer so the top copper pour (not shown) can be used as a heat spreader to minimize temperature variation along the serpentine path. The six wires soldered to thePCB 4330 may remove heat from the surrounding area, creating temperature gradients across the heater surface. To minimize this effect, wires may be soldered on both sides of the heater surface so the temperature roll off is symmetrical. - In some embodiments, the
lysing module 4300 can determine whether there is liquid in thefirst volume 4311 and/or thesecond volume 4321. Specifically, thelysing module 4300 includes electrical probes to determine electrical resistance of the fluid within the first volume. In some embodiments, the molecular diagnostic device (e.g., the device 1000) can include an electronic controller configured to determine when the user has actuated the elution module (e.g., by pressing an elution actuator, similar to thebutton 1070 described above) by detecting the presence of liquid in thefirst volume 4311. In this manner, the introduction of liquid into thefirst volume 4311 can trigger the start of the device. - Specifically, the control system and/or the
lysing module 4300 includes twoelectrodes first volume 4311. Theelectrodes electrodes electrodes electrodes 4971, 4972 (fluid detected). Use of a sample matrix with high salt concentration increases the conductivity of the fluid, which may make the fluid easily detectable even with variation across samples. - The
electrodes electrodes electrodes - Both DNA and cells have a net charge so they may migrate in the presence of an electric field. Because the resistance change between the
electrodes electrodes electrodes - As described, the solution within the
second volume 4321 is rapidly heated to temperatures of up to about 100 degrees Celsius. Thelysing module 4300 and/or the formulation of the input solution (e.g., the eluent), however, can collectively reduce the likelihood that the liquid portion of the input solution will boil during the lysing/inactivation operations. Such boiling can produce undesirable bubbles and/or air pockets and can reduce the repeatability of the lysing and/or inactivation operations. Moreover, to facilitate use of the device at a variety of different altitudes, thelysing module 4300 and/or the formulation of the input solution can collectively reduce the likelihood that the liquid portion of the input solution will boil at a temperature of 99 degrees Celsius or higher, 98 degrees Celsius or higher, 96 degrees Celsius or higher, 94 degrees Celsius or higher, 92 degrees Celsius or higher, 90 degrees Celsius or higher, or 88 degrees Celsius or higher. For example, in some embodiments, the input solution can include salts and/or sugars to raise the boiling temperature of the input solution. In other embodiments, thelysing module 4300 can include one or more vent openings into either thefirst volume 4311 or thesecond volume 4321 or both (to limit pressure build-up during heating). - After the lysing and inactivation operations, the output from the
lysing module 4300 can be conveyed into an (e.g., theamplification module 1600 or any other amplification modules described herein). Similarly stated, the output from thelysing module 4300, which contains the extracted nucleic acid molecules, can be conveyed to an amplification module. The amplification module can then perform a thermal reaction (e.g., an amplification reaction) on the prepared solution containing target nucleic acid mixed with required reagents. In some embodiments, the amplification module is configured to conduct rapid amplification of an input target. In some embodiments, the amplification module is configured to generate an output copy number that reaches or exceeds the threshold of the sensitivity of an associated detection module (e.g., the detection module 1800). - Although the device shown in
FIG. 10 is described as including a filter assembly, in some embodiments, a sample preparation device need not include a filter or filter assembly. For example, in some embodiments the sample input may be directly linked to an inactivation chamber, as shown schematically inFIG. 23 . Advantages of a device without a filter assembly include lower pressures in the device, no risk of breaking a filter, fewer parts, fewer reagents required, higher recovery of target organisms from the clinical sample matrix and higher recovery of DNA from target organisms.FIG. 23 shows a portion of amolecular test device 5000 that includes asample input module 5170 and an inactivation (or lysing)module 5300. Thedevice 5000 can be similar to thedevice 1000 described above, and can include an amplification module, a detection module or the like. In this case, thedevice 5000 differs from thedevice 1000 in that the sample is flowed from theinput module 5170 into the holding tank of theinactivation module 5300. The sample may be lysed either in theholding tank 5311 or in theinactivation segment 5321. In this case the sample may be lysed by heating without need for a specialized lysis buffer or lysis enzymes. Any proteases or nucleases released from the cells of the sample will be inactivated by heating. For example, a sample may be flowed into the holding tank and held until theinactivation segment 5321 reaches a se temperature (for example greater than 90 C) and then flowed through the inactivation segment. In the inactivation segment the sample is rapidly heated to 95 C causing the cells in the sample to lyse and proteins from within the cells to be inactivated. - As another example of an embodiment in which the sample is not conveyed through a filter,
FIG. 24 is a schematic illustration of a molecular diagnostic test device 6000 (also referred to as a “test device” or “device”), according to an embodiment. Thetest device 6000 includes ahousing 6010, asample input module 6170, alysing module 6300, and anamplification module 6600. Thehousing 6010 can be any structure within which thesample input module 6170, thelysing module 6300, and theamplification module 6600 are contained, in some embodiments, thetest device 6000 can have a size, shape and/or weight such that the device can be carried, held, used and/or manipulated in a user's hands (i.e., it can be a “handheld” device). In other embodiments, thetest device 6000 can be a self-contained., single-use device of the types shown and described herein (e.g., the device 1000) or in International Patent Publication No. WO2016/109691, entitled “Devices and Methods for Molecular Diagnostic Testing,” which is incorporated herein by reference in its entirety. - The
sample input module 6170 is disposed within thehousing 6010, and is configured receive a biological sample Si containing a biological entity. The biological sample S1 can be any of the sample types described herein, and the biological entity can be any of the entities described herein. Thesample input module 6170 defines asample volume 6174, and includes apiston 6180 that is movably disposed within thesample volume 6174. In use the biological sample S1 can be conveyed into thesample volume 6174 by any suitable mechanism, such as, for example, via a pipette, a dropper, or the like. In some embodiments, the biological sample S1 can be conveyed via an opening into thesample volume 6174 that can be blocked to prevent backflow of the sample back out of thesample input volume 6174. For example, in some embodiments, thesample input module 6170 can include any suitable flow control devices, such as check valves, duck-bill valves, or the like, to control the flow of the biological sample S1 within thedevice 6000. - The sample input module 6170 (and any of the sample input modules described herein) can be actuated by any suitable mechanism to convey the biological sample S1 towards the lysing
module 6300 to enable the nucleic acid extraction methods described herein. For example, in the embodiment shown, thesample input module 6170 is actuated by the sample actuator (or button) 6050. Thesample actuator 6050 is movably coupled to thehousing 6010, and is aligned with and can move thepiston 6180 when thesample input module 6170 is actuated. Thesample actuator 6050 is a non-electronic actuator that is manually depressed by a user to actuate thesample input module 6170. In other embodiments, however, thesample actuator 6050 can be an electronic actuator. In some embodiments, thesample actuator 6050 can include a lock tab (not shown) that is fixedly received within the notch or opening of thehousing 6010 to fix thesample actuator 6050 in its second or “actuated” position, as described above. In this manner, thedevice 6000 cannot be reused after the initial actuation. When thepiston 6180 is moved downward within thesample volume 6174, as shown by the arrow AA, the sample within thesample volume 6174 is conveyed towards the lysingmodule 6300. The flow of the biological sample S1 towards the lysingmodule 6300 is shown by the arrow S2 inFIG. 24 . - The lysing module 6300 (also referred to as the inactivation module), which can be a portion of a sample preparation module, is configured to process the biological sample S1 to facilitate detection of an organism therein that is associated with a disease. Specifically, the
lysing module 6300 is configured to concentrate and lyse cells in the biological sample S1, thereby allowing subsequent extraction of a nucleic acid to facilitate amplification (e.g., via the amplification module 6600) and/or detection (e.g., via a detection module, not shown). As shown, the processed/lysed sample (e.g., the sample S3) is pushed and/or otherwise transferred from thelysing module 6300 to other modules within the device 6000 (e.g., the amplification module 6600). By eliminating the need for external sample preparation and a cumbersome instrument, thedevice 6000 is suitable for use within a point-of-care setting (e.g., doctor's office, pharmacy or the like) or at the user's home, and can receive any suitable biological sample S1. The biological sample S1 (and any of the input samples described herein) can be, for example, blood, urine, male urethral specimens, vaginal specimens, cervical swab specimens, and/or nasal swab specimens gathered using a commercially available sample collection kit. - The lysing module includes a
flow member 6310 and aheater 6330. Theflow member 6310 includes aninput port 6312 and anoutput port 6313, and defines afirst volume 6311 and asecond volume 6321. As shown, thefirst volume 6311 can receive an input solution (identified as S2) containing at least the biological sample S1 and a lysis buffer. The lysis buffer can be any of the lysis buffers described herein. Moreover, the lysis buffer can be mixed with the biological sample S1 to form the input solution S2 in any suitable manner or at any suitable location within thedevice 6000. For example, in some embodiments, the lysis buffer can be stored within thesample input module 6170, and can be mixed with the biological sample S1 when the biological sample S1 is conveyed into thevolume 6174. In other embodiments, the lysis buffer can be stored in a reagent module (not shown) and can be mixed with the biological sample S1 when thesample input module 6170 is actuated (e.g., via the actuator 6050). In yet other embodiments, the lysis buffer can be stored in the lysing module 6300 (e.g., the first volume 6311). - The
heater 6330 is coupled to theflow member 6310 and is configured to produce thermal energy that is conveyed into thefirst volume 6311, thesecond volume 6321, or both thefirst volume 6311 and thesecond volume 6321 to lyse organisms within the biological sample S1 and/or the input solution S2. In this manner, thelysing module 6300 can release one or more nucleic acid molecules from within the cells and/or organisms within the biological sample S1 and/or the input solution S2. Specifically, theheater 6330 and theflow member 6310 are collectively configured to maintain the input solution S2 at a desired lysing temperature for a predetermined amount of time to facilitate and/or promote lysing of the organisms therein. For example, in some embodiments, thefirst volume 6311 and/or thesecond volume 6321 can be maintained at a temperature between about 55 degrees Celsius and about 600 degrees Celsius for a time period of about 25 seconds or more. In other embodiments, thefirst volume 6311 and/or thesecond volume 6321 can be maintained at a temperature between about 92 degrees Celsius and about 98 degrees Celsius. - In addition to lysing organisms within the input solution S2 to release nucleic acid molecules, the
heater 6330 and theflow member 6310 are configured to heat thefirst volume 6311, thesecond volume 6321, or both thefirst volume 6311 and thesecond volume 6321 to inactivate enzymes present within the biological sample S1 and/or the input solution S2. Specifically, by heating the input solution S2, thelysing module 6300 can denature certain proteins and/or inactivate certain enzymes present within organisms that are within the input solution S2. Such proteins and/or enzymes can, in certain instances, limit the efficiency or effectiveness of the desired amplification operation. Thus, rapid and efficient inactivation can improve the repeatability and accuracy of the amplification and/or the detection of the moleculardiagnostic device 6000. In some embodiments, for example, theheater 6330 and theflow member 6310 can collectively produce an inactivation temperature zone within which the input solution S2 can be heated to within the desired temperature range and/or for the desired time period to produce the desired inactivation. For example, in some embodiments, the input solution S2 within thelysing module 6300 can be maintained at a temperature between about 55 degrees Celsius and about 600 degrees Celsius for a time period of about 25 seconds or more, In other embodiments, the input solution S2 within thelysing module 6300 can be maintained at a temperature between about 92 degrees Celsius and about 98 degrees Celsius. - Although described as occurring in two separate heating operations, the lysing and the inactivation can be performed by a single heating operation. For example, in some embodiments, the input solution S2 can be heated to the desired temperature range to both lyse the organisms and inactivate the enzymes as the input solution S2 flows through the
first volume 6311 and/or thesecond volume 6321. Said another way, in some embodiments, thelysing module 6300 can perform “flow through” inactivation and lysing operations. For example, in some embodiments, either of thefirst volume 6311 or the second volume 6321 (or both) can define a tortuous flow path through which the input solution S2 flows during the lysing/inactivation operation. In this manner, the surface area-to-volume ratio of thefirst volume 6311 and/or thesecond volume 6321 can be high enough such that the heat transfer into the input solution S2 occurs rapidly as it flows through the lysing module. In some embodiments, for example, thefirst volume 6311 and/or thesecond volume 6321 can define a serpentine flow path. In some embodiments, a ratio of the surface area of thesecond volume 6321 to the volume of the second.volume 6321 is 20 cm−1. - In some embodiments, the flow member 6310 (and any of the flow members described herein) can have a volume about 650 microliters or greater, and the flow can be such that at least 60 microliters of the input solution S2 is prepared for amplification (i.e., has nucleic acids extracted therefrom). In other embodiments, at least 20 microliters of the input solution S2 is prepared for amplification by the methods and devices described herein. In other embodiments, at least 30 microliters of the input solution S2 is prepared for amplification by the methods and devices described herein. In yet other embodiments, at least 50 microliters of the input solution S2 is prepared for amplification by the methods and devices described herein.
- As described above, in some embodiments, the input solution S2 is rapidly heated to temperatures of up to about 100 degrees Celsius. The
lysing module 6300 and/or the formulation of the input solution S2, however, can collectively reduce the likelihood that the liquid portion of the input solution S2 will boil during the lysing/inactivation operations. Such boiling can produce undesirable bubbles and/or air pockets and can reduce the repeatability of the lysing and/or inactivation operations. Moreover, to facilitate use of the device at a variety of different altitudes, thelysing module 6300 and/or the formulation of the input solution S2 can collectively reduce the likelihood that the liquid portion of the input solution S2 will boil at a temperature of 99 degrees Celsius or higher, 98 degrees Celsius or higher, 96 degrees Celsius or higher, 94 degrees Celsius or higher, 92 degrees Celsius or higher, 90 degrees Celsius or higher, or 88 degrees Celsius or higher. For example, in some embodiments, the input solution S2 can include salts and/or sugars to raise the boiling temperature of the input solution S2. In other embodiments, thelysing module 6300 can include one or more vent openings into either thefirst volume 6311 or thesecond volume 6321 or both (to limit pressure build-up during heating). In such embodiments, the vent opening can be such that a limited amount of pressure is allowed within thefirst volume 6311 or thesecond volume 6321 to raise the boiling temperature of the input solution S2. - After the lysing and inactivation operations, the output from the
lysing module 6300 can be conveyed into theamplification module 6600. Similarly stated, the output from thelysing module 6300, which is identified as the prepared solution S3, and which contains the extracted nucleic acid molecules, can be conveyed to theamplification module 6600. Theamplification module 6600 can then perform a thermal reaction (e.g., an amplification reaction) on the prepared solution S3 containing target nucleic acid mixed with required reagents. In some embodiments, theamplification module 6600 is configured to conduct rapid amplification of an input target. In some embodiments, theamplification module 6600 is configured to generate an output copy number that reaches or exceeds the threshold of the sensitivity of an associated detection module. - The
amplification module 6600 includes aflow member 6610 and aheater 6630. Theflow member 6610 can be any suitable flow member that defines a volume or a series of volumes within which the that prepared solution S3 can flow and/or be maintained to amplify the target nucleic acid molecules within the solution S3. Theheater 6630 can be any suitable heater or group of heaters coupled to theflow member 6610 that can heat the prepared solution S3 within theflow member 6610 to perform any of the amplification operations as described herein. For example, in some embodiments, the amplification module 6600 (or any of the amplification modules described herein) can be similar to the amplification modules shown and described in U.S. Patent Application No. 65/494,145, entitled “Printed Circuit Board Heater for an Amplification Module,” which is incorporated herein by reference in its entirety. - In some embodiments, the
flow member 6610 defines a single volume within which the prepared solution S3 is maintained and heated to amplify the nucleic acid molecules within the prepared solution S3. In other embodiments, theflow member 6610 can define a “switchback” or serpentine flow path through which the prepared solution S3 flows. Similarly stated, theflow member 6610 defines a flow path that is curved such that the flow path 6618 intersects theheater 6630 at multiple locations. In this manner, theamplification module 6600 can perform a “flow through” PCR where the prepared solution S3 flows through multiple different temperature regions. - The flow member 6610 (and any of the flow members described herein) can be constructed from any suitable material and can have any suitable dimensions to facilitate the desired amplification performance for the desired volume of sample. For example, in some embodiments, the amplification module 6600 (and any of the amplification modules described herein) can perform 6000× or greater amplification in a time of less than 65 minutes. For example, in some embodiments, the flow member 6610 (and any of the flow members described herein) is constructed from at least one of a cyclic olefin copolymer or a graphite-based material. Such materials facilitate the desired heat transfer properties into the flow path 6620. Moreover, in some embodiments, the flow member 6610 (and any of the flow members described herein) can have a thickness of less than about 0.5 mm. In some embodiments, the flow member 6610 (and any of the flow members described herein) can have a volume about 150 microliters or greater, and the flow can be such that at least 10 microliters of sample is amplified. In other embodiments, at least 20 microliters of sample are amplified by the methods and devices described herein. In other embodiments, at least 30 microliters of sample are amplified by the methods and devices described herein. In yet other embodiments, at least 50 microliters of sample are amplified by the methods and devices described herein.
- The
heater 6630 can be any suitable heater or collection of heaters that can perform the functions described herein to amplify the prepared solution S3. In some embodiments, theheater 6630 can establish multiple temperature zones through which the prepared solution S3 flows and/or can define a desired number of amplification cycles to ensure the desired test sensitivity (e.g., at least 30 cycles, at least 34 cycles, at least 36 cycles, at least 38 cycles, or at least 40 cycles). The heater 6630 (and any of the heaters described herein) can be of any suitable design. For example, in some embodiments, theheater 6630 can be a resistance heater, a thermoelectric device (e.g. a Peltier device), or the like. In some embodiments, theheater 6630 can be one or more linear “strip heaters” arranged such that the flow path crosses the heaters at multiple different points. In other embodiments, theheater 6630 can be one or more curved heaters having a geometry that corresponds to that of theflow member 6610 to produce multiple different temperature zones in the flow path. - Although the
amplification module 6600 is generally described as performing a thermal cycling operation on the prepared solution S3, in other embodiment, theamplification module 6600 can perform any suitable thermal reaction to amplify nucleic acids within the solution S3. In some embodiments, the amplification module 6600 (and any of the amplification modules described herein) can perform any suitable type of isothermal amplification process, including, for example, Loop Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA), which can be useful to detect target RNA molecules, Strand Displacement Amplification (SDA), Multiple Displacement Amplification (MDA), Ramification Amplification Method (RAM), or any other type of isothermal process. -
FIG. 25 is a photograph of a molecular diagnostic test device that can perform any of the methods described herein. - The devices described herein may include and/or be coupled to an amplification module or PCR module of the types shown and described herein, in which a polymerase chain reaction may be performed. The amplification module may be proceeded by a mixing chamber in which the nucleic acid is mixed with components for performing a polymerase chain reaction. Examples of components which may be required for a polymerase chain reaction include nucleotide triphosphates, polymerase enzymes, nucleic acid primers, calcium ions and buffer. In some examples, all components of the reaction mixture may be present in the sample buffer. In other examples the sample buffer may comprise all components except for a polymerase enzyme which may be provided in the mixing chamber. The choice of polymerase enzyme may depend on the purification and lysis protocol used. In some examples, the devices may also comprise a detection module which is capable of detecting nucleic acids amplified in the amplification module.
- The devices described herein may be contained with a housing. In some cases, the device is self-contained. In some cases, the device is a handheld device. In some cases, the device is configured for one-time use (e.g., disposable). In some instances, the devices may generate a nucleic acid sample that may be collected prior to performing one or more downstream applications. For example, the sample can be held in a chamber or reservoir within the housing of the device or can be relayed to a chamber or reservoir that sits outside of the housing of the device. In other examples, the device is coupled to one or more additional devices that can perform the one or more downstream applications, for example, a device that can perform a polymerase chain reaction (PCR).
- The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. The present examples, along with the methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.
- In this example, DNA was extracted from clinical samples using either a standard DNA extraction protocol or a DNA extraction protocol using the methods described herein. Clinical samples that were positive for Neisseria gonorrhoeae and/or Chlamydia trachomatis (
Samples -
TABLE 1 Condition Sample Purification Method 1 105 Qiagen 2 117 Qiagen 3 101 Qiagen 4 108 Qiagen 5 122 Qiagen 6 105 Click SP 7 117 Click SP 8 101 Click SP 9 108 Click SP 10 122 Click SP 11 Positive Control N/ A 12 No template control (water) N/A - Each sample was mixed with PCR reagents. Primer/probe sets designed to amplify sequences from several different organisms were added to each sample. 1 μL of N. subflava DNA (1,000 copies/rxn) were added to the sample/PCR mix designated for the NS assay. The mixtures were divided into two wells of 20 μL each on a LightCycler® plate. The plate was loaded onto the LightCycler® Real-Time PCR System (Roche) and run under the following PCR conditions:
- Stage 1: 95 C for 20 seconds
Stage 2: 40 cycles of: 95 C for 1 second, 60 C for 6 seconds -
FIGS. 3 and 4 depict a comparison of data generated from real-time PCR reactions performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122) and a clinical sample positive for N. gonorrhoeae (Sample 117) utilizing the methods provided herein versus standard DNA extraction methods.Primer Set # 1 detected the presence of N. gonorrhoeae inSample 122 prepared using either method as shown inFIG. 3 .Primer Set # 2 detected the presence of N. gonorrhoeae in bothSample 122 andSample 117, prepared using either method as shown inFIG. 4 . Both the standard (“Qiagen sample”) and the new method (“Click sample”) yielded a Ct value of ˜36 with an endpoint signal of less than 5, indicating that the sample had a low titer of N. gonorrhoeae. (FIG. 4 ) -
FIGS. 5 and 6 depict a comparison of data generated from real-time PCR reactions performed on DNA extracted from a clinical sample positive for both N. gonorrhoeae and C. trachomatis (Sample 122), and clinical samples positive for C. trachomatis (Samples 101 and 108) utilizing the methods provided herein versus standard DNA extraction methods. Both standard (“Qiagen”) and new methods (“Click”) of DNA extraction did not detect the presence of C. trachomatis in Sample 105 using eitherPrimer Set # 3 orPrimer Set # 4.Primer Set # 3 was able to detect the presence of C. trachomatis inSamples FIG. 5 ).Primer Set # 4 was able to detect the presence of C. trachomatis inSample 101 for both sample preparation methods, and onlySample 122 for the standard method, and onlySample 108 for the new method (FIG. 6 ). -
FIGS. 7 and 8 depict a comparison of data generated from real-time PCR reactions performed on N. gonorrhoeae positive control DNA or C. trachomatis positive control DNA, respectively, utilizing different sets of primers. -
FIG. 9 depicts data generated from a real-time PCR reaction performed on N. gonorrhoeae DNA spiked into a sample and PCR mixture to test for sample inhibition. - In this example DNA was purified from a range of samples using the no filter method described herein. Briefly samples are flowed into the holding chamber of the inactivation module. the heat-treated fluid is flowed through the serpentine path and into a mixing chamber containing PCR reagents, PCR is performed and PCR products are detected. In this example, purified DNA is subjected to PCR using the probe sets of example 1.
-
FIG. 25 shows successful PCR amplification from DNA isolated from 19 different clinical samples, shown in Table 2, using this method. -
TABLE 2 Samples used in FIG. 25 Condition Sample Dilution factor 1 Positive Control No dilution 2 100 No dilution 3 101 No dilution 4 103 No dilution 5 104 No dilution 6 108 No dilution 7 110 No dilution 8 112 No dilution 9 113 No dilution 10 114 No dilution 11 118 No dilution 12 119 No dilution 13 121 No dilution 14 122 No dilution 15 123 No dilution 16 125 No dilution 17 126 No dilution 18 127 No dilution 19 106 No dilution 20 171 No dilution 21 Positive Control 1:3 22 100 1:3 23 101 1:3 24 103 1:3 25 104 1:3 26 108 1:3 27 110 1:3 28 112 1:3 29 113 1:3 30 114 1:3 31 118 1:3 32 119 1:3 33 121 1:3 34 122 1:3 35 123 1:3 36 125 1:3 37 126 1:3 38 127 1:3 39 106 1:3 40 171 1:3 -
FIG. 26 shows the results of PCR amplification on DNA extracted from the samples in Table 3. Samples in Table 2 were purified in buffer comprising 50 mM Tris pH 8.4, Tween-80, 2% (w/v), BSA, 0.25% (w/v), Proclin 300 0.03% (w/v), and Antifoam SE-15, 0002% (v/v) made up in purified water, (TT buffer). Amplification was seen in every sample indicating that the PCR reaction possesses high tolerance to inhibitors. -
TABLE 3 Samples used in FIG. 26 Condition Sample Microorganism present 1 Control NS cells NS 2 97 3 170 NG 4 172 CT 5 174 NS 6 175 NS 7 176 NS 8 177 TV 9 178 NS 10 179 NS 11 180 NS 12 271 CT 13 272 CT 14 273 CT 15 285 NG 16 288 NG 17 289 NG 18 340 NS 19 341 NS 20 342 NS 21 109 22 Control NS cells NS 23 Control NS cells NS 24 PCR positive control 25 No template control -
FIG. 26 depicts the result of an experiment comparing different sample buffers. The sample buffers used were the TT buffer described above, MSwab buffer (MS; Copan Diagnostics, CA), and Liquid Amies Buffer (LA; Copan Diagnostics, CA). PCR products were run on 4% agarose gels to determine the success of the PCR reaction. Samples rehydrated in TT buffer amplified as expected, equal to the controls. The other two medias MS and LA showed varying results, suggesting variable inhibition of the PCR by contaminants from the sample buffer. - While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
- The devices and methods described herein are not limited to performing a molecular diagnostic test on human samples. In some embodiments, any of the devices and methods described herein can be used with veterinary samples, food samples, and/or environmental samples.
- Although the fluid transfer assemblies are shown and described herein as including a piston pump (or syringe), in other embodiments, any suitable pump can be used. For example, in some embodiments any of the fluid transfer assemblies described herein can include any suitable positive-displacement fluid transfer device, such as a gear pump, a vane pump, and/or the like.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/508,519 US20220186208A1 (en) | 2016-05-11 | 2021-10-22 | Devices and methods for nucleic acid extraction |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662334982P | 2016-05-11 | 2016-05-11 | |
US201662356451P | 2016-06-29 | 2016-06-29 | |
US201662356596P | 2016-06-30 | 2016-06-30 | |
PCT/US2017/032035 WO2017197040A1 (en) | 2016-05-11 | 2017-05-10 | Devices and methods for nucleic acid extraction |
US16/186,240 US11193119B2 (en) | 2016-05-11 | 2018-11-09 | Devices and methods for nucleic acid extraction |
US17/508,519 US20220186208A1 (en) | 2016-05-11 | 2021-10-22 | Devices and methods for nucleic acid extraction |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/186,240 Division US11193119B2 (en) | 2016-05-11 | 2018-11-09 | Devices and methods for nucleic acid extraction |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220186208A1 true US20220186208A1 (en) | 2022-06-16 |
Family
ID=60267591
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/186,240 Active 2038-04-25 US11193119B2 (en) | 2016-05-11 | 2018-11-09 | Devices and methods for nucleic acid extraction |
US17/508,519 Pending US20220186208A1 (en) | 2016-05-11 | 2021-10-22 | Devices and methods for nucleic acid extraction |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/186,240 Active 2038-04-25 US11193119B2 (en) | 2016-05-11 | 2018-11-09 | Devices and methods for nucleic acid extraction |
Country Status (2)
Country | Link |
---|---|
US (2) | US11193119B2 (en) |
WO (1) | WO2017197040A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11952636B2 (en) | 2020-01-03 | 2024-04-09 | Visby Medical, Inc. | Devices and methods for antibiotic susceptibility testing |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10195610B2 (en) | 2014-03-10 | 2019-02-05 | Click Diagnostics, Inc. | Cartridge-based thermocycler |
EP4029606A1 (en) | 2014-12-31 | 2022-07-20 | Visby Medical, Inc. | Molecular diagnostic testing |
US10987674B2 (en) | 2016-04-22 | 2021-04-27 | Visby Medical, Inc. | Printed circuit board heater for an amplification module |
WO2017197040A1 (en) | 2016-05-11 | 2017-11-16 | Click Diagnostics, Inc. | Devices and methods for nucleic acid extraction |
MX2018015889A (en) | 2016-06-29 | 2019-05-27 | Click Diagnostics Inc | Devices and methods for the detection of molecules using a flow cell. |
EP3707276A4 (en) | 2017-11-09 | 2022-02-23 | Visby Medical, Inc. | Portable molecular diagnostic device and methods for the detection of target viruses |
MX2021012888A (en) * | 2019-04-28 | 2021-11-17 | Visby Medical Inc | Molecular diagnostic devices with digital detection capability and wireless connectivity. |
WO2021183333A1 (en) * | 2020-03-12 | 2021-09-16 | Lexagene, Inc. | Sample cartridges |
WO2022113112A1 (en) * | 2020-11-27 | 2022-06-02 | Reliance Industries Limited | Device for rna extraction for sars-cov-2 detection |
Family Cites Families (310)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3697227A (en) | 1966-05-13 | 1972-10-10 | Westinghouse Electric Corp | Chemical constituent sampler |
US4710355A (en) | 1984-06-14 | 1987-12-01 | Olympus Optical Co., Ltd. | Reagent delivery device |
US4889692A (en) | 1984-11-05 | 1989-12-26 | Holtzman Marc E | Disposable sample preparation container |
USRE33858E (en) | 1985-01-25 | 1992-03-24 | Mallinckrodt Sensor Systems Inc. | Apparatus for measuring a chemical entity in a liquid |
US4789630A (en) | 1985-10-04 | 1988-12-06 | Cetus Corporation | Ionic compounds containing the cationic meriquinone of a benzidine |
IE64511B1 (en) | 1988-03-11 | 1995-08-09 | Takeda Chemical Industries Ltd | Automated synthesizing apparatus |
US6645758B1 (en) | 1989-02-03 | 2003-11-11 | Johnson & Johnson Clinical Diagnostics, Inc. | Containment cuvette for PCR and method of use |
US5229297A (en) | 1989-02-03 | 1993-07-20 | Eastman Kodak Company | Containment cuvette for PCR and method of use |
US5270183A (en) | 1991-02-08 | 1993-12-14 | Beckman Research Institute Of The City Of Hope | Device and method for the automated cycling of solutions between two or more temperatures |
US5273905A (en) | 1991-02-22 | 1993-12-28 | Amoco Corporation | Processing of slide mounted material |
US7297313B1 (en) | 1991-08-31 | 2007-11-20 | The Regents Of The University Of California | Microfabricated reactor, process for manufacturing the reactor, and method of amplification |
US5587128A (en) | 1992-05-01 | 1996-12-24 | The Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification devices |
US5726026A (en) | 1992-05-01 | 1998-03-10 | Trustees Of The University Of Pennsylvania | Mesoscale sample preparation device and systems for determination and processing of analytes |
US5498392A (en) | 1992-05-01 | 1996-03-12 | Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification device and method |
WO1994001215A1 (en) | 1992-07-06 | 1994-01-20 | Beckman Instruments, Inc. | Fluid delivery system utilizing multiple port valve |
US5503985A (en) | 1993-02-18 | 1996-04-02 | Cathey; Cheryl A. | Disposable device for diagnostic assays |
US5429807A (en) | 1993-10-28 | 1995-07-04 | Beckman Instruments, Inc. | Method and apparatus for creating biopolymer arrays on a solid support surface |
US5631165A (en) | 1994-08-01 | 1997-05-20 | Abbott Laboratories | Method for performing automated hematology and cytometry analysis |
US5633168A (en) | 1995-06-07 | 1997-05-27 | Glasscock; Larry M. | Controlled dispersion flow analysis system |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US20050100946A1 (en) | 1995-06-29 | 2005-05-12 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device and method for in-situ confocal microscopy |
US6153425A (en) | 1995-07-13 | 2000-11-28 | Xtrana, Inc. | Self-contained device integrating nucleic acid extraction, amplification and detection |
US5773234A (en) | 1995-08-07 | 1998-06-30 | Quidel Corporation | Method and device for chlamydia detection |
AU6720096A (en) | 1995-08-09 | 1997-03-05 | Quidel Corporation | Test strip and method for one step lateral flow assay |
US7635597B2 (en) | 1995-08-09 | 2009-12-22 | Bayer Healthcare Llc | Dry reagent particle assay and device having multiple test zones and method therefor |
US7244622B2 (en) | 1996-04-03 | 2007-07-17 | Applera Corporation | Device and method for multiple analyte detection |
ES2243393T3 (en) | 1996-06-04 | 2005-12-01 | University Of Utah Research Foundation | MONITORING OF HYBRIDIZATION DURING PCR. |
US5800784A (en) | 1996-07-09 | 1998-09-01 | Horn; Marcus J. | Chemical sample treatment system and cassette, and methods for effecting multistep treatment process |
US5882903A (en) | 1996-11-01 | 1999-03-16 | Sarnoff Corporation | Assay system and method for conducting assays |
DE29623597U1 (en) | 1996-11-08 | 1999-01-07 | Eppendorf Geraetebau Netheler | Temperature control block with temperature control devices |
US5952664A (en) | 1997-01-17 | 1999-09-14 | Imaging Diagnostic Systems, Inc. | Laser imaging apparatus using biomedical markers that bind to cancer cells |
US6924153B1 (en) | 1997-03-06 | 2005-08-02 | Quidel Corporation | Quantitative lateral flow assays and devices |
US20030027203A1 (en) | 1997-03-24 | 2003-02-06 | Fields Robert E. | Biomolecular processor |
WO1999033559A1 (en) | 1997-12-24 | 1999-07-08 | Cepheid | Integrated fluid manipulation cartridge |
US6126804A (en) | 1997-09-23 | 2000-10-03 | The Regents Of The University Of California | Integrated polymerase chain reaction/electrophoresis instrument |
US6369893B1 (en) | 1998-05-19 | 2002-04-09 | Cepheid | Multi-channel optical detection system |
US6303081B1 (en) | 1998-03-30 | 2001-10-16 | Orasure Technologies, Inc. | Device for collection and assay of oral fluids |
US6146591A (en) | 1998-05-01 | 2000-11-14 | Miller; C David | Biochemical detection system for rapid determination of the presence of toxins, bacteria, and other substances |
US5976470A (en) | 1998-05-29 | 1999-11-02 | Ontogen Corporation | Sample wash station assembly |
US7799521B2 (en) | 1998-06-24 | 2010-09-21 | Chen & Chen, Llc | Thermal cycling |
US6780617B2 (en) | 2000-12-29 | 2004-08-24 | Chen & Chen, Llc | Sample processing device and method |
US6313471B1 (en) | 1998-08-18 | 2001-11-06 | Molecular Devices Corporation | Scanning fluorometer |
US20010055799A1 (en) | 1998-12-15 | 2001-12-27 | David Baunoch | Method and apparatus for automated reprocessing of tissue samples |
US6261431B1 (en) | 1998-12-28 | 2001-07-17 | Affymetrix, Inc. | Process for microfabrication of an integrated PCR-CE device and products produced by the same |
US6235479B1 (en) | 1999-04-13 | 2001-05-22 | Bio Merieux, Inc. | Methods and devices for performing analysis of a nucleic acid sample |
US20020177135A1 (en) | 1999-07-27 | 2002-11-28 | Doung Hau H. | Devices and methods for biochip multiplexing |
CA2374423C (en) * | 1999-05-28 | 2013-04-09 | Cepheid | Apparatus and method for analyzing a liquid sample |
GB9922971D0 (en) | 1999-09-29 | 1999-12-01 | Secr Defence | Reaction system |
JP2001186881A (en) | 1999-10-22 | 2001-07-10 | Ngk Insulators Ltd | Method for producing dna chip |
US6699713B2 (en) | 2000-01-04 | 2004-03-02 | The Regents Of The University Of California | Polymerase chain reaction system |
FR2812306B1 (en) | 2000-07-28 | 2005-01-14 | Gabriel Festoc | POLYMERSIS CHAIN AMPLIFICATION SYSTEM OF TARGET NUCLEIC SEQUENCES |
US6374684B1 (en) | 2000-08-25 | 2002-04-23 | Cepheid | Fluid control and processing system |
US8048386B2 (en) | 2002-02-25 | 2011-11-01 | Cepheid | Fluid processing and control |
US6610499B1 (en) | 2000-08-31 | 2003-08-26 | The Regents Of The University Of California | Capillary array and related methods |
US6680617B2 (en) | 2000-09-20 | 2004-01-20 | Neocera, Inc. | Apertured probes for localized measurements of a material's complex permittivity and fabrication method |
US6911181B1 (en) | 2000-10-03 | 2005-06-28 | Isis Pharmaceuticals, Inc. | Self-dispensing storage device |
SE0004297D0 (en) | 2000-11-23 | 2000-11-23 | Gyros Ab | Device for thermal cycling |
US6780380B2 (en) | 2001-01-16 | 2004-08-24 | Triangle Biomedical Sciences, Inc. | Tissue processor |
WO2002064253A2 (en) | 2001-02-09 | 2002-08-22 | Microchem Solutions | Method and apparatus for sample injection in microfabricated devices |
US6426215B1 (en) | 2001-04-06 | 2002-07-30 | Pe Corporation (Ny) | PCR plate cover and maintaining device |
US6905885B2 (en) | 2001-06-12 | 2005-06-14 | The Regents Of The University Of California | Portable pathogen detection system |
US20040018502A1 (en) | 2001-06-14 | 2004-01-29 | Yoshihiko Makino | Method for analyzing a target nucleic acid fragment and a kit for analyzing a target nucleic acid fragment |
US6514750B2 (en) | 2001-07-03 | 2003-02-04 | Pe Corporation (Ny) | PCR sample handling device |
EP1952886B1 (en) | 2001-07-16 | 2021-06-23 | BioFire Defense, LLC | Thermal cycling system and method of use |
US7265833B2 (en) | 2001-07-25 | 2007-09-04 | Applera Corporation | Electrophoretic system with multi-notch filter and laser excitation source |
US7280207B2 (en) | 2001-07-25 | 2007-10-09 | Applera Corporation | Time-delay integration in a flow cytometry system |
AUPR707101A0 (en) | 2001-08-16 | 2001-09-06 | Corbett Research Pty Ltd | Continuous flow thermal device |
US6855561B2 (en) | 2001-09-10 | 2005-02-15 | Quidel Corporation | Method for adding an apparent non-signal line to a lateral flow assay |
US7879293B2 (en) | 2001-09-28 | 2011-02-01 | Orasure Technologies, Inc. | Sample collector and test device |
JP2005504323A (en) | 2001-10-01 | 2005-02-10 | ヴィジョン バイオシステムズ リミテッド | Histological tissue specimen processing |
WO2003029397A1 (en) | 2001-10-02 | 2003-04-10 | Stratagene | Side-wall heater for thermocycler device |
US7691333B2 (en) | 2001-11-30 | 2010-04-06 | Fluidigm Corporation | Microfluidic device and methods of using same |
US20030116552A1 (en) | 2001-12-20 | 2003-06-26 | Stmicroelectronics Inc. | Heating element for microfluidic and micromechanical applications |
US6813568B2 (en) | 2002-01-09 | 2004-11-02 | Memorial Sloan-Kettering Cancer Center | System and process for microfluidics-based automated chemistry |
US6677151B2 (en) | 2002-01-30 | 2004-01-13 | Applera Corporation | Device and method for thermal cycling |
US8030000B2 (en) | 2002-02-21 | 2011-10-04 | Alere San Diego, Inc. | Recombinase polymerase amplification |
JP3892743B2 (en) | 2002-03-01 | 2007-03-14 | 日本碍子株式会社 | Reaction cell and method of use thereof |
US7179639B2 (en) | 2002-03-05 | 2007-02-20 | Raveendran Pottathil | Thermal strip thermocycler |
EP1376131A1 (en) | 2002-06-27 | 2004-01-02 | Inverness Medical Switzerland GmbH | Assay device for liquid sample |
JP4013671B2 (en) | 2002-07-05 | 2007-11-28 | 松下電器産業株式会社 | Polymerase chain reaction vessel and method for producing the same |
US7452712B2 (en) | 2002-07-30 | 2008-11-18 | Applied Biosystems Inc. | Sample block apparatus and method of maintaining a microcard on a sample block |
US7291459B2 (en) | 2002-12-10 | 2007-11-06 | University Of Alabama At Huntsville | Nucleic acid detector and method of detecting targets within a sample |
US7560272B2 (en) | 2003-01-04 | 2009-07-14 | Inverness Medical Switzerland Gmbh | Specimen collection and assay container |
CA2513880A1 (en) | 2003-01-21 | 2004-08-05 | Micronics Inc. | Method and system for microfluidic manipulation, amplification and analysis of fluids, for example, bacteria assays and antiglobulin testing |
US6781056B1 (en) | 2003-02-28 | 2004-08-24 | Motorola, Inc. | Heater for temperature control integrated in circuit board and method of manufacture |
US6901217B2 (en) | 2003-02-28 | 2005-05-31 | Motorolr, Inc. | Conduits integrated in circuit board and method of manufacture |
US7041481B2 (en) | 2003-03-14 | 2006-05-09 | The Regents Of The University Of California | Chemical amplification based on fluid partitioning |
US7151270B2 (en) | 2003-05-02 | 2006-12-19 | Leica Microsystems Cms Gmbh | Method for classifying object image regions of an object to be detected using a scanning microscope |
US7148043B2 (en) | 2003-05-08 | 2006-12-12 | Bio-Rad Laboratories, Inc. | Systems and methods for fluorescence detection with a movable detection module |
FI20030778A0 (en) | 2003-05-22 | 2003-05-22 | Licentia Oy | Determination or prediction of disease |
US7648835B2 (en) | 2003-06-06 | 2010-01-19 | Micronics, Inc. | System and method for heating, cooling and heat cycling on microfluidic device |
WO2005027714A2 (en) | 2003-07-12 | 2005-03-31 | Accelr8 Technology Corporation | Sensitive and rapid biodetection |
US7517495B2 (en) | 2003-08-25 | 2009-04-14 | Inverness Medical Switzerland Gmbh | Biological specimen collection and analysis system |
WO2005028635A2 (en) | 2003-09-19 | 2005-03-31 | Microfluidic Systems Inc. | Microfluidic differential extraction cartridge |
EP1664781B1 (en) | 2003-09-22 | 2013-05-08 | Quidel Corporation | Devices for the detection of multiple analytes in a sample |
DE212004000058U1 (en) | 2003-11-14 | 2006-09-28 | Oakville Hong Kong Co., Ltd. | Sample collection container with integrated activatable sample analysis system |
US20050202568A1 (en) | 2003-11-14 | 2005-09-15 | Tung Hsiaoho E. | Fluid sample analysis device with sealable sample storage reservoir |
CN1879016B (en) | 2003-11-14 | 2012-03-28 | 因韦尔尼斯医药瑞士股份有限公司 | Sample collection cup with integrated sample analysis system |
US7767439B2 (en) | 2003-12-10 | 2010-08-03 | Samsung Electronics Co., Ltd. | Real-time PCR monitoring apparatus and method |
KR100750586B1 (en) | 2003-12-26 | 2007-08-20 | 한국전자통신연구원 | Micro-fluidic heating system |
WO2005080606A1 (en) | 2004-02-18 | 2005-09-01 | Xiaochuan Zhou | Fluidic devices and methods for multiplex chemical and biochemical reactions |
WO2005083390A1 (en) | 2004-02-20 | 2005-09-09 | Research Foundation Of The State University Of New York | Method and device for manipulating liquids in microfluidic systems |
KR100552706B1 (en) | 2004-03-12 | 2006-02-20 | 삼성전자주식회사 | Method and apparatus for nucleic acid amplification |
EP1733232A1 (en) | 2004-03-23 | 2006-12-20 | Quidel Corporation | Hybrid phase lateral flow assay |
KR101270676B1 (en) | 2004-04-07 | 2013-06-07 | 액세스 바이오 인코포레이티드 | Nucleic acid detection kit |
CA2502549C (en) | 2004-04-23 | 2016-02-16 | Becton, Dickinson And Company | Use of an extraction control in a method of extracting nucleic acids |
EP1598429A1 (en) | 2004-05-19 | 2005-11-23 | Amplion Ltd. | Detection of amplicon contamination during PCR exhibiting two different annealing temperatures |
US7871143B2 (en) | 2004-06-30 | 2011-01-18 | Lexmark International, Inc. | Ground structure for temperature-sensing resistor noise reduction |
US7662562B2 (en) | 2004-08-10 | 2010-02-16 | Becton, Dickinson And Company | Method for rapid identification of microorganisms |
US7192721B1 (en) | 2004-08-26 | 2007-03-20 | Chembio Diagnostic Systems, Inc. | Universal rapid test and method for detection of tuberculosis in multiple host species |
US7592139B2 (en) | 2004-09-24 | 2009-09-22 | Sandia National Laboratories | High temperature flow-through device for rapid solubilization and analysis |
US9132398B2 (en) * | 2007-10-12 | 2015-09-15 | Rheonix, Inc. | Integrated microfluidic device and methods |
RU2460804C2 (en) | 2004-10-18 | 2012-09-10 | Брандейс Юнивесити | Method for homogenous detection of one-strand amplification product |
CA2587085C (en) | 2004-10-27 | 2017-08-08 | Cepheid | Closed-system multi-stage nucleic acid amplification reactions |
CA2592204C (en) | 2004-12-23 | 2013-03-12 | I-Stat Corporation | Nucleic acid diagnostics system and methods |
KR100601982B1 (en) | 2005-01-20 | 2006-07-18 | 삼성전자주식회사 | Cell lysis by heating-cooling process through endothermic reaction |
WO2006081558A2 (en) | 2005-01-28 | 2006-08-03 | Duke University | Apparatuses and methods for manipulating droplets on a printed circuit board |
WO2006094149A2 (en) | 2005-03-01 | 2006-09-08 | Exact Sciences Corporation | Methods and compositions for detecting adenoma |
US7189522B2 (en) | 2005-03-11 | 2007-03-13 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
US20060246493A1 (en) | 2005-04-04 | 2006-11-02 | Caliper Life Sciences, Inc. | Method and apparatus for use in temperature controlled processing of microfluidic samples |
US20070026391A1 (en) | 2005-04-11 | 2007-02-01 | Ghc Technologies, Inc. | Methods and compositions for identifying chemical or biological agents using multiplexed labeling and colocalization detection |
US7235216B2 (en) | 2005-05-01 | 2007-06-26 | Iba Molecular North America, Inc. | Apparatus and method for producing radiopharmaceuticals |
KR100695148B1 (en) | 2005-05-02 | 2007-03-14 | 삼성전자주식회사 | Module for polymerase chain reaction and multiple polymerase chain reaction system |
US20070042427A1 (en) | 2005-05-03 | 2007-02-22 | Micronics, Inc. | Microfluidic laminar flow detection strip |
EP3714979A1 (en) | 2005-05-09 | 2020-09-30 | BioFire Diagnostics, LLC | Self-contained biological analysis |
WO2006122310A2 (en) | 2005-05-11 | 2006-11-16 | The Trustess Of The University Of Pennsylvania | System for testing |
JP2008539759A (en) | 2005-05-11 | 2008-11-20 | ナノリティックス・インコーポレイテッド | Method and apparatus for performing biochemical or chemical reactions at multiple temperatures |
CA2610793A1 (en) | 2005-05-31 | 2007-05-10 | Labnow, Inc. | Methods and compositions related to determination and use of white blood cell counts |
CA2613078A1 (en) | 2005-06-24 | 2007-01-04 | Board Of Regents, The University Of Texas System | Systems and methods including self-contained cartridges with detection systems and fluid delivery systems |
TW200714898A (en) | 2005-08-02 | 2007-04-16 | 3M Innovative Properties Co | Apparatus and method for detecting an analyte |
US7618588B2 (en) | 2005-08-10 | 2009-11-17 | Microfluidic Systems, Inc. | Disposable integrated heater and tube assembly for thermally-driven chemical reactions |
US7569382B2 (en) | 2005-10-05 | 2009-08-04 | Instantlabs Medical Diagnostic Corp. | Disposable reactor module and detection system |
US8916375B2 (en) | 2005-10-12 | 2014-12-23 | University Of Virginia Patent Foundation | Integrated microfluidic analysis systems |
US7754148B2 (en) | 2006-12-27 | 2010-07-13 | Progentech Limited | Instrument for cassette for sample preparation |
CN100478671C (en) | 2005-10-25 | 2009-04-15 | 艾康生物技术(杭州)有限公司 | Detector and method for liquid sampler |
US7858396B2 (en) | 2005-10-31 | 2010-12-28 | Orasure Technologies, Inc. | Lateral flow assay device with multiple equidistant capture zones |
WO2007062575A1 (en) | 2005-11-30 | 2007-06-07 | Inverness Medical Switzerland Gmbh | A device for detecting the presence or amount of an analyte in a fluid sample and method thereof |
WO2007078833A2 (en) | 2005-12-16 | 2007-07-12 | The Curators Of The University Of Missouri | Reusable pcr amplification system and method |
US7959877B2 (en) | 2005-12-22 | 2011-06-14 | Chembio Diagnostic Systems, Inc. | Immunoassay apparatus and kit |
US7377291B2 (en) | 2005-12-28 | 2008-05-27 | Serveron Corporation | Multiport rotary valve |
CA2634735A1 (en) | 2005-12-29 | 2007-07-12 | I-Stat Corporation | Molecular diagnostics amplification system and methods |
US7794656B2 (en) | 2006-01-23 | 2010-09-14 | Quidel Corporation | Device for handling and analysis of a biological sample |
US7871568B2 (en) | 2006-01-23 | 2011-01-18 | Quidel Corporation | Rapid test apparatus |
US20080050735A1 (en) | 2006-02-01 | 2008-02-28 | Elena Pushnova | Nucleic acid testing method for point-of-care diagnostics and genetic self-monitoring |
GB0603965D0 (en) | 2006-02-28 | 2006-04-05 | Centeo Biosciences Ltd | Incubator apparatus and method |
WO2007106579A2 (en) * | 2006-03-15 | 2007-09-20 | Micronics, Inc. | Integrated nucleic acid assays |
US8088616B2 (en) | 2006-03-24 | 2012-01-03 | Handylab, Inc. | Heater unit for microfluidic diagnostic system |
ES2692380T3 (en) | 2006-03-24 | 2018-12-03 | Handylab, Inc. | Method to perform PCR with a cartridge with several tracks |
EP2016611A2 (en) | 2006-04-25 | 2009-01-21 | University Of South Florida | Portable reactor for real-time nucleic acid amplification and detection |
US8900828B2 (en) | 2006-05-01 | 2014-12-02 | Cepheid | Methods and apparatus for sequential amplification reactions |
US8232091B2 (en) | 2006-05-17 | 2012-07-31 | California Institute Of Technology | Thermal cycling system |
US8137626B2 (en) | 2006-05-19 | 2012-03-20 | California Institute Of Technology | Fluorescence detector, filter device and related methods |
EP2035540A2 (en) | 2006-06-15 | 2009-03-18 | Stratagene | System for isolating biomolecules from a sample |
US20080153078A1 (en) | 2006-06-15 | 2008-06-26 | Braman Jeffrey C | System for isolating biomolecules from a sample |
AU2007265628B2 (en) | 2006-06-23 | 2012-12-06 | Perkinelmer Health Sciences, Inc. | Methods and devices for microfluidic point-of-care immunoassays |
US7629124B2 (en) | 2006-06-30 | 2009-12-08 | Canon U.S. Life Sciences, Inc. | Real-time PCR in micro-channels |
US8187557B2 (en) | 2006-07-13 | 2012-05-29 | Cepheid | Reagent reservoir system for analytical instruments |
EP1878802A1 (en) | 2006-07-14 | 2008-01-16 | Roche Diagnostics GmbH | Disposable device for analysing a liquid sample containing a nucleic acid with a nucleic acid amplification apparatus |
US8980561B1 (en) | 2006-08-22 | 2015-03-17 | Los Alamos National Security, Llc. | Nucleic acid detection system and method for detecting influenza |
US20090047673A1 (en) | 2006-08-22 | 2009-02-19 | Cary Robert B | Miniaturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids |
GB0617035D0 (en) | 2006-08-30 | 2006-10-11 | Inverness Medical Switzerland | Fluidic indicator device |
GB0718250D0 (en) | 2007-08-29 | 2007-10-31 | B G Res Ltd | Improvements in and relating to reaction apparatus |
US7985716B2 (en) | 2006-09-22 | 2011-07-26 | Uchicago Argonne, Llc | Nucleic acid sample purification and enrichment with a thermo-affinity microfluidic sub-circuit |
WO2008147382A1 (en) | 2006-09-27 | 2008-12-04 | Micronics, Inc. | Integrated microfluidic assay devices and methods |
EP2082061B8 (en) | 2006-10-06 | 2020-10-07 | Applied DNA Sciences, Inc. | Method for a continuous rapid thermal cycle system |
WO2008061165A2 (en) | 2006-11-14 | 2008-05-22 | Handylab, Inc. | Microfluidic cartridge and method of making same |
WO2008061129A2 (en) | 2006-11-14 | 2008-05-22 | University Of Utah Research Foundation | Methods and compositions related to continuous flow thermal gradient pcr |
US20080113391A1 (en) | 2006-11-14 | 2008-05-15 | Ian Gibbons | Detection and quantification of analytes in bodily fluids |
US8735103B2 (en) | 2006-12-05 | 2014-05-27 | Electronics And Telecommunications Research Institute | Natural convection-driven PCR apparatus and method using disposable polymer chip |
GB0625309D0 (en) | 2006-12-19 | 2007-01-24 | Inverness Medical Switzerland | Device |
US8338166B2 (en) | 2007-01-04 | 2012-12-25 | Lawrence Livermore National Security, Llc | Sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture |
AU2008209598B2 (en) | 2007-01-22 | 2013-11-28 | Orasure Technologies, Inc. | Container and method for supporting home testing and diagnosis of infectious diseases |
US20110039303A1 (en) | 2007-02-05 | 2011-02-17 | Stevan Bogdan Jovanovich | Microfluidic and nanofluidic devices, systems, and applications |
US8298763B2 (en) | 2007-03-02 | 2012-10-30 | Lawrence Livermore National Security, Llc | Automated high-throughput flow-through real-time diagnostic system |
WO2009011942A2 (en) | 2007-04-04 | 2009-01-22 | Network Biosystems, Inc. | Methods for rapid multiplexed amplification of target nucleic acids |
JP4992524B2 (en) | 2007-04-13 | 2012-08-08 | 株式会社島津製作所 | Reaction vessel plate and reaction processing method |
WO2008132871A1 (en) | 2007-04-13 | 2008-11-06 | Shimadzu Corporation | Reaction container plate and reaction treatment method |
JP2010525322A (en) | 2007-04-20 | 2010-07-22 | クイデル コーポレイション | Analyzer with integrated desiccant |
KR101228308B1 (en) | 2007-05-23 | 2013-01-31 | 삼성전자주식회사 | Disk type microfluidic device using microfluidic chip and disk type microfluidic device using biomolecule microarray chip |
GB0710957D0 (en) * | 2007-06-07 | 2007-07-18 | Norchip As | A device for carrying out cell lysis and nucleic acid extraction |
US9458451B2 (en) | 2007-06-21 | 2016-10-04 | Gen-Probe Incorporated | Multi-channel optical measurement instrument |
JP5045268B2 (en) | 2007-06-28 | 2012-10-10 | ソニー株式会社 | Reaction processing equipment |
US8133671B2 (en) | 2007-07-13 | 2012-03-13 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
US8076129B2 (en) | 2007-07-26 | 2011-12-13 | Shimadzu Corporation | Reactor plate and reaction processing method |
JP5852781B2 (en) | 2007-07-31 | 2016-02-03 | マイクロニクス, インコーポレイテッド | Hygienic swab collection system, microfluidic assay device and method for diagnostic assays |
US7955840B2 (en) | 2007-08-23 | 2011-06-07 | Akonni Biosystems | Thermal cycler for PCR including temperature control bladder |
CL2008003007A1 (en) | 2007-10-12 | 2009-10-02 | Bigtec Private Ltd | A microchip with layers of low temperature firing ceramics (ltcc) forming a reaction chamber, conductive rings that surround the reaction chamber and a heater that supplies heat to the rings, the microchip manufacturing method and a micro polymerase chain reaction (pcr) device. |
US8222048B2 (en) * | 2007-11-05 | 2012-07-17 | Abbott Laboratories | Automated analyzer for clinical laboratory |
US8075854B2 (en) | 2007-11-08 | 2011-12-13 | The Ohio State University Research Foundation Bioprocessing Innovative Company | Microfluidic chips for rapid multiplex ELISA |
DE102007062441A1 (en) | 2007-12-20 | 2009-06-25 | Aj Innuscreen Gmbh | Mobile rapid test system for nucleic acid analysis |
WO2009117167A1 (en) | 2008-01-02 | 2009-09-24 | Blood Cell Storage, Inc. | Devices and processes for nucleic acid extraction |
US20090253181A1 (en) | 2008-01-22 | 2009-10-08 | Microchip Biotechnologies, Inc. | Universal sample preparation system and use in an integrated analysis system |
KR101465701B1 (en) | 2008-01-22 | 2014-11-28 | 삼성전자 주식회사 | Apparatus for amplifying nucleic acids |
US20090186344A1 (en) | 2008-01-23 | 2009-07-23 | Caliper Life Sciences, Inc. | Devices and methods for detecting and quantitating nucleic acids using size separation of amplicons |
WO2009092564A2 (en) | 2008-01-23 | 2009-07-30 | Roche Diagnostics Gmbh | Integrated instrument performing synthesis and amplification |
US20090215050A1 (en) | 2008-02-22 | 2009-08-27 | Robert Delmar Jenison | Systems and methods for point-of-care amplification and detection of polynucleotides |
CN101538567B (en) * | 2008-03-20 | 2012-09-19 | 杭州优思达生物技术有限公司 | Method for quickly processing filter-type micro nucleic acid clinical samples |
JP2011522521A (en) | 2008-05-05 | 2011-08-04 | ロスアラモス ナショナル セキュリティ,エルエルシー | Highly simplified lateral flow-based nucleic acid sample preparation and passive fluid flow control |
WO2009137055A1 (en) | 2008-05-05 | 2009-11-12 | Los Alamos National Security, Llc | Nanocrystal-based lateral flow microarrays and low-voltage signal detection systems |
WO2010011828A1 (en) | 2008-07-23 | 2010-01-28 | Ancora Pharmaceuticals Inc. | Automated oligosaccharide synthesizer |
EP2163620A1 (en) * | 2008-09-03 | 2010-03-17 | Qiagen GmbH | Method for isolating and cleaning nucleic acids |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
US9156010B2 (en) | 2008-09-23 | 2015-10-13 | Bio-Rad Laboratories, Inc. | Droplet-based assay system |
WO2010035063A1 (en) | 2008-09-23 | 2010-04-01 | Koninklijke Philips Electronics N.V. | Thermocycling device |
EP2172703A1 (en) | 2008-10-03 | 2010-04-07 | J & H ApS | Emergency light device for marine environments |
US8058005B2 (en) | 2008-10-23 | 2011-11-15 | Honeywell International Inc. | Method for single nucleotide polymorphism and mutation detection using real time polymerase chain reaction microarray |
CA2742598A1 (en) * | 2008-11-04 | 2010-05-14 | Blood Cell Storage, Inc. | Nucleic acid extraction on curved glass surfaces |
US8110148B2 (en) | 2008-11-06 | 2012-02-07 | Siemens Medical Solutions Usa, Inc. | Apparatus and method using rotary flow distribution mechanisms |
EP2366027B1 (en) | 2008-11-20 | 2017-01-11 | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO | Rapid fret-based diagnosis of bacterial pathogens |
KR101066010B1 (en) | 2008-12-31 | 2011-09-20 | 동아대학교 산학협력단 | Pharmaceutical Composition for Treatment of Neurological Disorders Associated with Demyelination Containing Proteasome Inhibitor |
CN101556277B (en) | 2009-01-05 | 2012-12-26 | 艾博生物医药(杭州)有限公司 | Detecting device |
US8058630B2 (en) | 2009-01-16 | 2011-11-15 | Fluidigm Corporation | Microfluidic devices and methods |
EP2391883B1 (en) | 2009-01-30 | 2018-03-07 | Micronics, Inc. | Portable high gain fluorescence detection system |
CN102422143A (en) | 2009-03-10 | 2012-04-18 | 新加坡科技研究局 | Apparatus for processing a biological and/or chemical sample |
JP5766178B2 (en) | 2009-03-24 | 2015-08-19 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | Slipchip apparatus and method |
EP3360974A1 (en) | 2009-06-05 | 2018-08-15 | Alere San Diego, Inc. | Recombinase polymerase amplification reagents |
SG176669A1 (en) | 2009-06-05 | 2012-01-30 | Integenx Inc | Universal sample preparation system and use in an integrated analysis system |
US9625454B2 (en) | 2009-09-04 | 2017-04-18 | The Research Foundation For The State University Of New York | Rapid and continuous analyte processing in droplet microfluidic devices |
US8008080B2 (en) | 2009-09-23 | 2011-08-30 | Ecolab Usa Inc. | Valve analytical system |
EP2480681A4 (en) | 2009-09-25 | 2013-07-10 | Alere San Diego Inc | Detection of nucleic acids in crude matrices |
EE201000013A (en) | 2010-01-29 | 2011-10-17 | Selfdiagnostics O� | Method and rapid assay device for detecting target rk molecule from sample material |
CA2977845C (en) | 2010-02-23 | 2020-08-04 | Luminex Corporation | Apparatus and methods for integrated sample preparation, reaction and detection |
US8791675B2 (en) | 2010-03-22 | 2014-07-29 | Pine Valley Investments, Inc. | Mobile wireless communications device including removable electrical power supply module and related methods |
CN103003448B (en) | 2010-04-09 | 2015-06-17 | 生命技术公司 | Improved thermal uniformity for thermal cycler instrumentation using dynamic control |
WO2011130629A1 (en) | 2010-04-16 | 2011-10-20 | Claros Diagnostics, Inc. | Systems and devices for analysis of samples |
US8435737B2 (en) | 2010-06-02 | 2013-05-07 | Cal Poly Corporation | Primers for the rapid and specific detection of propane-oxidizing and butane-oxidizing microorganisms and methods of using same |
WO2011156835A1 (en) | 2010-06-17 | 2011-12-22 | Geneasys Pty Ltd | Test module incorporating spectrometer |
US9725754B2 (en) | 2010-07-29 | 2017-08-08 | Sean F. Boyle | Generic sample preparation |
KR20120020528A (en) | 2010-08-30 | 2012-03-08 | 삼성전자주식회사 | Polymerase chain reaction apparatus |
EP2426201A1 (en) | 2010-09-06 | 2012-03-07 | Qiagen GmbH | Method of isolating purified RNA with reduced DNA contaminations |
WO2012033765A1 (en) | 2010-09-07 | 2012-03-15 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Microdroplet-manipulation systems and methods for automated execution of molecular biological protocols |
EP2618932A1 (en) | 2010-09-22 | 2013-07-31 | Corning Incorporated | Microporous microfluidic device |
US8795592B2 (en) | 2010-09-23 | 2014-08-05 | Analogic Corporation | Sample thermal cycling |
US8945843B2 (en) | 2010-12-09 | 2015-02-03 | Analogic Corporation | Thermocooler with thermal breaks that thermally isolate a thermocycling region from at least one guard heat region |
EP2668501B1 (en) | 2011-01-27 | 2019-06-12 | Invisible Sentinel, Inc. | Analyte detection devices, multiplex and tabletop devices for detection of analytes, and uses thereof |
US8603835B2 (en) | 2011-02-10 | 2013-12-10 | Chembio Diagnostic Systems, Inc. | Reduced step dual path immunoassay device and method |
EP2682480B1 (en) | 2011-03-04 | 2017-05-03 | Kaneka Corporation | Nucleic acid detection method, and device and kit for use in same |
WO2012129157A2 (en) | 2011-03-23 | 2012-09-27 | California Institute Of Technology | System for performing polymerase chain reaction nucleic acid amplification |
US8911941B2 (en) | 2011-04-14 | 2014-12-16 | Kenneth J. Michlitsch | Methods and apparatus for point-of-care nucleic acid amplification and detection |
US9469871B2 (en) | 2011-04-14 | 2016-10-18 | Corporos Inc. | Methods and apparatus for point-of-care nucleic acid amplification and detection |
CN103608467B (en) | 2011-04-20 | 2017-07-21 | 美飒生物技术公司 | Vibration amplified reaction for nucleic acid |
US9447456B2 (en) | 2011-04-25 | 2016-09-20 | University Of Notre Dame Du Lac | Systems and methods for bead-free detection of nucleotides |
CN107338189B (en) | 2011-05-04 | 2021-02-02 | 卢米耐克斯公司 | Apparatus and method for integrated sample preparation, reaction and detection |
JP2012242118A (en) | 2011-05-16 | 2012-12-10 | Canon Inc | Heat treatment apparatus using fluid device, and fluid handling method |
US8629264B2 (en) | 2011-05-19 | 2014-01-14 | Blood Cell Storage, Inc. | Gravity flow fluidic device for nucleic acid extraction |
US9435765B2 (en) | 2011-07-22 | 2016-09-06 | Tecan Trading Ag | Cartridge and system for manipulating samples in liquid droplets |
US20150258273A1 (en) | 2011-08-31 | 2015-09-17 | Forrest W. Payne | Electrochemically-Actuated Microfluidic Devices |
US9352312B2 (en) | 2011-09-23 | 2016-05-31 | Alere Switzerland Gmbh | System and apparatus for reactions |
US8894946B2 (en) | 2011-10-21 | 2014-11-25 | Integenx Inc. | Sample preparation, processing and analysis systems |
CN104040238B (en) | 2011-11-04 | 2017-06-27 | 汉迪拉布公司 | Polynucleotides sample preparation apparatus |
WO2013071258A1 (en) | 2011-11-11 | 2013-05-16 | Icubate, Inc. | Systems and methods for performing amplicon rescue multiplex polymerase chain reaction (pcr) |
TWI582425B (en) | 2011-11-25 | 2017-05-11 | 凸版印刷股份有限公司 | Sample analysis chip, sample analysis method, and gene analysis method |
CN103184143A (en) | 2011-12-29 | 2013-07-03 | 三星电子株式会社 | Solid reagent dissolving device and method of dissolving solid reagent by using the same |
US9533308B2 (en) | 2012-02-10 | 2017-01-03 | California Institute Of Technology | PC board-based polymerase chain reaction systems, methods and materials |
US9322054B2 (en) * | 2012-02-22 | 2016-04-26 | Lockheed Martin Corporation | Microfluidic cartridge |
US9035204B2 (en) | 2012-02-29 | 2015-05-19 | Reliance Controls Corporation | Switch assembly with sequentially actuated power and neutral switching |
WO2013131057A1 (en) | 2012-03-01 | 2013-09-06 | Quidel Corporation | System and apparatus for point-of-care diagnostics |
WO2013132645A1 (en) | 2012-03-09 | 2013-09-12 | 独立行政法人産業技術総合研究所 | Nucleic acid amplification method |
US9238833B2 (en) | 2012-04-17 | 2016-01-19 | California Institute Of Technology | Thermally controlled chamber with optical access for high-performance PCR |
US9150907B2 (en) | 2012-04-27 | 2015-10-06 | General Electric Company | Microfluidic flow cell assemblies and method of use |
US10443085B2 (en) * | 2012-06-20 | 2019-10-15 | Toray Industries, Inc. | Method for detecting nucleic acid and nucleic acid detection kit |
US9044729B2 (en) | 2012-07-27 | 2015-06-02 | International Park Of Creativity | Methods and devices for electromagnetic amplification of nucleic acids |
EP2882534A4 (en) | 2012-08-07 | 2016-04-13 | California Inst Of Techn | Ultrafast thermal cycler |
US9387478B2 (en) | 2012-08-17 | 2016-07-12 | Lexmark International, Inc. | Micro-fluidic modules on a chip for diagnostic applications |
EP2890966B1 (en) * | 2012-08-28 | 2018-03-07 | Akonni Biosystems, Inc. | Method and kit for purifying nucleic acids |
US20140098252A1 (en) | 2012-09-05 | 2014-04-10 | Cepheid | Universal Docking Bay and Data Door in a Fluidic Analysis System |
US9580679B2 (en) | 2012-09-21 | 2017-02-28 | California Institute Of Technology | Methods and devices for sample lysis |
US20150290639A1 (en) | 2012-12-03 | 2015-10-15 | Vladimir Evtodienko | Pressure assisted lateral flow diagnostic device |
KR20150097764A (en) | 2012-12-21 | 2015-08-26 | 마이크로닉스 인코포레이티드. | Portable fluorescence detection system and microassay cartridge |
US20150361419A1 (en) * | 2013-01-21 | 2015-12-17 | Nanobiosys Inc. | Microfluidic chip for extracting nucleic acids, device for extracting nucleic acids comprising same, and method for extracting nucleic acids using same |
US9995412B2 (en) | 2013-03-01 | 2018-06-12 | Wave 80 Biosciences, Inc. | Long-throw microfluidic actuator |
US9623409B2 (en) | 2013-03-11 | 2017-04-18 | Cue Inc. | Cartridges, kits, and methods for enhanced mixing for detection and quantification of analytes |
US20140274770A1 (en) | 2013-03-13 | 2014-09-18 | Quidel Corporation | Pcr assays and reagents for molecular detection of infectious agents |
EP4144439A1 (en) | 2013-03-15 | 2023-03-08 | Nanobiosym, Inc. | System for analysis of a biological sample |
US10233483B2 (en) | 2013-07-03 | 2019-03-19 | Qvella Corporation | Methods of targeted antibiotic susceptibility testing |
WO2015019522A1 (en) | 2013-08-08 | 2015-02-12 | パナソニック株式会社 | Nucleic acid amplification device, nucleic acid amplification apparatus, and nucleic acid amplification method |
JP2017503175A (en) | 2013-12-31 | 2017-01-26 | キヤノン ユー.エス. ライフ サイエンシズ, インコーポレイテッドCanon U.S. Life Sciences, Inc. | Rapid primary results microfluidic system in small format for field deployment |
US20180135108A1 (en) | 2014-01-20 | 2018-05-17 | Board Of Trustees Of Michigan State University | Method for detecting bacterial and fungal pathogens |
US10195610B2 (en) | 2014-03-10 | 2019-02-05 | Click Diagnostics, Inc. | Cartridge-based thermocycler |
EP3698874A1 (en) | 2014-03-11 | 2020-08-26 | Illumina, Inc. | Disposable, integrated microfluidic cartridge and methods of making the same |
WO2015160863A1 (en) | 2014-04-14 | 2015-10-22 | Sri International | Portable nucleic acid analysis systemand high-performance microfluidic electroactive polymer actuators |
US10253357B2 (en) | 2014-04-24 | 2019-04-09 | Diassess Inc. | Colorimetric detection of nucleic acid amplification |
EP2942394A1 (en) | 2014-05-09 | 2015-11-11 | Molzym GmbH & Co. KG | New method for isolating microbial DNA |
WO2015200717A2 (en) | 2014-06-27 | 2015-12-30 | The Regents Of The University Of California | Pcr-activated sorting (pas) |
CA2991918A1 (en) | 2014-07-11 | 2016-01-14 | Advanced Theranostics Inc. | Point of care polymerase chain reaction device for disease detection |
WO2016040523A1 (en) | 2014-09-12 | 2016-03-17 | Click Diagnostics, Inc. | Multiplex optical detection |
USD776290S1 (en) | 2014-12-31 | 2017-01-10 | W.H.P.M. Bioresearch And Technology | Fecal occult blood detector |
EP4029606A1 (en) | 2014-12-31 | 2022-07-20 | Visby Medical, Inc. | Molecular diagnostic testing |
EP3248018B1 (en) | 2015-01-22 | 2020-01-08 | Becton, Dickinson and Company | Devices and systems for molecular barcoding of nucleic acid targets in single cells |
EP4282532A3 (en) | 2015-04-24 | 2024-02-28 | Mesa Biotech, Inc. | Fluidic test cassette |
GB201510723D0 (en) | 2015-06-18 | 2015-08-05 | Alere Switzerland Gmbh | High throughput isothermal nucleic acid amplification |
EP3314262A1 (en) | 2015-06-23 | 2018-05-02 | POC Medical Systems Inc. | Device and methods to detect biomarkers using ologonucleotides |
CN105239164B (en) * | 2015-07-22 | 2017-12-08 | 广州市达瑞生物技术股份有限公司 | Quantitative standard items in a kind of fetus dissociative DNA library and preparation method thereof |
US10040069B2 (en) | 2015-07-23 | 2018-08-07 | General Electric Company | Amplification and detection of nucleic acids |
EP3325975A1 (en) | 2015-07-24 | 2018-05-30 | Cepheid | Molecular diagnostic assay system |
IL242807A0 (en) | 2015-11-26 | 2016-04-21 | Novamed Ltd | Assay device |
EP3400284A4 (en) | 2016-01-08 | 2019-10-23 | Advanced Theranostics Inc. | Fully integrated, stand-alone, point-of-care device to detect target nucleic acids |
WO2017151195A1 (en) | 2016-02-29 | 2017-09-08 | The Penn State Research Foundation | Nucleic acid molecular diagnosis |
EP3429543A4 (en) | 2016-03-14 | 2019-11-06 | Lucira Health, Inc. | Selectively vented biological assay devices and associated methods |
JP6949864B2 (en) | 2016-03-14 | 2021-10-13 | ルシラ ヘルス インコーポレイテッド | Biological Assays Equipment and Methods for Sample Preparation and Delivery |
WO2017160839A1 (en) | 2016-03-14 | 2017-09-21 | Diassess Inc. | Devices and methods for modifying optical properties |
WO2017160836A1 (en) | 2016-03-14 | 2017-09-21 | Diassess Inc. | Systems and methods for performing biological assays |
US10987674B2 (en) | 2016-04-22 | 2021-04-27 | Visby Medical, Inc. | Printed circuit board heater for an amplification module |
WO2017197040A1 (en) | 2016-05-11 | 2017-11-16 | Click Diagnostics, Inc. | Devices and methods for nucleic acid extraction |
MX2018015889A (en) | 2016-06-29 | 2019-05-27 | Click Diagnostics Inc | Devices and methods for the detection of molecules using a flow cell. |
CN109661273B (en) | 2016-06-30 | 2022-11-04 | 维斯比医学公司 | Device and method for nucleic acid extraction |
WO2018119443A1 (en) | 2016-12-23 | 2018-06-28 | The Regents Of The University Of California | Method and device for digital high resolution melt |
EP3612306A4 (en) | 2017-04-21 | 2021-01-13 | Mesa Biotech, Inc. | Fluidic test cassette |
EP3707276A4 (en) | 2017-11-09 | 2022-02-23 | Visby Medical, Inc. | Portable molecular diagnostic device and methods for the detection of target viruses |
WO2021138544A1 (en) | 2020-01-03 | 2021-07-08 | Visby Medical, Inc. | Devices and methods for antibiotic susceptibility testing |
-
2017
- 2017-05-10 WO PCT/US2017/032035 patent/WO2017197040A1/en active Application Filing
-
2018
- 2018-11-09 US US16/186,240 patent/US11193119B2/en active Active
-
2021
- 2021-10-22 US US17/508,519 patent/US20220186208A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11952636B2 (en) | 2020-01-03 | 2024-04-09 | Visby Medical, Inc. | Devices and methods for antibiotic susceptibility testing |
Also Published As
Publication number | Publication date |
---|---|
WO2017197040A1 (en) | 2017-11-16 |
US20190136226A1 (en) | 2019-05-09 |
US11193119B2 (en) | 2021-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220186208A1 (en) | Devices and methods for nucleic acid extraction | |
AU2017290753B2 (en) | Devices and methods for nucleic acid extraction | |
US20200406257A1 (en) | Devices and methods for the detection of molecules using a flow cell | |
US11168354B2 (en) | Portable molecular diagnostic device and methods for the detection of target viruses | |
Paul et al. | Advances in point-of-care nucleic acid extraction technologies for rapid diagnosis of human and plant diseases | |
US20210237090A1 (en) | Printed circuit board heater for an amplification module | |
JP6026570B2 (en) | Highly simplified lateral flow-based nucleic acid sample preparation and passive fluid flow control | |
JP2018186816A (en) | Method and system for sample preparation | |
US10683496B2 (en) | Method and apparatus for isolating nucleic acids | |
US9528105B2 (en) | Nucleic acid extraction using organic solvents to remove inhibitors | |
Soni et al. | based nucleic acid sample preparation for point-of-care diagnostics | |
AT512416B1 (en) | ARRANGEMENT AND METHOD FOR DETECTING MICROORGANISMS IN A CULTURAL VESSEL | |
Paul | Applications of Microneedle Patches and Smartphone-Based Diagnostic Devices for Tackling Emerging Plant Diseases | |
Kim et al. | Based Nucleic Acid Detection for Point-of-Care Diagnostics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VISBY MEDICAL, INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:CLICK DIAGNOSTICS, INC.;REEL/FRAME:057975/0515 Effective date: 20190624 Owner name: CLICK DIAGNOSTICS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALBRECHT, JENNIFER;CENA, RYAN;BIBA, EDWARD;AND OTHERS;SIGNING DATES FROM 20170621 TO 20170622;REEL/FRAME:057958/0657 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |